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Abstract:  
Background 
The role of aspirin (100 mg daily) and omega-3 fatty acids (FA) (1 g daily) for 
primary prevention of cardiovascular disease in diabetes is being 
investigated in the 2x2 factorial design ASCEND trial. To support the 
interpretation of the trial’s efficacy findings, it is important to compare self-
reported compliance by participants with measures of the biochemical effects 
of each intervention. The previous data on the effect of supplementation with 
omega-3 FA on coronary heart disease is uncertain. 
Methods 
The ASCEND trial randomly allocated 15480 people with diabetes (94% type 
2 DM) who do not already have diagnosed occlusive arterial disease to 
receive aspirin or placebo and to omega-3 FA or placebo. Blood and urine 
samples were collected by mail at baseline and after 3 years follow-up. The 
effectiveness of aspirin to suppress urinary thromboxane B2 (UTxB2), a 
marker of platelet activity, and, of omega-3 FA supplements to increase red 
cell membrane omega-3 index were assessed. A systematic review of 
previous trials of omega-3 FA was conducted to summarize the prior 
evidence for the effects of omega-3 FA supplements on major vascular 
events (MVEs).  
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Results 
Aspirin reduced UTxB2 levels by 67% (63-70%) (p <0.0001) compared with 
placebo, from 3453 pg/mg (95% CI 3061-3895) at baseline to 1190 pg/mg 
(1100-1287) on those allocated to aspirin during the trial. During follow-up, 
the omega-3 index increased by 33% (95% CI 26%-39%) in those allocated 
omega-3 FA compared to placebo (p<0.0001). The meta-analysis of previous 
studies of omega-3 FA showed no effect on MVEs (HR 0.97; [0.93-1.01]) 
overall or in any pre-specified sub-groups. 
Conclusions 
Low dose aspirin and omega-3 FA are biochemically effective at reducing 
UTxB2 and increasing the omega-3 index, respectively. Previous trials show 
that supplementation with omega-3 FA had no significant effect on MVEs. 
The results of the ASCEND trial, assessing the effects of both aspirin and 
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1  Introduction 
This thesis represents a sub-study of the ASCEND trial for which I was 
primarily responsible. I also carried out a systematic review and tabular data 
meta-analysis of the trials of omega-3 fatty acid (FA) for prevention of 
cardiovascular disease. This involved setting up the Omega-3 FA Treatment 
Trialists’ Collaboration (OTTC). The two main objectives of my thesis were: 
1. To investigate the reliability of questionnaire-based, self-reported 
compliance of study medications in the large mail-based ASCEND trial. 
2. To review the literature on the effect of omega-3 FA supplementation 
for the prevention of cardiovascular disease.  
1.1 The aims of the thesis 
The aims of this thesis were:  
To review the epidemiology of diabetes mellitus (DM) and the current 
strategies for reduction of cardiovascular disease risk in people with DM. 
To examine the baseline characteristics of 15,480 participants in the ASCEND 
trial; describe details of follow-up and current levels of compliance with study 
treatments, and methods for maintaining it. 
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To assess the biochemical effects on various biomarkers of treatment with 
either aspirin or placebo, and omega-3 fatty acids (FA) or placebo in a random 
sample after 3 years follow-up and to relate results to reported compliance. 
To assess the known effects of omega-3 FA supplementation on components 
of major vascular events (MVE) (coronary heart disease, stroke, and 
revascularisation), cancer, all-cause mortality overall, and on MVE in pre-
specified sub-groups, by undertaking a meta-analysis of published randomised 
trials.  
1.2 How these aims will be addressed in the thesis 
Background: Chapter 2 includes a detailed literature review of the global 
burden of diabetes and its cardiovascular complications, evidence-based 
current prevention and treatment strategies for the reduction of cardiovascular 
disease (CVD) in diabetes.   
Methodology: The first part of chapter 3 describes the ASCEND trial and the 
substudy which forms the basis of this thesis. This includes the baseline 
characteristics of 15,480 participants in the ASCEND trial, a description of the 
details of follow-up, current levels of compliance and methods for maintaining 
compliance.  
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The second part of chapter 3 describes the methods of my substudy to 
investigate the biochemical effects of aspirin, in order to demonstrate that it is 
delivering its expected anti-platelet effect in this diabetic population, and of 
omega-3 FA in order to show that blood levels have increased as expected. 
The results of the biochemical effects of each intervention will be compared to 
self-reported compliance from follow-up questionnaires.  
Results: A systematic review of randomised trials of omega-3 FA was 
conducted to summarize the prior evidence for effects of omega-3 FA 
supplements on MVEs. Chapter 4 describes results of the meta-analysis of 
completed trials on the Omega-3 FA Treatment Trialists’ Collaboration (OTTC). 
This has involved writing to Principal Investigators, seeking summary data from 
10 collaborating trials involving nearly 78,000 participants. 
The results of biochemical measurements for the effectiveness of aspirin and 
omega-3 FA in ASCEND will form the second part of chapter 4. The results of 
laboratory analysis of omega-3 Index and urinary thromboxane B2 (UTxB2) are 
also described in chapter 4. 
Discussion and conclusion: A summary of the findings and contribution of 
this thesis to the literature is discussed in chapter 5. 
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2 Background 
2.1 Diabetes mellitus and its complications 
Diabetes mellitus (DM) is a chronic disorder of glucose metabolism. It is 
associated with long-term macrovascular and microvascular complications 
and is associated with significant morbidity, mortality, socio-economic impact, 
and health care costs (1, 2). Macrovascular complications include 
cardiovascular disease, peripheral arterial disease, and cerebrovascular 
disease. Microvascular complications include retinopathy, nephropathy, and 
neuropathy.  
This chapter reviews the epidemiology of diabetes mellitus and its vascular 
complications, current strategies and treatment options, and prevention 
strategies for cardiovascular disease focusing on the role of aspirin and 
omega-3 FA.  
Epidemiology and the disease burden of diabetes 2.1.1
mellitus 
The prevalence of DM is increasing rapidly and DM has become a global 
epidemic which represents a major health burden in both developed and 
developing countries (3). The reasons behind this increase are multifactorial 
including the combined effects of changing lifestyles, rising levels of obesity 
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and inactivity, increasing lifespan, and improved detection of the disease. 
The number of people with diabetes has risen from 108 million in 1980 to 422 
million in 2014 (4). The global prevalence of diabetes among adults over 18 
years of age has increased from 4.7% in 1980 to 8.5% in 2014. If present 
trends continue, between 2010 and 2030, there will be a 69% increase in the 
prevalence of diabetes in developing countries and a 20% increase in 
developed countries (5). In 2013, it was reported that 382 million people had 
diabetes; but this number is expected to increase to 592 million by 2035 (6). 
A systematic analysis of health examination surveys and epidemiological 
studies (representing 370 country-years and 2.7 million people surveyed) 
also confirmed that the prevalence of diabetes is rising globally, driven mainly 
by the population growth and aging (3). A particular cause of concern is the 
dramatic rise of type 2 diabetes in children and adolescents (International 
Diabetes Federation -IDF Diabetes Atlas report) with a longer exposure to 
the disease and increased risk of complications. 
The number of people living with diabetes in the UK reached above 4 million 
in early 2016 according to GP- data described by the Diabetes UK. A further 
5 million people in England are at high risk of developing diabetes (State of 
the Nation Report July 2016, Diabetes UK). The prevalence of DM is nearly 
three times higher than all cancers combined (7) (Figure 2.1). If current 
trends persist, one in ten people will develop DM in 2034. 
24 
Figure 2.1: Prevalence of diabetes compared to other diseases (Adapted 
from State of the nation report 2016 (Diabetes UK)) 
Prolonged exposure to hyperglycaemia is associated with an increased risk 
of atherosclerosis and is the primary determinant of diabetic complications 
(pathophysiology of prolonged hyperglycaemia will be discussed in section 
2.2 of this chapter). Patients with diabetes are at high risk for several 
cardiovascular disorders (8): including coronary heart disease, 
cardiomyopathy and congestive heart failure (9, 10). Cardiovascular 
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complications are the leading causes of diabetes-related morbidity and 
mortality (10, 11).  
Many studies indicate that diabetes is an independent risk factor not only for 
cardiac disease but also for other vascular complications including stroke, 
sight-threatening retinopathy, kidney disease, and peripheral vascular 
disease and foot complications leading to diabetic foot ulcers, limb 
amputations, cognitive decline and dementia, and overall increased mortality 
(11).  
A meta-analysis of data from 102 prospective studies coordinated by the 
Emerging Risk Factor Collaboration (ERFC), which included data from over 
690,000 participants (with 52,765 fatal or non-fatal cardiovascular outcomes 
and 8.49 million person-years at risk) demonstrated that having diabetes was 
independently associated with about a two-fold excess risk for developing 
vascular disease (cardiovascular disease, cerebrovascular disease, and 
peripheral vascular disease [PVD]) compared to no diabetes and after 
adjusting for conventional risk factors (coronary heart disease HR 2.00 (95% 
CI 1.83-2.19); ischaemic stroke HR 2.27 (1.95-2.65); vascular death HR 1.73 
(1.08-1.26)) (8). The hazard ratios (HR) for coronary heart disease with 
diabetes were significantly higher in women HR 2.59 (2.29-2.93) than in men 
HR 1.89 (1.73-2.06) (8).  
There is also an increased incidence of ischaemic stroke in people with 
diabetes. A different meta-analysis of data from 64 cohort studies (775,385 
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individuals, 12,539 fatal and non-fatal strokes) reported that the relative risk 
of stroke associated with diabetes was 2·28 (95% CI 1.93-2.69) in women 
and 1.83 (1.60-2.08) in men (12). Data suggest there is also a significant 
variation by age and that the excess vascular risk is most prominent in 
younger age group (e.g. before age of 55) (13).  
The risks of PVD are higher in people with diabetes, PVD occurs earlier and 
is often more severe and diffuse than in people without diabetes. The 
presence of PVD results in higher risks of claudication, ischaemic ulcers, 
gangrene, and amputation. PVD is also a marker for generalized 
atherosclerosis and a strong predictor of ischaemic cardiovascular 
events. Individuals with diabetes have a 2 to 4-fold increased risk of PVD 
(14). Overall mortality from PVD tends to be higher in people with diabetes 
compared to people without diabetes (51.7 vs. 25.6%, OR 3.1, P = 0.002), 
and in one study, diabetic patients who died were younger at presentation 
than non-diabetic patients (64.7 +/- 11.4 vs. 71.1 +/- 8.7 years, P = 0.04) and 
the duration and severity of diabetes correlated with the incidence and extent 
of their PVD (15). 
Having diabetes is also associated with an increased risk of premature 
mortality compared with those without the disease. For example on average, 
a 50-year old with diabetes but with no history of any vascular disease is 
about 6 years younger at the time of death than a counterpart without 
diabetes. The ERFC quotes a HR of 1.8 (95% CI 1.71-1.9) for death from any 
cause; and HR 2.32 (95% CI 2.11 to 2.56) for death from a vascular cause 
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(11). The crude overall death rates, as reported in Emerging Risk Factor 
Collaboration study, were higher among participants with diabetes than 
among those without diabetes: 29 per 1000 person-years vs 12 per 1000 
person-years for men, respectively, and 23 per 1000 person-years vs 7 per 
1000 person-years for women, respectively (11). The Multiple Risk Factor 
Intervention Study (MRFIT) screening data study reported that the absolute 
risks of CVD death were higher for men with diabetes than non-diabetic men 
in every age stratum, by ethnic background, and by risk factor level—overall 
three times higher after adjustment for age, race, income, serum cholesterol 
level, systolic blood pressure and reported number of cigarettes/day (P 
<0.0001) (16). A more recent study also has highlighted that mortality among 
persons with type 2 diabetes as compared with that in the general population 
varied greatly depending on age, glycemic control, and renal complications. 
A recent Swedish study which included more than 90% of all the people with 
type 2 diabetes in Sweden reported that overall, 77,117 of 435,369 patients 
with diabetes (17.7%) died, as compared with 306,097 of 2,117,483 controls 
(14.5%) (adjusted hazard ratio HR, 1.15; 95% confidence interval [CI], 1.14 
to 1.16) at the mean follow up of 4.6 years. The rate of cardiovascular death 
was 7.9% among patients versus 6.1% among controls (HR 1.14; 95% 
CI,1.13 to 1.15) (17). Hence this suggests that the excess risk of mortality in 
type 2 diabetes has reduced over time compared to the result of MRFIT 
study. Not only in type 2 diabetes, another Swedish nationwide population-
based observational cohort study (with median follow-up of 8.3 and 8.9 
years) recently reported for individuals with type 1 diabetes and controls, 
1500 (4.5%) and 1925 (1.2%) respectively, experienced non-fatal AMI or died 
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from CHD, adjusted HR 4.07 (95% CI 3.79 to 4.36). This excess risk 
increased with younger age, female sex, worse glycaemic control and 
severity of renal complications (18).  Diabetes was estimated to cause 4.6 
million deaths worldwide in 2011, and 10% of vascular deaths in developed 
countries were attributable to DM (estimated 325,000 deaths per year) (8). 
The WHO projects that DM will be the 7th leading cause of death worldwide in 
2030 (19).  
Diabetic retinopathy (DR) and diabetic macular oedema (DME) are common 
complications in people with diabetes and associated with significant 
disability. DR is an important cause of blindness and accounts for 2.6% of 
global blindness (20). DR is accountable for 0.8 million cases of blindness 
and 3.7 million cases of visual impairment with a significant increasing trend 
from 1990 to 2010 (21). DR is a long-term complication of diabetes mellitus 
and after 15 years of having the disease, 10% of people with diabetes 
develop severe visual impairment and of those, about 2% will go blind (19). 
In patients with type 1 DM, the cumulative 14-yr incidence of visual 
impairment and blindness were 12.7% and 2.4% respectively (22). An 
individual participant data analysis (of >22 000 individuals with diabetes) 
reported that the prevalence of any DR was about 35%, proliferative DR of 
about 7% and DME of about 7%. Translated globally, this means that 
approximately 93 million people with diabetes have some degree of DR, 17 
million have proliferative DR and 21 million have DME worldwide (23).  With 
increased awareness of the risk factors for retinopathy, early diagnosis (with 
a national screening program for DR) and treatment of retinopathy as well as 
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its risk factors, the rate of progression of DR to proliferative diabetic 
retinopathy (PDR) and severe visual loss has decreased since 1985 in the 
United States (24). However, the increasing prevalence of DM suggests that 
this diabetes-related blindness and visual impairment will continue to cause a 
significant impact on the health and an economic burden. Fortunately, control 
of metabolic abnormalities of diabetes can slow the progression of DR.  
Diabetes has also become the most common cause of chronic kidney 
disease (CKD) and end-stage renal disease (ESRD) in the US and Europe 
(25) and 10-20% of people with diabetes die from renal failure (19). The 
prevalence of various degrees of CKD among people with type 2 DM 
increased to 40% in the US in the 1999-2006 National Health and Nutritional 
Examination Survey. Diabetic nephropathy is characterised by albuminuria 
(microscopic or overt) and a reduced glomerular filtration rate (GFR). 
Microalbuminuria is an important clinical finding in patients with diabetes as it 
is associated with progression to CKD. CKD is also increasingly recognised 
as an independent risk factor for cardiovascular disease (26).  A low GFR 
(<60 ml/min/1.73 m2) is also known to be an independent risk factor for 
cardiovascular events and death (27). CKD is also associated with an 
increased risk of cardiovascular disease, ESRD, and mortality (28).  
Diabetic foot disease represents a composite of pathologies including 
peripheral neuropathy, vascular insufficiency, and infection. About 50% of 
diabetic patients develop peripheral neuropathy and as many as 20% have 
neuropathy at the time of diagnosis (29). People with diabetes are 25-times 
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more likely to lose a leg because of diabetic foot problems than those without 
this condition and 85% of amputations are preceded by active foot ulcers 
(30). Diabetic foot disease causes significant pain, sensory loss, gait 
disturbance, falls, foot deformity, foot ulceration and amputation and not only 
impacts on patients’ lives but also on the lives of family members and society 
in general. The lifetime risk of a person with diabetes developing a foot ulcer 
is thought to be as high as 25% (31). The nature of diabetic foot ulcers (DFU) 
is that they tend to be recurrent (>50% after 3 years) and need long-term 
structured multi-disciplinary care (30). One meta-analysis, including 3619 
events of all-cause mortality during 81,116 person-years of follow-up, 
reported that DFU were associated with an increased risk of all-cause 
mortality (RR 1.89, CI 1.6-2.2) compared with diabetic patients without a 
history of DFU (32).  
People with diabetes have an increased risk of dementia and cognitive 
impairment (33). In 1996, the Rotterdam study reported strong associations 
of dementia with diabetes treated with insulin (odds ratio: 3.2, 95% 
confidence interval: 1.4-7.5).  The associations were strongest for vascular 
dementia but were also observed for Alzheimer's disease. These 
associations were independent of smoking, body mass index, 
atherosclerosis, blood pressure and antihypertensive drug treatment (34). An 
add-on project of the Anglo-Danish-Dutch Study of Intensive Treatment in 
People with Screen Detected Diabetes in Primary Care (ADDITION) study in 
the Netherlands reported in that modest cognitive decrements were already 
present at the early stage of type 2 diabetes (35).  Individuals with diabetes 
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had a 1.2 to 1.5-fold greater decline in cognitive function compared with 
those without diabetes. When assessed by the Mini-Mental State Exam and 
the Digit Symbol Span tests, a diagnosis of diabetes increased the odds of 
cognitive decline by 1.2-fold (95% CI 1.05-1.4) and 1.7-fold (95% CI 1.3-2.3), 
respectively. Diabetes also increased the odds of future dementia by 1.6-fold 
(95% CI 1.4-1.8) compared to people without diabetes and also people with 
diabetes have a greater rate of decline in cognitive function and a greater risk 
of cognitive decline (36). The precise mechanism by which diabetes causes 
cognitive decline are not fully understood but may include vascular disease 
and alterations in glucose, insulin, and amyloid metabolism (37). 
Degeneration of neurons in the brain, impaired regional blood supply, and 
genetic predisposition are all involved in diabetes-associated dementia or 
cognitive impairments (38). Further high-quality studies are needed to 
establish the contribution of vascular disease and other comorbidities to 
dementia. 
Health-care economic costs 2.1.2
With a rising prevalence of the disease, the diabetic population consumes a 
disproportionate share of health resources not only because of the disease 
itself but also because of the associated complications that are described 
earlier. The health-care costs worldwide for diabetes include: (i) the direct 
costs of the disease (hospitalisation, treatment of complications); (ii) indirect 
costs associated with lost production; (iii) intangible costs (pain, anxiety, 
inconvenience and generally lower quality of life, not only for the patient but 
also of family and friends); and (iv) costs for the prevention of diabetes. The 
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estimated total economic cost of diagnosed diabetes in 2012 in the United 
States was $245 billion ($176 billion for direct medical costs and $69 billion in 
reduced productivity), a 41% increase from the previous estimate of $174 
billion (in 2007 dollars) (39). On average, people diagnosed with DM, have a 
medical expenditure that is approximately 2.3-times higher than it would be in 
the absence of diabetes (40). A study from 5 European countries (France, 
Germany, Italy, Spain and the UK) reported that the estimated total annual 
costs for diabetes for 2010 ranged from €5.45 billion (Spain) to €43.2 billion 
(Germany); across these 5 EU countries the total direct health care cost for 
people with diabetes was estimated to be €90 billion (41). The WHO 
estimates that the overall direct healthcare costs of DM (excluding other 
indirect costs) range from 2.5% to 15% of annual health care budgets 
depending on local diabetes prevalence and the treatment options available 
worldwide (WHO fact sheet No 236) (4). In the UK, it is currently estimated 
that the NHS spends about £10 billion every year which is about 10% of the 
NHS budget. The combined direct and indirect cost associated with diabetes 
is about £23.7 billion. This figure is predicted to rise with increasing 
prevalence of the disease to £39.8 billion by 2035-36 (7). 
2.2 Pathophysiology of diabetes mellitus  
Plasma glucose concentrations are maintained within normal narrow range 
through tightly regulated insulin secretion and its action in peripheral tissues. 
Endogenous glucose production is inhibited to maintain normal glucose level 
(42). Type 2 DM is the predominant form of diabetes and accounts for about 
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90% of all diabetes cases with increasing prevalence (43). The abnormal 
glucose homeostasis in DM is mainly due to inadequate secretion of insulin, 
and/or peripheral resistance to secreted insulin, to match metabolic needs 
(44). Chronic hyperglycaemia triggers changes in cellular metabolism 
causing tissue damage leading to long-term diabetic complications (45). The 
extent of diabetic tissue damage is also determined by genetic determinants 
of individual susceptibility (46). The presence of independent accelerating 
factors, such as hypertension and dyslipidaemia, also cause atherosclerosis. 
Excessive caloric intake, lack of exercise and a sedentary lifestyle lead to 
obesity which is also a major risk factor for developing DM (47, 48).  
Figure 2.2 summarizes a schematic representation of the metabolic basis of 
increased atherosclerosis risk in diabetes. Hyperglycaemia and insulin 
resistance (IR) increase atherothrombotic risks via endothelial dysfunction by 
decreasing nitric oxide (NO), increasing advanced glycated end-products 
(AGE) and reactive oxygen species (ROS pathway) which lead to vascular 
inflammation and a prothrombotic state (increased thrombosis and reduced 
fibrinolysis) (45). Adipose tissue releases free fatty acids (FFAs) and 
cytokines which directly impair insulin sensitivity by increasing FFA-induced 
ROS production, reducing activation of insulin receptor substrate 1 (IRS-1) 
and phosphatidylinositide 3-kinase (PI3K-Akt) signaling, leading to down-
regulation of insulin-responsive glucose transporter 4 (GLUT-4) resulting in 
IR (49, 50). 
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Figure 2.2: Hyperglycaemia, insulin resistance, and cardiovascular disease 
(50) 
(AGE = advanced glycated end-products; FFA = free fatty acids; GLUT-4 = 
glucose transporter 4; HDL-C = high-density lipoprotein cholesterol; LDL = 
low-density lipoprotein particles; NO = nitric oxide; PAI-1 = plasminogen 
activator inhibitor-1; PKC = protein kinase C; PPARy = peroxisome 
proliferator-activated receptor y; PI3K = phosphatidylinositide 3-kinase; 
RAGE = AGE receptor; ROS = reactive oxygen species; SR-B = scavenger 
receptor B; tPA = tissue plasminogen activator)  
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The mechanisms which cause tissue damage by hyperglycaemia have been 
previously thoroughly investigated and reported with different pathways 
described including (1) increased flux of glucose through the polyol pathway; 
(2) increased intracellular formation of AGEs; (3) increased expression of the 
receptor for AGEs and its activating ligands; (4) activation of protein kinase 
(PK) C isoforms; and (5) overactivity of the hexosamine pathway (46). 
However, overproduction of superoxide by the mitochondrial electron-
transport chain is now believed to be the underlying single mechanism 
causing tissue damage by hyperglycaemia (46). Increased ROS by 
intracellular hyperglycaemia activates pathogenic signaling pathways which 
in turn decrease mitochondrial biogenesis (51). This oxidative stress has an 
impact on susceptible pancreatic islets (β cells), adipocytes and peripheral 
tissues which in turn cause impaired insulin secretion by islet cells and IR in 
adipocytes and peripheral tissues (52). Inadequate insulin secretion and IR 
lead to hyperglycaemia (both post-prandial and type 2 DM with chronic 
hyperglycaemia) which acts as a feedback mechanism for the development 
of oxidative stress which causes IR (Figure 2.3) (52).  
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Figure 2.3 Mechanism of hyperglycaemia and dyslipidaemia-induced 
inflammation for the development of IR and type 2 diabetes (52) 
Figure 2.4: Mechanism of hyperglycaemia: Impaired insulin secretion and 
increased insulin resistance in type 2 diabetes (52) 
37 
Chronic IR stimulates pancreatic secretion of insulin, generating a complex 
phenotype that includes progressive beta cell dysfunction (49). Insulin 
deficiency in diabetes results in disruption of the regulation of glucose 
production in the liver (imbalance between gluconeogenesis, glycogenolysis, 
and loss of hepatic autoregulation of glucose), glucose uptake from muscle 
and the release of fatty acids from adipose tissue (53). Risk factors that are 
associated with peripheral IR include visceral fat deposition, obesity/high 
BMI, genetic factors, and conditions of abnormal hormone production such 
as Cushing’s syndrome, acromegaly, and polycystic ovary syndrome. Long-
term hyperglycaemia leads to diabetic endothelial dysfunction which is 
regarded as an important factor in the pathogenesis of diabetic vasculopathy, 
including CHD (54).  
Lipid changes associated with diabetes mellitus are attributed to increased 
free fatty acid influx secondary to IR, although the precise mechanism of 
diabetic dyslipidaemia is not clear.  Dyslipidaemia in diabetes includes 
various patterns of lipid abnormalities, however, three main features 
constitute the diabetic dyslipidaemia triad including i) high levels of plasma 
triglycerides (TG); ii) low high-density lipoprotein (HDL) cholesterol levels; 
and iii) high levels of small dense low-density lipoprotein (LDL) cholesterol 
particles (55). IR causes increased breakdown of TG in the adipocytes which 
increase the release of fatty acids into the circulation. This increases fatty 
acid delivery to the liver resulting in increased synthesis of TG and very low-
density lipoprotein (VLDL). Increased VLDL dissociates apolipoprotein A-I 
from HDL leading to quick clearance of free apolipoprotein A-I causing a 
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reduction in HDL. This also reduces the protective effect of HDL on 
atherogenesis and thereby increases the likelihood of developing lipid-laden 
plaques (56). Moreover, activation of lipase activity increases the synthesis of 
inflammatory mediators, and greater abdominal adiposity promotes the 
generation of small dense LDL particles. These are more likely to undergo 
oxidative modification, leading to a greater susceptibility to foam cell 
formation and propagation of atherosclerotic plaque (Figure 2.5). 
Fig. 2.5: Dyslipidaemia: Abnormal lipoprotein synthesis due to excess FFA 
availability in liver because of insulin resistance in Type 2 DM (56) 
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2.3 Modifiable risk factors for cardiovascular disease in addition to 
diabetes 
Cardiovascular disease (CVD) is a major cause of death globally (4). There 
are well-recognized risk factors for CVD, including both non-modifiable risk 
factors (age, sex, ethnicity, social-economic status and family history), and 
modifiable risk factors (blood pressure, blood lipids, smoking, obesity, 
lifestyle). The risks of incident CVD or CVD mortality are directly proportional 
to the number of risk factors (Figure 2.6) (16). Hence this chapter also 
includes a brief description of effects of modifiable risk factors for CVD. 
Figure 2.6: Age-adjusted CVD death rate by presence of number of risk 
factors (smoking, dyslipidaemia, hypertension) with and without diabetes (16) 
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Blood pressure 
Hypertension is a major global health problem. It is also a major risk factor for 
cardiovascular disease. About 970 million people worldwide suffer from 
hypertension according to the World Health Organization data (4). One 
recent study on the prevalence of hypertension by measured conventional 
blood pressure (BP) and 24-hour ambulatory BP (N=6546, aged 40 to 79 
years, in 10 cohorts on 3 continents) reported that the overall prevalence of 
hypertension is as high as  49.3% (range between cohorts, 40.0%–86.8%) 
for conventional hypertension (conventional BP ≥140/90 mm Hg) and 48.7% 
(35.2%–66.5%) for 24-hr ambulatory hypertension (ambulatory BP ≥130/80 
mm Hg) (57). Socio-economic factors influence the prevalence in different 
cohorts in this study. Another study reported that in 2010, 31.1% (95% CI, 
30.0%–32.2%) of the world’s adults had hypertension; 28.5% (95% CI 
27.3%–29.7%) in high-income countries and 31.5% (95% CI 30.2%–32.9%) 
in low- and middle-income countries (58). With increasing awareness and 
treatment, from 2000 to 2010, the age-standardized prevalence of 
hypertension reduced by 2.6% in high-income countries, but increased by 
7.7% in low- and middle-income countries. Diabetes and hypertension are 
common coexisting conditions and over 50% of people with diabetes mellitus, 
either type 1 or 2, ultimately develop hypertension as a vascular complication 
(59). 
Uncontrolled high BP leads to a variety of changes in the myocardial 
structure, coronary vessels and the conduction system which results in the 
development of left ventricular hypertrophy (LVH), coronary artery disease 
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(CAD), abnormalities of the conduction system and systolic or diastolic 
dysfunction of the myocardium. Such anatomical changes manifest clinically 
as angina or myocardial infarction, cardiac arrhythmias (especially atrial 
fibrillation), and congestive heart failure (CHF). Studies have clearly shown a 
continuous log-linear relationship between blood pressure (BP) and 
cardiovascular risk in the whole population (both diabetic and non-diabetic) 
(60-62). Each difference of 20 mm Hg SBP is associated with more than a 
twofold difference in the stroke death rate and with twofold differences in the 
death rates from IHD and from other vascular causes (61). Throughout 
middle and old age, blood pressure is strongly and directly related to vascular 
mortality (Figure 2.7). 
Figure 2.7: Ischaemic heart disease (IHD) mortality rate in each decade of 
age versus blood pressure at the start of that decade (61) 
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Lipids 
In addition to hyperglycaemia and hypertension, dyslipidaemia is a modifiable 
cardiovascular risk factor for patients with or without diabetes and remains 
largely uncontrolled (63). In the Prospective Studies Collaboration meta-
analysis a 1 mmol/L lower total cholesterol was associated with about a 
halving in the risk of IHD mortality at ages 40-49 years (hazard ratio 0.44 
[95% CI 0.42-0.48]), and about a third (0.66 [0.65-0.68]), and a sixth (0.83 
[0.81-0.85]) lower IHD mortality in both sexes at ages, 50-69, and 70-89 
years, respectively (62). In the prospective meta-analysis of data from 90 056 
participants in 14 randomised trials of statins, it was reported that a 1 mmol/L 
lower LDL cholesterol was associated with a 9% proportional reduction in all-
cause mortality in people with diabetes (rate ratio [RR] 0·91, 99% CI 0·82–
1·01; p=0·02) compared to the 13% reduction in those without diabetes 
(0·87, 0·82–0·92; p<0·0001) (64). The relationship between the absolute 
reductions in LDL cholesterol achieved and the proportional reductions in the 
incidence of coronary and other major vascular events in both people with 
and without DM are already established.  
Smoking 
Smoking is another major cause of cardiovascular disease, responsible for 
about one-third of all cardiovascular death in Western populations and is the 
most common preventable cause of cardiovascular morbidity and mortality 
(65). Smoking is associated with a 2 to 4-fold higher risk of coronary heart 
disease, a >70% higher risk of death from coronary heart disease, and an 
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elevated risk of sudden death (65).  Many epidemiological studies have 
reported that smoking in both men and women substantially increases the 
incidence of cardiovascular disease (66-71).  
Obesity 
The prevalence of obesity has increased over time. According to the Health 
Survey for England in 2012-2014, 7 out of 10 men and 6 out of 10 women in 
the UK are overweight or obese. The trends (Figure 2.8) indicate that the 
prevalence of obesity continues to rise. Obesity is a chronic disorder 
associated with an increased risk of CHD and this is likely to be mediated via 
combined effects on lipids, blood pressure, and diabetes. Obesity, 
particularly in association with high waist circumference, indicating visceral 
fat deposition, and high body mass index (BMI), are independent risk factors 
for coronary heart disease (CHD) and diabetes. It was reported that marginal 
(5 lb) to moderate (11 to 22 lb) weight gain in adulthood increases the risk of 
chronic disease and negatively affects CHD risk status (72). Men and women 
with BMI >30 kg/m2 have about twice the risk of CHD compared to the people 
with BMI 18.5 to 22.9 kg/m2 (73). A collaborative analysis of 57 prospective 
studies in 894 576 participants reported that in both sexes, mortality was 
lowest at BMI of about 22.5-25 kg/m2. Above this range, each 5 kg/m2 higher 
BMI was on average associated with about 30% higher overall mortality: 40% 
for vascular mortality (HR 1.41 [1.37-1.45]) and 60-120% for diabetes (74).  
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Figure 2.8: Trends in obesity prevalence among adults (Health survey for 
England 1993-2014), Adults 16+ year of age, BMI obesity ≥ 30 kg/m2 
Figure 2.9 describes deaths attributable to the individual and combined 
effects of high body mass index, blood pressure, cholesterol, and glucose in 
2010, by disease (1). Overall 44% of deaths attributable to the combined 
effects of these risk factors in 2010 were from IHD, 30% from stroke, and 
11% from diabetes. Direct diabetes deaths accounted for only 46% of deaths 
due to non-optimal glucose control, with the remainder having IHD, 
ischaemic stroke, or CKD as the underlying causes of death (1). 
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Figure 2.9: Deaths attributable to the individual and combined effects of high 
body mass index, blood pressure, cholesterol, and glucose in 2010, by 
disease (1) 
2.4 Current strategies aimed at reducing risk of cardiovascular 
disease in diabetes 
With management and intensification of treatment for these modifiable 
cardiovascular risk factors over the last few decades, it has been reported 
that the risk of developing CHD among DM patients is falling (75). The 
Framingham Heart Study investigated the incidence rate of CVD among 
people with or without DM. Rates were compared between 1950-1966 and 
1977-1995.  From the earlier to the later period (there was a 50% reduction in 
the incidence of CVD events among people with diabetes, although the 
absolute risk of having CVD in people with diabetes was still 2-fold greater 
than in people without diabetes (75). Overall in the United States, the 
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estimated 10-year risk of developing CHD among adults with DM has 
improved significantly from 1999-2000 to 2007-2008 (76). Sustained efforts 
at improving risk factors should further benefit the cardiovascular health of 
people with diabetes (77).  
One recent study assessing the effects of multifactorial risk factor control in 
diabetes and cardiovascular disease showed that patients with diabetes who 
were at target levels for HbA1c (<53 mmol/mol), BP (<130/80 mmHg), and 
LDL-C (<2.6 mmol/L) had substantially (∼60%) lower risks for CVD and CHD 
than persons who were not at target levels for those risk factors (78) (Figure 
2.10). For each individual risk factor, persons at target levels had lower CVD 
event rates than those who were not at target levels (78). 
Figure 2.10: Unadjusted CVD and CHD event rates per 1,000 person-years 
for subjects with DM, by status of being at target level for individual risk 
factors BP, LDL-C, and HbA1c (A) and by the number of risk factors at target 
levels (B) (78) 
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Optimisation of glycaemic control and cardiovascular 2.4.1
outcome in diabetes 
The landmark United Kingdom Prospective Diabetes Study (UKPDS) 
randomised participants to intensive versus standard glucose control and 
was able to assess the long-term impact of a 0.9% lower HbA1c on all-cause 
mortality in 4585 patients with type 2 DM. It reported that each 1% reduction 
in mean HbA1c was associated with a 21% reduction in the risk of death 
related to diabetes, and the incidence of myocardial infarction and 
microvascular complications were reduced by 14% and 37% respectively 
(79). The relative risk reduction persisted for several years even after 
stopping intensive glucose treatment in a 10-year follow-up of the UKPDS 
study (risk reduction for myocardial infarction by 15% and death from any 
cause by 13% for the sulphonyl-insulin group) (80). However, three other 
large RCTs, the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD), Action in Diabetes and Vascular Disease Preterax and 
Diamicron Modified Release Controlled Evaluation (ADVANCE), and the 
Veterans Administration Diabetes Trial (VADT) did not show that intensive 
blood glucose control, achieving HbA1c levels less than 7%, significantly 
reduced the risk of cardiovascular events compared to controls but only 
achieved modest risk reduction of about 10% (81-83). It was also reported to 
be associated with a significant increase in hypoglycaemic episodes (RR 
2.03 (1.46-2.81) (84). One possible explanation for discrepant findings 
between UKPDS and more recent trials is that the latter were targeting much 
lower HbA1C level. 
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Several meta-analyses of the randomised trials investigating the effect of 
intensive glycaemic control on cardiovascular outcomes have also reported 
mixed results over the last few years. There is a reasonable consensus that 
intensive glucose control reduces the risk of microvascular complications 
(retinopathy, nephropathy, and neuropathy) in both type 1 and 2 diabetes 
patients (See Table 2.1). Most meta-analyses report a 10-15% proportional 
reduction in non-fatal myocardial infarction (MI) with intensive glucose control 
compared to standard control (84-87). However, there was no clear effect on 
stroke, cardiovascular death or all-cause mortality in the intensive glucose 
control group compared to standard control group (88-90). However, 
compared to the standard glucose control, intensive glucose control was 
associated with more serious hypoglycaemia (84). Another meta-analysis 
investigating similar outcomes (which included five prospective randomised 
controlled trials, 33,040 participants) showed that intensive versus standard 
glycaemic control significantly reduced coronary events without an increased 
risk of death (85). Similar results were reported in another meta-analysis 
(which included 13 studies with 34,533 patients) with a risk reduction of 15% 
for non-fatal MI, however, the benefit on all-cause mortality was uncertain 
(89). The HbA1c target range for each diabetic individual requires 
consideration of several factors (e.g. comorbidity, capacity for self-care, 
family and social support system) and assessment of the patient's risk for 
hyperglycaemia-related complications versus the risks of therapy. The 
individualization of HbA1c targets has become a treatment goal for glycaemic 
control (91). 
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Table 2.1: Summary table of meta-analyses of trials assessing the effect of intensive glucose control on cardiovascular 
events in diabetes mellitus 
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Optimising blood pressure and cardiovascular 2.4.2
outcomes  
The UKPDS randomised people with diabetes and hypertension into a sub-
study which evaluated the effect of intensive versus less intensive 
antihypertensive therapy (92). Treatment of hypertension was the first 
intervention proven to reduce cardiovascular risk in people with diabetes. 
Overall in the UKPDS, more intensive therapy significantly reduced the risk of 
stroke by 44% (95% CI 11-65, p=0.013) and there was also a 21% lower (-7-
41) risk of MI, although the latter did not achieve statistical significance. More 
recently the ADVANCE study randomised over 11,000 people with type 2 
diabetes to treatment with a fixed combination of an angiotensin-converting 
enzyme (ACE) inhibitor/diuretic versus placebo (93). In those allocated active 
treatment the relative risk of a major macrovascular or microvascular event 
was reduced by 9% (0-17, p=0.04). A reduction in macrovascular events 
alone was similar but not independently significant (HR 0.92; 0.81-1.04, 
p=0.16). The UKPDS also demonstrated that lowering BP reduced the 
progression of retinopathy and the development of albuminuria (92). 
A meta-analysis of individual data from one million adults in 61 prospective 
studies clearly showed that having a lower BP was associated with a lower 
risk of mortality from ischaemic heart disease and other vascular causes 
(61). The risk of cardiovascular events was 2-fold higher for every 20/10 
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mmHg higher level of systolic blood pressure (SBP). A recent meta-analysis 
of 40 RCTs trials (100 354 participants) determined the association between 
BP-lowering treatment and vascular disease in type 2 DM (94). Lowering 
SBP by 10 mmHg was associated with a significantly lower risk of mortality 
(relative risk (RR), 0.87; 95% CI, 0.78-0.96); including a reduction in risk of 
cardiovascular events, coronary heart disease, stroke, retinopathy and 
albuminuria (94).  
Treatment of hypertension in people with diabetes has been shown to 
improve cardiovascular outcomes. However, the benefits of intensive BP 
lowering (SBP 120-130 mmHg or DBP 80 mmHg) are inconclusive. There is 
still a debate about how low a BP target should be when treating 
hypertension in people with diabetes. Recent studies have examined whether 
intensive BP lowering will further prevent cardiovascular events compared 
with a standard BP target (SBP 140-160 mmHg, DBP 85-100 mmHg). The 
ACCORD BP trial investigated the effect of intensive antihypertensive 
therapy and did not demonstrate a significant reduction in the primary 
cardiovascular outcome or the rate of death from any cause, despite the fact 
that there was a significant and sustained difference between the intensive-
therapy group and the standard-therapy group in mean systolic blood 
pressure (95). The SPRINT trial (Systolic Blood Pressure Intervention Trial), 
involving a longer duration of treatment and a larger number of participants 
demonstrated benefits of intensive management of SBP to a target <120 
mmHg compared with managing SBP to a target of less than 140 mm Hg. 
Intensive management of SBP to a target of <120 mm Hg reduced risks of 
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complications of high blood pressure, including heart attacks, heart failure, 
and stroke, by 25 percent and lowered the risk of death by 27 percent (96). 
Because of clear superior benefit, the trial was recommended to stop early by 
the Data Monitoring Committee. A systematic review reported that the use of 
intensive compared with standard blood pressure targets was associated 
with a small reduction in the risk of stroke, but no evidence of a reduced risk 
for all-cause mortality or myocardial infarction. However, this review involved 
a relatively small number of trials (N=5) with a short duration of follow-up 
(97). NICE guidelines recommend adding medications if lifestyle advice does 
not reduce blood pressure to below 140/80 mmHg (below 130/80 mmHg if 
there is kidney, eye or cerebrovascular damage).  
There are several different classes of medication available for treatment of 
high BP including beta blockers, calcium channel blockers, ACE inhibitors, 
angiotensin receptor blockers and thiazides diuretics. The use of BP-lowering 
drugs for the prevention of cardiovascular disease was investigated in a 
meta-analysis of 147 RCTs, comprising data from 958 000 people (98). It 
reported that all the classes of BP- lowering drugs have a similar effect, in 
general, reducing cardiovascular events. The NICE guideline recommends a 
once-daily, generic angiotensin-converting enzyme (ACE) inhibitor as the 
first-line antihypertensive medication in diabetic population except for people 
of African or Caribbean family origin, where a calcium channel blocker should 
be used as first-line antihypertensive therapy. An angiotensin-converting 
enzyme inhibitor (ACE-I) or an angiotensin-receptor-blocker (ARB) is the 
preferred drug of choice for treatment of hypertension in people with diabetes 
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at high risk of cardiovascular disease (99-102). Recently developed drugs, 
such as glucagon-like peptide -1 (GLP-1) receptor agonists and Sodium-
glucose co-transporter-2 (SGLT2) inhibitors, also have hypotensive actions to 
use in diabetics with hypertension. SGLT2 inhibitors and GLP-1 receptor 
agonists also suppress the onset and progression of cardiovascular disease, 
as well as diabetic nephropathy (103). 
Optimising lipid profiles 2.4.3
Cholesterol-lowering, particularly using statins, is also of clear and proven 
benefit in reducing cardiovascular risk in people with diabetes (104, 105). 
Many observational studies have shown that a continuous positive (log-
linear) relationship between coronary heart disease and blood cholesterol 
level, and randomised trials have shown this to be causal (64, 104).  
The Heart Protection Study (HPS) included 5963 people with diabetes, about 
half of whom did not have diagnosed vascular disease at baseline. Overall in 
HPS, allocation to simvastatin 40mg daily reduced LDL-cholesterol by an 
average of 1 mmol/L and among the participants with diabetes there was a 
highly significant 22% (95% CI 13-30; p <0.0001) reduction in major vascular 
events (106). Other RCTs have also shown that lowering LDL-cholesterol 
can significantly reduce the incidence of CHD among participants with 
diabetes (107).  
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An individual participant meta-analysis including 14 RCTs of statins in 90,056 
individuals showed that lowering LDL-cholesterol by 1 mmol with a statin can 
safely reduce the 5-year incidence of major cardiovascular events (including 
major coronary events, coronary revascularisation, and stroke) by about one-
fifth (104). The 19% proportional reduction in CHD death per mmol/L LDL-
cholesterol reduction translated into 14 fewer deaths per 1000 among 
participants with pre-existing CHD. This meta-analysis indicated that the 
proportional reduction in risk of major vascular events was approximately 
related to the absolute reduction in LDL-cholesterol achieved with statin 
treatment in both diabetic and non-diabetic participant groups (64). The role 
of fibrates added to a statin was also investigated in the ACCORD lipid trial, 
but the findings did not support the routine combined use of a fibrate and a 
statin in diabetic patients (108).  
In the Cholesterol Treatment Trialists’ Collaborative meta-analyses of data 
from over 90,000 individuals in 14 trials, 21% of participants had diabetes at 
baseline (64, 104). The incidence of major vascular events in this group was 
reduced by 21% (99% CI 14-28; p<0.0001) per 1 mmol/L lower LDL-
cholesterol concentration (Figure 2.11).  
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Figure 2.11: Proportional effects on major vascular events per mmol/L 
reduction in LDL-cholesterol by baseline prognostic factors in participants 
with diabetes (64) 
Groups Events (%)
Treatment Control RR (CI)    
Type of diabetes:
Type I diabetes 147 (20·5) 196 (26·2) 0·79 (0·62 - 1·01) 
Type 2 diabetes 1318 (15·2) 1586 (18·5) 0·79 (0·72 - 0·87) 
Body mass index:
<25.0 276 (15·7) 362 (20·4) 0·78 (0·64 - 0·95) 
≥25.0,<30.0 639 (15·9) 774 (19·8) 0·77 (0·68 - 0·88) 
≥30.0 532 (15·1) 628 (17·6) 0·82 (0·71 - 0·95) 
Systolic Blood Pressure (mm Hg):
<160 993 (15·0) 1276 (19·1) 0·76 (0·69 - 0·85) 
≥160 472 (17·1) 505 (19·2) 0·83 (0·71 - 0·96) 
All diabetes 1465 (15·6) 1782 (19·2) 0·79 (0·74 - 0·84)
0·5 1·0 1·5
Treatment better Control better
Effect p < 0·00001
RR: 99% or 95% limits
Heterogeneity/Trend test    
21 = 0·0; p = 1·0
21 = 0·5; p = 0·5
21 = 1·3; p = 0·3
LDL cholesterol (mmol/L):
≤3.5 694 (13·9) 812 (16·3)
>3.5,≤4.5 591 (17·0) 721 (21·1)
>4.5 166 (23·0) 216 (30·5)
0·79 (0·69 - 0·92)
0·82 (0·73 - 0·93)
0·78 (0·63 - 0·96)
= 0·0; p = 1·021
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Current guidelines advocate prescribing statins using an individualized 
approach according to calculated cardiovascular risks (Figure 2.12) (109). 
Figure 2.12: Recommendation of statin use per current guidelines with 
cardiovascular risk assessment (109) 
The NICE guidelines recommend that use of statins depends on the 
individualised assessment including blood tests. The assessment before 
recommending statin therapy for the prevention of cardiovascular disease 
includes assessment of smoking status, alcohol consumption, blood 
pressure, body mass index or other measure of obesity, total cholesterol, non
-HDL cholesterol, HDL cholesterol and triglycerides, HbA1c, renal function 
and eGFR, transaminase level (fatty liver), and thyroid-stimulating hormone. 
For the primary prevention of CVD to people with type 2 diabetes who have a 
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10% or greater 10-year risk of developing CVD, statin therapy is 
recommended (NICE guideline CG 181).  
Lifestyle and BMI modification 2.4.4
Aspects of lifestyle, especially less physical activity, and more sedentary 
behavior play a major role in the risk of developing diabetes and, in turn, the 
risk of CVD (110). Lifestyle intervention is an affordable, safe and feasible 
approach for the prevention of CVD. Previous large trials, including the 
Diabetes Prevention Program (DPP), the Finnish Diabetes Prevention Study 
(DPS), the Indian Diabetes Prevention Programme (IDPP) and the Da Qing 
study clearly showed that interventions with diet and exercise can prevent or 
delay diabetes incidence and that these interventions were cost-effective in 
high-risk populations (111-116).  A recent review and meta-analysis which 
included 18 observational studies with 794 577 participants showed that 
higher levels of sedentary (sitting) time (comparing the greatest sedentary 
time compared with the lowest) was associated with an increased risk of 
diabetes (RR 2.12 95% confidence interval (CI) 1.61-2.78),  CVD (RR 2.47 
95% CI 1.44-4.24) and a 90% increase in the risk of cardiovascular mortality 
(HR 1.90 95% CI 1.36-2.66) (117). The Look AHEAD study  (N= 5145 
overweight or obese patients with type 2 diabetes) randomly assigned 
individuals into an intensive lifestyle intervention that promoted weight loss 
through reduced caloric intake and increased physical activity (intervention 
group) or to receive diabetes support and education (control group). Although 
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primary cardiovascular outcomes were not statistically significant (HR in the 
intervention group 0.95, 95% CI 0.83-1.09, P   =0.51) at median follow-up of 
9.6 years, weight loss was greater in the intervention group than in the 
control group throughout the study (8.6% vs. 0.7% at 1 year; 6.0% vs. 3.5% 
at study end). The intensive lifestyle intervention produced greater reductions 
in HbA1C and greater initial improvements in fitness and all cardiovascular 
risk factors (118). A meta-analysis investigating the effects of all lifestyle 
interventions vs standard advice (HR 0.51, 95% CI 0.44 to 0.60, P<0.001) 
reported a relative 49% reduction in risk of developing diabetes(119). Hence 
a healthy diet, regular physical activity, maintaining a healthy body weight 
and avoiding tobacco appear to prevent or delay the onset of type 2 DM and 
its complications including prevention of CHD (19). Newer pharmacological 
treatments are available, such as the medical therapy orlistat, non-surgical 
endoscopic intervention (gastric balloon, endo-barrier) and bariatric 
procedures (Gastric bypass surgery, sleeved gastrectomy) for people with 
morbid obesity. The Swedish Obese Subjects (SOS) study reported, at 15 
years, weight loss (percent of total body weight) was 27 ± 12% for gastric 
bypass, and 13 ± 14% for gastric banding compared with a slight weight gain 
for control subjects (120). Long-term medical (nonsurgical) weight loss rarely 
exceeded 8% of excess weight loss (118). Bariatric surgery in overweight 
and obese people with diabetes improves glycaemic control and is even 
reported to diabetes remission in the early phase of the disease (121). Other 
weight management measures including very low-calorie liquid diet (VLCD) 
has been proven to be beneficial after 1 year, mean (±SD) weight changes of 
11.4 ± 9.1 kg with the VLCD, -6.8 ± 6.4 kg with the LCD, and -5.1 ± 5.9 kg 
60 
with the restricted normal food diet (122) and the amount of weight loss with 
those diet plans was comparable with or without diabetes (123). 
In summary, more than half of the reduction in cardiovascular mortality in the 
last three decades has been attributed to population-level changes in 
cardiovascular risk factors, primarily reductions in cholesterol and blood 
pressure levels and smoking. However, other major risk factors, such as 
obesity, type 2 diabetes, and aging of the population have contributed to an 
increased absolute number of CVD events. Recently, the European Society 
of Cardiology (ESC) and the European Atherosclerosis Society (EAS) 
reviewed the available evidence and set a reasonable and cost-effective 
target approach for cardiovascular disease prevention and Figure 2.13 
describe the treatment target and goals for managing modifiable risk factor 
for cardiovascular disease. 
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Figure 2.13: Treatment target goals for cardiovascular disease prevention 
adopted from 2016 ESC/EAS Guidelines (124) 
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2.5 Role of aspirin and omega-3 FA for primary prevention of 
cardiovascular disease in diabetes 
Aspirin and prevention of cardiovascular disease 2.5.1
Platelets are anucleated blood cells formed by fragmentation of 
megakaryocyte’s cytoplasm, with a maximum circulating life span of 10 days 
in humans (125). Approximately 1011 platelets are produced each day with a 
capacity to increase up to 10 times under conditions of increased demand 
(125). Platelets are a vital component of physiological haemostasis, with the 
capacity to adhere to and accumulate at the site of an injured blood vessel 
wall and to activate the release of biochemical factors to stop bleeding such 
as cytokines, chemokines and growth factors. For example, activated 
platelets synthesize prostanoids such as thromboxane A2 from arachidonic 
acid released from cell membrane phospholipids. Aspirin irreversibly 
acetylates platelet prostaglandin H-synthase 1 or cyclooxygenase-1 (COX 1) 
or H-synthase 2 (COX-2) (Figure 2.14) (126). This results in a reduction in 
thromboxane A2 production (TxA2) which is a potent vasoconstrictor and 
promoter of platelet aggregation. TxA2 rapidly metabolises to thromboxane 
B2 which is then excreted via the urine. It was previously reported that aspirin 
inhibits platelet COX 1 activity by about 95% (127). Platelets produce 70% of 
the thromboxane in the human body and the remaining 30% is produced by 
extra-platelet sources such as monocytes and macrophages in the setting of 
acute inflammation (128). By virtue of these actions, aspirin mediates 
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beneficial anti-inflammatory and anti-platelet effects which may have 
important roles in preventing atherosclerotic risk in individuals with diabetes 
(see Section 2.2 and Figure 2.2 of this chapter). 
Figure 2.14: Arachidonic acid metabolism and mechanism of action of aspirin 
(126) 
For the secondary prevention of cardiovascular disease, it is well established 
that aspirin reduces CVD risk and the proportional benefits appear to be 
similar whether or not such individuals have diabetes (129). Antiplatelet 
therapy is used both for the short-term treatment of patients after an acute 
coronary syndrome event and for secondary prevention in high-risk patients 
who have had a previous MI, stroke or transient ischaemic attack (TIA). 
Aspirin is the most commonly used antiplatelet drug prescribed and a dose of 
75-325 mg is as effective as higher doses for long-term treatment. The 
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collaborative meta-analysis of RCTs of antiplatelet therapy in high-risk 
patients involving 287 studies and 135,000 participants compared antiplatelet 
therapy versus control using an outcome measure of major vascular events: 
(i.e. non-fatal MI, non-fatal stroke or vascular death). The results showed that 
allocation to antiplatelet therapy reduced the combined outcome of any major 
vascular event by about one quarter; non-fatal MI was reduced by one-third, 
non-fatal stroke by one-quarter and vascular mortality by one-sixth. It also 
showed that the absolute benefits in these high-risk patients substantially 
outweighed the absolute risks of major bleeding (130).   
However, the majority of people with diabetes (70-80%) do not have clinically 
established occlusive arterial disease and it is currently unclear whether they 
should take aspirin for primary prevention of major vascular events (MVEs). 
A meta-analysis of individual participant data from six primary prevention 
RCTs, (involving 95,000 individuals, 660,000 person-years, and 3554 serious 
vascular events) showed that aspirin is of uncertain net value (131). Aspirin 
allocation showed a 12% proportional reduction in major vascular events but 
vascular mortality did not differ significantly (Figure 2.15). In contrast, aspirin 
allocation increased the risk of major gastrointestinal and extracranial 
bleeding (131). Although diabetic patients are at higher vascular risk and 
may, therefore, have more to gain from aspirin’s anti-platelet effects, they are 
also at greater risk of bleeding than non-diabetic patients (131) and aspirin 
will increase this risk. Other meta-analyses of aspirin for primary prevention 
of CVD results suggest a modest (~9%) relative reduction in risk for CVD 
events, however, ≥2-fold increase relative risk of bleeding, mainly from the 
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gastrointestinal system (132-134). However, the majority of people with 
diabetes do not have established occlusive arterial disease. In this 
intermediate-risk group, it is unclear whether they should take aspirin for the 
primary prevention of cardiovascular disease. Hence there is a need for more 
randomised evidence to explore aspirin’s safety and efficacy in this context. 
The large ASCEND study was established to address this question and is the 
largest ongoing primary prevention trial of aspirin in diabetes. 
Figure 2.15: Serious vascular events in primary prevention trials-proportional 
effects of aspirin allocation (131) 
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Aspirin resistance 2.5.2
Aspirin reduces the risk of cardiovascular disease by about 25% in patients 
with vascular disease, which is believed to result from its ability to reduce 
clotting via its antiplatelet effect (131).  The term “aspirin resistance” has 
been used in the literature to describe variability in the response to aspirin’s 
antiplatelet activity especially in patients with diabetes. Aspirin resistance is 
thought to be due to a failure to adequately suppress thromboxane 
generation resulting in an increased risk of occlusive events. Although the 
exact causes are still unclear, the possible mechanisms include rapid platelet 
turnover, possible extra-platelet sources of thromboxane A production, and 
drug interactions, for example, NSAIDs competing with aspirin for a common 
molecular action site (126). In aspirin resistance, the assumption is that 
aspirin either fails to suppress TxA2 production or incompletely inhibits COX-
1 leading to the faster recovery of platelet COX-1 activity (135). The 
implication of faster recovery of COX-1 activity is that once-daily dosing may 
not be adequate to achieve sustained suppression of COX-1 and that some 
patients may need a twice-daily regimen in order to maintain complete 
suppression of TxA2 production (136). 
Aspirin irreversibly acetylates platelet prostaglandin H-synthase 1 or 
cyclooxygenase-1 (COX 1) or H-synthase 2 (COX-2) (as described earlier 
Figure 2.9). The half-life of TxA2 is very short (about 30 seconds). It is rapidly 
converted to its stable metabolite, thromboxane B2 (TxB2) (137). Trials have 
been conducted to assess aspirin resistance using urinary thromboxane B2 
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(UTxB2) as a biomarker of in-vivo thromboxane generation. In the Heart 
Outcomes Prevention Evaluation (HOPE) Study, UTxB2 was measured in 
488 people treated with aspirin who had a myocardial infarction, stroke, or 
cardiovascular death during 5 years of follow-up and in 488 sex- and age-
matched control subjects also receiving aspirin who did not have an event 
(138). It was reported that among aspirin-treated patients at high risk of 
cardiovascular events, persistent thromboxane generation predicts the risk of 
the cardiovascular outcomes. It was also suggested that high UTxB2 can 
prospectively identify aspirin resistance patients (138). The Leukotrienes and 
Thromboxane In Myocardial Infarction (LTIMI) study (n=60+119) also 
evaluated the relationship between UTxB2 and MVEs in patients with acute 
myocardial infarction (AMI) (139). The study found that UTxB2 levels 
predicted the 1-year cumulative MVEs in AMI patients and they provide 
prognostic information on the left ventricular performance (139). This recent 
trial result also supported the utility of UTxB2 measurements as a predictive 
biomarker of MVEs in high-risk patients. 
It has been suggested that the clinical efficacy of low-dose aspirin in patients 
with diabetes may be substantially lower than in people without diabetes 
(140-142). In two small studies, there was reduced response to antiplatelet 
activity in people with diabetes. Using a platelet function analyser (PFA)-100, 
both studies measured levels of TxB2, platelet aggregation (PA), and platelet 
COX-1 and COX-2 expression. There was a suggestion of a higher dose of 
aspirin being required by people with DM to achieve full TxA2 suppression 
and to have a desired cardioprotective effect (143, 144). Differing levels of 
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UTxB2 were measured before and after aspirin therapy in people with type 2 
DM, indicating the biological variability of TxA2 suppression by aspirin (145). 
It was also thought that there is the faster recovery of inhibition of 
prostaglandin synthesis from arachidonic acid (AA-dependent platelet 
function) and rapid platelet turnover in diabetes (146). However, a further 
study from the same research group concluded that variability in the recovery 
of platelet COX activity after low-dose aspirin occurs in patients with and 
without diabetes and is related more to BMI (147).  
A single-centre, randomised, prospective double-blind study examined the 
effect of 2-week treatment periods with aspirin 100 mg once daily, 200 mg 
once daily or 100 mg twice daily in people with diabetes without a pre-
existing cardiovascular event (148). The UTxB2 reduction was greater with 
100 mg twice daily dosing in type 2 diabetes compared with once-daily 
dosing prompting the need for the further trials evaluating the effects of twice-
daily dosing for prevention of cardiovascular outcomes (148).  
Although some studies report a lack of suppression of COX2 by aspirin in 
diabetes, others report no difference in UTxB2 measurement in people with 
or without diabetes after taking aspirin. One study reported (n=161) that 
aspirin treatment inhibited UTxB2 by 72.5% in diabetic patients and by 75.1% 
in controls and in that study there was no statistically significant difference 
between diabetic and control patients in the proportion labelled as poor 
aspirin responders defined by their UTxB2/mg creatinine ratio being higher 
than 1500 pg (127). Our own small pilot study (n=11) showed similar results 
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with a change in UTxB2 after aspirin of 68.15% ± 8.65 (mean ± SD) in 
healthy volunteers.  
Therefore, it would be helpful to know that TxA2 is adequately suppressed in 
patients taking aspirin in ASCEND to help inform the interpretation and 
generalizability of the results in patients with diabetes. The pilot study in 
ASCEND also represents an opportunity to assess the time-dependent 
recovery of platelet COX-1 activity during once-daily dosing of aspirin, by 
profiling the concentration of aspirin metabolites over time. Further 
discussion on the plausible markers of compliance with aspirin and 
measurement of urinary thromboxane B2 in ASCEND will be described in the 
methodology chapter, section 3.4. 
Omega-3 FA and prevention of cardiovascular disease 2.5.3
Omega-3 FAs are n-3 polyunsaturated fatty acids (3-PUFA) that humans are 
unable to synthesize de novo. The principal n-3 PUFAs [eicosapentaenoic 
acid (EPA, 20:5n–3) and docosahexaenoic acid (DHA, 22:6n–3)] are either 
synthesized from α-linolenic acid (ALA, 18:3n-3) (Figure 2.16) or absorbed 
from the diet as a pre-formed nutrient. ALA is an essential fatty acid for 
humans and cannot be synthesized from saturated fatty acids. Humans are 
unable to insert a double bond at the C-15 position of a fatty acid carbon 
chain because of a lack of the desaturase enzyme (149). Oily fish and 
various other seafoods are rich in omega-3 FA. Many dietary 
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recommendations encourage people to consume fish meals twice a week 
(preferably containing oily fish). Omega-3 FA is consumed by individuals for 
prevention of cardiovascular and other disease outcomes, but whether such 
supplements are beneficial is uncertain.  
Figure 2.16: Biosynthesis of docosahexaenoic acid (DHA) from alpha-
linolenic acid (ALA) (Adopted from Philip Calder, Journal of Nutrition (150)) 
The possible link between 3-PUFA and the prevention of CVD was first 
recognised in the 1940s after very low rates of CHD were observed among 
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Greenland Eskimos compared to native Danish populations (151). Greenland 
Eskimos typically consumed a greater intake of dietary fish compared to the 
Danes, despite high total fat intakes in both groups. Since then the possible 
cardioprotective effects of 3-PUFA or fish intake have been tested in various 
secondary prevention trials published before ASCEND was designed, which 
suggested a modest benefit of supplementation with omega-3 FA (152-154).  
2.5.3.1 Possible effects of omega-3 FA on cardiovascular disease 
The possible effects of omega-3 FA on cardiovascular disease have been 
extensively investigated. Previous reports suggest that omega-3 FA can 
increase arrhythmic thresholds, reduce blood pressure, improve arterial and 
endothelial function, reduce platelet aggregation, and has effects on 
lipids(155). Figure 2.17 summarises the beneficial cardiovascular protective 
effects of omega-3 FA on lipids, blood vessels, and platelets. 
Figure 2.17: Beneficial effects of omega-3 fatty acids. TG, triglycerides; RLP, 
remnant lipoproteins; RBC, red blood cells (155) 
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Triglycerides and lipoproteins 
It was first reported that fish oil has an effect on lipoproteins in 1977 after a 
scientist put himself on an Inuit diet which had very high content of omega-3 
FA for 100 days (156). A reduction in the triglyceride-rich VLDL cholesterol 
was observed, along with an increase in HDL-cholesterol. The dose-
dependent effect of omega-3 FA to lower triglycerides (TG) is now well 
recognised (157). Various possible mechanisms for lowering TGs have been 
proposed. It appears that reduction of the fatty acid delivery to the liver 
reduces denovo lipogenesis, which is the process of converting 
carbohydrates into fat and is an important step in reducing the fatty acid 
availability for TG synthesis (158).  
A systematic review and meta-analysis of 23 RCTs in type 2 DM (with a 
mean treatment duration of about 9 weeks with a mean dose of omega-3 FA 
of 3.5 g/day) concluded that omega-3 FAs significantly reduced plasma 
levels of TG by 25% (mean: 0.45 mmol/L), VLDL-cholesterol by 36% (mean: 
0.07 mmol/L) and VLDL-TG by 39.7% (mean: 0.44 mmol/L), and a slightly 
increased LDL-c (mean: 5.7% (159). Another meta-analysis of 26 trials also 
reported a similar TG-lowering effect with a reduction by almost 30% (160). 
Recently the possible different effects of DHA and EPA on cardiovascular 
outcomes were investigated given their different effects on lipoproteins (161, 
162). A systematic review and meta-analysis of randomised placebo-
controlled trials of monotherapy with EPA (n=10), DHA (n=17) or EPA versus 
DHA (n=6) reported that although both EPA and DHA reduce triglyceride, 
DHA increased LDL-c, while EPA non-significantly reduced LDL-c (161). 
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However, it was not clear what the underlying mechanism might be or what 
the significance of these differences might be on clinical outcomes in clinical 
trials. However, neither of these meta-analyses explored the effects of higher 
doses of omega-3 FA on lipoprotein levels. In hypertriglyceridemic patients, 
supplementation with omega-3 FA lowers triglycerides level modestly and 
omega-3 FA can be considered as a reasonable therapeutic strategy in these 
individuals to prevent cardiovascular disease. 
Effects of omega-3 FA on blood glucose 
Early non-randomised studies in individuals with type 2 diabetes suggested 
that omega-3 FA might have an impact on glycemic control. One study used 
a high dose of omega-3 FA (8g/day) for 8 weeks duration in people with 
diabetes and reported that after omega-3 FA supplementation, fasting 
plasma glucose levels increased by 22% (p=0.005) and meal-stimulated 
glucose increased by 35% (P=0.036) (163). Similar result was reported in a 
small study (N=6) after 1 month of dietary omega-3 FA supplement (164). in 
a prospective study (36,328 women, mean age: 54.6 y, follow-up from 1992 
to 2008) suggested an increased risk of type 2 diabetes with the intake of 
long-chain omega-3 fatty acids, especially with higher intakes (>/= 0.20 g 
omega-3/d or >/= 2 servings of fish/d) (165).The diagnosis of diabetes in this 
trial was self-reported. Since then, RCTs were done for further investigation 
on this aspect and, a meta-analysis of 26 RCTs reported that the use of 
omega-3 FA has no adverse effects on HbA1c in people with diabetes 
treated with omega-3 FA supplementation. Fasting blood glucose levels were 
slightly increased with  in non-insulin dependent DM (0.43 mmol/l [95% CI, 
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0.00-0.87], P = 0.06) and were significantly lower in insulin dependent DM 
subjects (-1.86 mmol/l [95% CI, -3.1 to -0.61], P < 0.05) (160). Another 
systematic review included 18 RCTs with a mean duration of 12 weeks with 
doses ranging from 3 to 18 g/day reported no significant effects of omega-3 
FA on glycaemic control (166). A Cochrane review including 23 RCTs 
confirmed that there were no statistically significant effects of omega-3 FA on 
glycaemic control or on fasting insulin concentration (167). A recent review 
and meta-analysis included 540 184 individuals also came to a similar 
conclusion that omega-3 FA intake was not associated with an increased 
incidence of type 2 diabetes (168).  Hence, although there were some 
suggestion that omega-3 FA supplementation in people with diabetes can 
increase blood glucose in early non-randomised and observational trials, 
many RCTs, reviews and meta-analysis do not suggest this but show no 
effects on HbA1c or blood sugar level in people with diabetes. 
Effects of omega-3 FA on cardiac rhythm 
There are suggestions of effects of omega-3 FA on ventricular arrhythmia, 
sudden cardiac death, and atrial fibrillation (AF) mainly post-operative AF. 
Animal studies suggested both direct and indirect anti-arrhythmic effects of 
omega-3 FA mediated by anti-oxidant, anti-inflammatory, and anti-fibrotic 
properties (169). Some animal and epidemiological evidence suggests an 
inverse association between the incidence of sudden cardiac death and high 
dietary omega-3 FA intake (170). These observations prompted trials to 
assess the possible anti-arrhythmic effects of omega-3 FA have been 
investigated since. In a meta-analysis of 27 animal studies, DHA and EPA 
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appeared to have protective effects against ventricular tachycardia and 
ventricular fibrillation in ischaemia but not on reperfusion-induced 
arrhythmias (171).  
Several clinical trials which examined the anti-arrhythmic effect of omega-3 
FA have reported results. The hypothesis that fish consumption may 
protective against sudden cardiac death was derived from the DART trial 
which showed a 33% reduction in cardiac mortality in people who consumed 
at least two portions of fatty fish weekly. One population-based case-control 
study suggested that omega-3 FA level in the RBC membrane was directly 
related to a reduced rate of primary cardiac arrest (172). However, further 
RCTs have failed to confirm these results. The Omega-3 Fatty Acids for 
Prevention of Post-operative Atrial Fibrillation (OPERA) RCT (N=1516 
patients scheduled for cardiac surgery), where perioperative supplementation 
with omega-3 FA compared with placebo, reported no reduction of the risk of 
postoperative AF (173). Another RCT (N=200) was conducted to determine 
whether omega-3 FA supplementation may have beneficial antiarrhythmic 
effects in people with a history of sustained ventricular tachycardia (VT) or 
ventricular fibrillation (VF) and reported that among patients with a recent 
episode of sustained ventricular arrhythmia and an ICD, omega-3 FA 
supplementation does not reduce the risk of VT/VF but the possible signal 
that this could be pro-arrhythmic (174). Other RCTs including the Study on 
Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) RCT (175) 
investigating the effect of omega-3 FA on ventricular arrhythmias in people 
with ICD devices and meta-analysis of RCTs, those did not show any 
76 
reduction in ICD discharge but indicated heterogeneous responses among 
those people to fish-oil supplementation (176). The heterogeneity results of 
the effect of omega-3 FA from earlier animal and observational studies and 
later RCTs could result from the different underlying pathophysiological 
mechanisms of cardiac arrhythmias (e.g. ischaemia, reperfusion, scarring, 
and inflammation) and different background diet and intake of fish. In 
summary, the effect of supplementation of omega-3 FA on prevention of 
cardiac arrhythmias is still uncertain and it is still difficult to predict or confirm 
the exact pathophysiological pathway affected by the supplementation in the 
myocardium. Recent RCTs on cardiovascular outcome not directed to the 
anti-arrhythmic effect of omega-3 FA will be discussed in the OTTC meta-
analysis section of this thesis (section 4.1). 
Possible anti-thrombotic effects 
Omega-3 FA has been shown to have a wide range of antiatherosclerotic 
and antithrombotic effects in animal and human studies. Omega-3 FA causes 
a reduction in synthesis of thromboxane A2, a potent promoter of platelet 
aggregation, and an increase in the formation of thromboxane A3, which is a 
weak platelet aggregation factor (177). Omega-3 FAs at a very high dose 
may increase bleeding time (e.g. 15 g/day) but up to 3g/day appears to be 
safe in clinical practice and without any untoward effects (178). Recent study 
also reported the safe consumption of omega-3 FA, even at short-term doses 
up to 10 g/day or consumed for up to 52 weeks above 1.5 g/day, in selected 
vulnerable populations such as subjects with gastrointestinal cancer or 
patients in an intensive care unit (177). Several clinical trials have 
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investigated whether omega-3 FA alters fibrin clot properties in patients 
undergoing percutaneous coronary intervention (OMEGA-PCI clot) and they 
reported favorable antithrombotic effects induced by omega-3 FA (179).  
Omega-3 FA supplementation and ASCEND  
The possible mechanisms of omega-3 FA, theoretically, should be beneficial 
in the pathogenesis of atherosclerosis in diabetes.  Review of the literature 
as discussed earlier, demonstrated shows that omega-3 FA consistently 
lower elevated plasma TG levels in a dose-dependent fashion; smaller 
effects on increasing plasma levels of HDL; no consistent effects on other 
lipids, plasma glucose level, anti-arrhythmia or plaque stabilization 
parameters but no bleeding risks have been identified. However, uncertainty 
remains about their role in primary prevention. Since the ASCEND trial was 
started, several large RCTs have been reported which have investigated the 
role of omega-3 FA in the prevention of cardiovascular disease but results 
have been conflicting (180, 181). To help clarify the role of omega-3 FA 
supplementation for cardiovascular disease prevention, a tabular data meta-
analysis of RCTs of omega-3 FA supplementation was undertaken. This 
meta-analysis forms the first part of the results chapter of this thesis.  
Biochemical effectiveness of study medications 2.5.4
Monitoring the biochemical effectiveness of trial medication is helpful during an 
RCT to ensure that the intervention is producing its expected effect(s) thus 
allowing the trial to address its hypothesis. The thesis includes a literature 
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review of the biochemical methods used in ASCEND to investigate the 
biochemical effectiveness of aspirin and omega-3 FA. 
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3 Methodology 
3.1 Overview of the ASCEND trial: methods, baseline characteristics, 
monitoring and plans to ensure good compliance 
In light of the uncertainty around the value of aspirin and omega-3 FA for 
primary prevention in diabetes, “A Study of Cardiovascular disease iN 
Diabetes” known as ASCEND was established with funding from the British 
Heart Foundation. ASCEND is a large mail-based, ongoing randomised trial 
of aspirin 100 mg daily and/or omega-3 FA 1 g daily (Figure 3.1) (182). The 
Anti-Thrombotic Trialists’ (ATT) collaborative meta-analysis of previous trials 
found that high doses of 500-1500 mg aspirin daily (which are more 
gastrotoxic) were no more effective than lower doses of 75-100 mg/day either 
in direct comparisons or in indirect comparisons (130). As a consequence, 
daily doses of 75-150 mg are generally preferred for long-term treatment as 
protection against serious vascular events in high-risk patients. Hence, a 
daily dose of 100 mg aspirin was selected to use in ASCEND. In the large 
GISSI Prevenzione trial, 90% of participants were taking aspirin, but no 
excess of bleeding was observed with the addition of 1 g omega-3 FA daily. 
The only side-effects reported in that open-label study were a slight fishy 
after-taste and some gastrointestinal disturbances, but only 3.8% of 
participants stopped their omega-3 FA supplements because of these side 
effects (153). For ASCEND, a daily dose of approximately 1 g of omega-3 FA  
(0.4 g EPA and 0.3 g DHA were used (as in GISSI), which can be 
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conveniently provided in 1 capsule of the concentrated preparation (with 
matching placebo capsules containing olive oil). ASCEND aims to 
demonstrate whether aspirin and/or omega-3 FAs, safely reduces the risk of 
cardiovascular events in individuals with diabetes who do not already have 
diagnosed occlusive arterial disease (183). Most prevalent cases of diabetes 
in young and middle age are unlikely to have a history of vascular disease. A 
recent US survey reported that an estimated 27% of adults with diabetes had 
CVD, and an additional 71% have one or more CVD risk factors (184). 
Aspirin was used regularly by 37% of those with CVD and by 13% of those 
without CVD (184). The people with diabetes entered into the UK Prospective 
Diabetes Study were aged between 25 and 65 (mean age 52 years) and only 
33% had either an abnormal ECG or retinopathy, but the remainder did not 
have any clinical cardiovascular disease (185). Hence when ASCEND was 
planned, it was estimated that up to 70% of people with diabetes who were 
young or middle-aged did not have established a clinical diagnosis of 
cardiovascular disease.  Between 2005 and 2011, 15 480 diabetic individuals 
from around the UK were randomised and are being followed up with a 
planned average duration of 7.5 years, concluding in late 2017. This chapter 
provides a summary overview of the trial’s design including its recruitment 
methods, follow-up procedures, and measures in place for maintaining 
compliance. (Detailed background to the trial, including sample size 
calculations, are provided in the ASCEND protocol including in the appendix 
of this thesis) 
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3.1.1.1 Central coordination and local coordination 
The Clinical Trial Service Unit (CTSU) at Oxford University coordinated 
ASCEND and had overall responsibility for the administration and analysis of 
the trial. CTSU was responsible for obtaining Multicentre Research Ethics 
Committee approval; for the identification (with the assistance of the local 
medical collaborators and GPs), of potentially eligible participants; for 
obtaining any relevant permissions to invite suitable patients to participate; 
for all initial invitations of participants, subsequent randomisation and follow-
up by mail; and finally for the provision of a 24-hour Freefone telephone 
82 
giving clinical or administrative support to participants, their relatives or 
carers, or healthcare professionals involved in their care 
3.1.1.2 Identification of participants 
The main challenge of recruitment was to identify a large number of 
potentially suitable individuals to be able to randomise at least 15,000 eligible 
patients. Randomisation of 15,000 patients with a follow-up of 7.5 years 
should provide robust statistical power (i.e. >90% at 2p<0.05) to detect 
plausible risk reductions of 12-15% with an estimated annual vascular event 
rate of 1.3 % (Further details about power calculations are provided in the 
ASCEND protocol in the appendix of this thesis). Potential study participants 
with diabetes were sought from 3 main sources: 1) diabetes registers, 2) trial 
databases and 3) general practice registers. Consultants from around the UK 
were invited to collaborate and allow invitation of potentially eligible 
individuals from locally held diabetes registers (such as those held for 
retinopathy screening or for service provision). Other people with diabetes 
were identified from among the populations taking part in the Heart 
Protection Study and other trials that were coordinated by CTSU. In order to 
streamline the invitation process, the contact details of potentially eligible 
people were sought electronically whenever possible, to allow central 
mailings in the name of the local doctor. This approach enabled large 
numbers to be recruited and was more efficient and cost-effective than 
mailings sent from individual centres or practices. It also facilitated over-
selection of certain groups (e.g. older individuals) to ensure an appropriate 
balance of different subtypes of the participants. The third source of potential 
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participants came from general practices. Randomised participants were also 
able to recommend any friend or relative they thought might be eligible and 
interested in participating in the study. Finally, people with diabetes could 
volunteer themselves if they heard about the study from any source.  
In addition, with the collaboration of the Diabetes Research Network (DRN) 
and the Primary Care Research Network (PCRN), general practices (GP) 
agreed to send pre-assembled invitation packs to people on their locally held 
registers. Responses from participants were collected on questionnaires, 
which were returned to the coordinating centre. The data were entered into 
the coordinating centre computer (following an operating procedure for data 
handling). Overall recruitment status by route is summarised in Table 3.1. A 
total of 423,403 potentially eligible individuals were invited via the different 
routes of recruitment, of whom 29% (121,254 people) returned a screening 
questionnaire to the coordinating centre. About two-thirds of those who 
responded declined to join the trial and a further 14,000 did not meet the 
eligibility criteria. After review of the questionnaire data, 26,462 participants 
(6% of those originally invited) were willing and eligible to join ASCEND and 
entered the 2-month run-in period. About 40% of all patients who entered the 
run-in dropped out before randomization. Around half of those who dropped 
out prior to randomisation had no clinical reason to stop the trial but simply 
declined to continue, highlighting the value of a run-in period in the trial 
design. Without this pre-randomization phase, many such withdrawals may 
have occurred shortly after randomization, resulting in a substantial reduction 
in the statistical power of the trial. Towards the end of the 2-month run-in, 
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randomization questionnaires were sent to 22,579 patients. Of these, 15,480 
people returned a completed questionnaire, indicating that they were still 
willing and eligible to be randomised into ASCEND. Overall 3.7% of all 
individuals invited were randomised into ASCEND (Table 3.1).  
3.1.1.3 Summary of recruitment 
The detailed methodology is described in the trial protocol of the ASCEND 
trial (183) (Figure. 3.2 summarises practical procedures for recruitment into 
ASCEND). To facilitate recruitment, the trial design was straightforward with 
simple inclusion and exclusion criteria. Double sided A3 questionnaires were 
used for screening, randomisation, and follow-up. Potentially suitable patients 
who were identified from any source were invited to take part by letter. The 
invitation letter also enclosed an information leaflet and a Screening 
questionnaire that was intended to help the coordinating centre determine 
eligibility and to confirm consent to participate, along with a Freepost return 
envelope. Preliminary eligibility for the pre-randomisation run-in phase was 
based on information provided on the completed Screening questionnaire 
(i.e. diagnosis of diabetes, no history of diagnosed occlusive arterial disease, 
no contraindication to regular aspirin and signed a consent to participate). 
Once those forms were returned, database algorithms and review by clinical 
staff were used to confirm eligibility to take part. 
Run-in packs of medication were sent to all eligible patients. ASCEND had a 
placebo run-in phase, which used placebo aspirin tablets and placebo 
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omega-3 FA capsules. The purpose of this was to ensure that only those 
patients who were compliant with study treatment and still enthusiastic about 
participating were randomised into the trial. About 2-4 weeks after the run-in 
pack was sent, participants were sent an optional blood and urine sampling 
kit, and asked to take this kit to their general practice for sample collection. 
Those samples were then mailed to the central laboratory in the containers 
provided. A supplementary information leaflet was provided and separate 
consent sought for this 5-10ml blood and urine collection which allowed 
baseline stratification by important biochemical prognostic variables. About 2 
months after the run-in pack was sent, a randomisation questionnaire was 
mailed. If participants were still willing and eligible, they were randomised to 
the trial. 







Others * Total 
Invitations sent 300188 120875 2223 423286 
Forms returned 101323 19930 1262 122507 
Patients enter Run-in 16104 9741 635 26480 
Drop out during Run-in 5009 2496 144 7648 










*HPS study database/self-referral/Friend and Family  
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Figure 3.2 Summary of practical procedures in trial recruitment 
Potentially eligible
 Diabetes mellitus (type 1 or 2) 
 Male or female 
 No diagnosed occlusive arterial disease 
 Aged ≥ 40 years 
Identification and invitation
 Potentially eligible patients identified from existing diabetes registers or 
databases and other sources 
 Invited by GP, diabetologist or study coordinators, either in person or 
by mail. Invitation includes Information Leaflet, Consent Form, and brief 
Screening Questionnaire  
 Central Freefone number for any questions 
Screening process (-2 months) 
 Screening Questionnaire returned, which identifies eligible and 
consenting patients 
 Run-in pack with 2-month supply of placebo treatment mailed to patient 
 GP informed of patient's possible participation and asked to return form 
if patient not to be randomised 
 Blood and urine samples (optional) collected locally and mailed to 
central laboratory 
 Freefone number (0800 585323) for medical advice and any questions 
Randomisation (0 months) 
 Randomisation Questionnaire sent to re-confirm eligibility, and to 
characterize the patient more fully 
 Randomisation Questionnaire returned, and eligible patient randomised 
by central computer 
 Allocated treatment pack mailed to patient: 100 mg aspirin daily or 
matching placebo tablet, and 1g omega-3 FA daily or matching 
placebo capsule 
 GP informed of patient's randomisation 
Follow-up questionnaires (6-monthly)
 Follow-up Questionnaires and treatment packs sent 6-monthly  
 Freefone number (0800 585323) for medical advice and any questions 
 Further details sought from responsible clinicians about any relevant 
events reported on Follow-up questionnaires  
 Flagging for mortality and cancer at central registries
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Baseline characteristics 3.1.2
The baseline characteristics of the 15,480 randomised ASCEND participants 
are summarized in Table 3.2. A total of 15,480 people with diabetes 
throughout the UK, with an average age of 63 years (mean (SD) 62.8 (9.2)) 
were randomised into ASCEND between 2005 and 2011. Of these, 96% 
were Caucasian, 63% were men (9684 participants), and 94% (14 559 
participants) had type 2 diabetes. The diagnosis of diabetes was based on a 
broad clinical definition involving age of diagnosis, use of insulin within one 
year of diagnosis and BMI. About 46% (7201participants) are obese with BMI 
(kg/m2) ≥30. The mean duration of diabetes before randomisation was 9.8 
years (SD 9.4). At randomisation, 8% (1280 participants) were reported as 
current smokers, 62% (9534 participants) reported having hypertension, and 
20% (3023 participants) reported having diabetic retinopathy. Prior to joining 
ASCEND, 36% (5508 participants) were taking regular aspirin. Both they and 
their GP were happy for them to stop it in order to participate in the trial. 
Table 3.3 shows the principal non-study treatments being used at 
randomisation. During run-in, baseline blood and urine sample were sent. 
74% of all randomised patients returned their samples. Among those, the 
mean HbA1c was 55 mmol/mol or 7.2% (SD 1.2), the mean total cholesterol 
level was 4.2 mmol/L (SD 0.9), and mean eGFR was 94 (SD 34) (Table 3.2). 
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Table 3.2: Baseline characteristics of 15,480 randomised patients  
Sex 
     Male 9684 (63%) 
     Female 5796 (37%) 
Age (years) 
    <50 1090 (7%)  
    ≥50, <60 4501 (29%)  
    ≥60, <70 6247 (40%)  
    ≥70 3643 (24%)  
Mean age (SD) 62.8 (9.2) 
Ethnic Origin 
    White 14935 (96%) 
Diabetes type 2 14559 (94%) 
BMI (kg/m2) 
    <25 2250 (15%)  
    ≥25, <30 5529 (36%)  
    ≥30 7201 (46%)  
Mean BMI (SD) 30.7 (6.2) 
Duration of diabetes (years) 
    <5 4891 (31%)  
    ≥5,<10 4334 (28%)  
    ≥10, <20 3538 (23%)  
    >20 1862 (12%)  
Mean duration of diabetes (SD) 9.8 (9.4) 
Other Cardiovascular Risk Factors 
    Reported Hypertension 9534 (62%) 
    Current Smoker 1280 (8%) 
    Diabetic retinopathy 3023      (20%) 
Biochemical measurement 
    Mean HbA1c (%) (SD) 7.2 (1.2)  
    Mean total cholesterol (mmol/L) (SD) 4.2 (0.9)  
    Mean eGFR (SD) 94 (34)  
    Albuminuria present 1603 (10%)  
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Table 3.3: The principal non-study treatments being used at randomisation 
ACE inhibitor = angiotensin converting enzyme inhibitor, Ca channel blocker 
= calcium channel blocker, ARB =angiotensin receptor blocker 
It was recorded that only 205 individuals (1.6% of all participants in 
ASCEND) reported taking Omega-3 FA supplementation at randomisation as 
participants were asked to avoid any form of fish oil supplementation during 
run-in and in the trial. 
Strategies to ensure good compliance in ASCEND 3.1.3
The success of RCTs is highly dependent on both maintaining compliance 
with the study treatments and ensuring complete follow-up of all participants 
irrespective of whether they are still continuing to take their allocated study 
treatments in order to ensure unbiased complete ascertainment of all 
Treatment N (%)
Insulin 3931 25% 
Metformin 10093 65% 
Sulphonylurea 4145 27% 
ACE inhibitor 6625 43% 
ARB 2634 17% 
Beta-blocker 2024 13% 
Ca channel blocker 3773 24% 
Statin 11653 75% 
Thiazide or related diuretics 2930 19% 
Aspirin (at screening) 5508 36% 
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relevant study outcomes. Maintaining compliance with study treatment by 
participants can be the most labour-intensive and difficult phase of trials 
particularly for long-term mail-based trials like ASCEND.  
During a trial, it was important to monitor the degree of compliance with 
treatment: a) to understand whether the statistical power of the study to 
address its aims is being maintained; b) to develop and implement strategies 
for improving it if it is falling to unacceptable levels; and c) to allow any 
treatment effect to be interpreted in the light of the in-trial compliance. Poor 
compliance can have a major adverse effect on the statistical power of a 
study to detect a clinically relevant treatment effect. For a clinical endpoint 
study, such as ASCEND, the statistical power is inversely proportional to the 
square of the compliance, indicating that relatively small losses of 
compliance can have a large impact on the study power.  
3.1.3.1 Previous successful experience of conducting cost-effective 
randomised trials by mail 
Both aspirin and omega-3 FA are widely available and used, the hazards are 
low and well characterised, and neither requires biochemical monitoring. 
Several large RCTs have been conducted using mailed drug supply and 
follow-up, including the CTSU-coordinated British Doctors’ Study (186) and 
the (first) US Physicians Health Study (187) of aspirin for the prevention of 
MI. Other large studies (188, 189) of either aspirin or various supplements 
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being conducted entirely by mail in the US: the (second) US Physicians’ 
Health Study ll, the Women’s Antioxidant Study (WACS) and the Women’s 
Health Study (WHS) also run by mail. Experience from these studies shows 
that with information leaflets, consent forms and questionnaires, good 
response rates and compliance can be achieved and reliable information 
about medical events gathered. In addition, the 24-hour Freefone service 
established by CTSU for other large heart disease trials allows study 
participants to discuss any aspects of the study with experienced clinical staff 
and so helps ensure good compliance and the early identification of serious 
problems. 
Follow-up methods in ASCEND 3.1.4
3.1.4.1 6-Monthly follow-up questionnaires sent by mail (with telephone 
back-up) 
Follow-up questionnaires were sent to all ASCEND participants on a 6-
monthly basis. The questionnaire included questions on cardiovascular 
events, other serious adverse events (including bleeding episodes), 
compliance with study treatment and use of relevant non-study treatments. 
Questions on the questionnaire were designed in collaboration with patient 
forums to ensure that the wording was easily understandable. Supplies of the 
participant’s allocated study treatment are also mailed with the follow-up 
questionnaires 6-monthly. All randomised patients were encouraged to return 
their questionnaire, but if forms were not returned, up to 2 mailed reminders 
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are then sent. If there is still no response, following reminders, a study 
administrator telephoned the patient in order to complete the Follow-up 
questionnaire. At the time of writing, about 86% of live participants had 
returned a follow-up form within the last year and 89% within the last 18 
months. Additional efforts were used, including direct contact of those 
participants who did not return questionnaires to ensure that as many as 
possible were accounted for and ensure complete follow-up. The remaining 
participants were being followed-up via their general practitioner. In addition, 
data were sought on all hospital admissions and on deaths and cancers from 
the Health and Social Care Information Centre and other central registries. 
All randomised patients were flagged through the Office for National 
Statistics and other central registries for death, cancer and other relevant 
events. Consequently, unbiased cause-specific mortality and site-specific 
cancer incidence data for all patients could be obtained, independent of 
whether they were still complying with study medication or responding to 
questionnaires (190). 
3.1.4.2 Maintaining compliance in ASCEND 
The follow-up questionnaire included questions about compliance over the 
previous 6 months. Participants were asked how regularly they have taken 
their tablets (aspirin or placebo) or capsules (omega-3 FA or placebo) in the 
last 6 months with the options of every day, most days, only occasionally or 
never. The first two categories (every day and most days) were defined as 
being “compliant” and last two as “non-compliant”. Once forms arrived back 
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to CTSU, they were electronically scanned and reviewed by administrative 
staff. If queries arose they were also reviewed by clinical staff. I have 
reviewed several thousand follow-up forms which dealt with clinical queries 
and recorded relevant reported events in the study database. Keeping in 
touch with participants is crucial. In order to maintain enthusiasm for the trial 
and encourage compliance, I have been responsible for writing 6 monthly 
newsletters which were also mailed to participants. Each newsletter updated 
participants about the study, reassured patients about alarmist reports about 
aspirin or fish oils in the popular media, introduced team members from 
CTSU, and presented interesting stories that were invited from other trial 
participants. One example was when there were media reports on the use of 
aspirin for prevention of colon cancer, the number of telephone calls from 
participants of ASCEND increased and I prepared a special edition of the 
newsletter with a summary of available evidence on this subject at that time. 
Emphasis was always placed on the importance of continuing trial medication 
and reporting adverse events, and contact details were provided for 
participants to call CTSU to discuss any concerns with a member of the 
team.  
By the estimated mid-point of the study (45 months), over two-thirds (69%) of 
those allocated aspirin or placebo remained compliant (i.e. taking treatment 
most days) with their allocated treatment (which is comparable with other 
studies in the Antithrombotic Trialists' (ATT) Collaboration). For the omega-3 
FA or placebo capsules, the proportion reporting taking study treatment most 
days was higher at 78%. Of those who have stopped their study aspirin or 
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placebo, about 40% gave no specific reason except wishing to stop (many of 
whom have been in the study for several years), a further 17% were taking 
aspirin for a clinical reason (some of whom will have had a primary endpoint 
or report angina), 8% were taking aspirin by choice but without a clear clinical 
indication, 7% reported a variety of other symptoms as reasons for non-
compliance, 6% have upper gastrointestinal symptoms and 6% are taking a 
contra-indicated drug (mainly anti-coagulants), the remainder give a variety 
of other medical or non-medical reasons for discontinuation. 
Based on self-reports of compliance with the study medications, the 
estimated adherence (having taken treatment on every day/most days) 
across both active and placebo aspirin groups was 88% at 1 year, 80% at 2 
and 72% at 3 years after randomisation; and for omega-3 FA or placebo 
capsules 91%, 86% and 80% at 1, 2 and 3 years respectively. However, it 
was recognized that self-reports of compliance can be subject to social 
desirability bias and recall bias. Given this, objective indicators of compliance 
may be helpful, such as measuring biomarkers of drug effects. Importantly, 
by triangulating sources of compliance data in this way, ASCEND will provide 
realistic estimates of compliance which will help inform the interpretation and 
generalizability of the results at the end of the study. This leads to my project 
on evaluating the biochemical effectiveness of the trial medications in 
ASCEND. 
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3.2 Evaluation of the biochemical effectiveness of omega-3 FA and 
aspirin in ASCEND 
The aim of this project was to assess the biochemical effects of aspirin, in 
order to demonstrate that it is having its expected biochemical effect in this 
diabetic population and of omega-3 FA in order to show that blood levels 
have increased as expected at a median follow-up of 3.5 years. Being a mail-
based trial, it is important to compare self-reported compliance by 
participants to measures of the biochemical effect of each intervention in the 
trial follow-up phase. If the results of this sub-study show that mail-based 
self-reported compliance and measured biochemical compliance are the 
same, the final results of ASCEND would have a meaningful impact of study 
medication without reporting bias from participants. Recruitment started in 
April 2005 and was completed in August 2011.  A total of 15,480 patients 
were randomised and median duration of follow-up was about 3.5 years in 
2012 (with a planned median follow-up of at least 7 years). During a placebo 
run-in phase, baseline blood and urine samples were collected by mail and 
74% of randomised participants provided samples. The study protocol stated 
that as well as asking all participants routinely about their compliance with 
allocated study treatments, biochemical effects will be assessed in a random 
sample of participants at intervals during the study. A randomly selected 




A total number of 1800 participants (10% as stated and aimed from the study 
protocol) for follow-up sampling was selected randomly from different arms of 
study medications (50% of those from the treatment group and 50% from the 
placebo group), and from that 74% of participants who provided baseline 
sample with the aim to interpret the follow-up sample results in light of 
baseline value for comparison if necessary.   
Sample collection and processing 3.2.1
During 2012, blood and urine sampling kits (Figure 3.3) which contained a 
10ml EDTA blood sample and two containers of urine (one 10ml container 
and one 5ml container without preservative) were sent to 1800 randomly 
selected randomised participants, along with an information leaflet, 
instruction letter and consent form. Ethics committee approval was applied 
and granted for this purpose. The participants were asked to go to their local 
GP practice for the blood test and blood and urine samples were collected 
using the sampling kit provided. The samples were then posted in the mailing 
container provided along with the completed consent form to the coordinating 
centre laboratory in Oxford. The CTSU Wolfson Laboratories are accredited 
by the United Kingdom Accreditation Service (UKAS) to ISO 17025:2005 
(General requirements for the competence of testing and calibration 
laboratories) which demonstrates technical competence for a defined list of 
tests and the operation of a laboratory quality management system.   
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Figure 3.3: Picture of mailing sampling kit sent out for blood and urine 
collection in the ASCEND follow-up sample collection. 
In total 1288 samples were returned (1265 returned blood and urine samples, 
6 blood only, 17 urine only, 512 did not return any samples). On arrival at the 
central laboratory, an aliquot of whole blood was removed for the HbA1c 
assay. The remainder of the blood sample was centrifuged and plasma 
extracted for the pre-specified assays (total- and HDL-cholesterol, 
apolipoproteins A1 and B, cystatin C) as in the protocol to see the study 
medications were not having impacts on other factors that might be relevant 
to the cardiovascular outcome in ASCEND. The remaining plasma and red 
blood cells were aliquoted into barcoded cryovials and frozen at -80°C. The 
urine samples were also aliquoted into barcoded cryovials and frozen at -
80°C.  
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I investigated appropriate and reliable biomarkers for assessing aspirin and 
omega-3 FA compliance in the context of the ASCEND trial. The design of 
ASCEND imposes some practical constraints regarding which biomarkers 
can be reliably assessed. In designing my compliance sub-study, 
compromises needed to be made to take account of the fact that direct 
contact with the participants was not possible. A novel aspect of this work is 
the collection of samples by mail so a significant challenge has been finding 
suitable analytes that might be stable in whole blood or urine during transport 
in the post. The appropriate biomarkers for aspirin and omega-3 FA will be 
discussed in detail in section 3.3. As part of the compliance sub-study during 
the follow-up phase, information about non-study treatment use, blood 
pressure, and BMI were asked in addition to information about compliance 
from the randomly selected participants. Analyses of HbA1c, total 
cholesterol, HDL-cholesterol, Apo A1, Apo B, and cystatin C) and urinary 
microalbumin/creatinine ratio) were undertaken on the follow-up samples in 
addition to the measurements of the biochemical effectiveness of trial 
medications.  
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3.3 Omega-3 fatty acid biomarkers 
Monitoring of biochemical effectiveness of trial medications during the follow-
up phase of the trial is needed for the reliable interpretation of the trial results 
as previously described in section 2.5. It is particularly relevant in a long-term 
mail-based trial like ASCEND which will last for more than 7 years and where 
the estimated compliance relies on self-reported questionnaires. In clinical 
trials investigating omega-3 FA as an intervention, one of the practical 
difficulties could be the lack of a generally accepted biomarker that reflects 
the biochemical efficacy of its intake. This section reviews the available 
biomarkers for omega-3 FA intake, describes the suitable methodology of a 
most appropriate biomarker to use in the context of ASCEND.  
Literature review of methods for omega-3 fatty acid 3.3.1
biomarkers 
One systematic review including 41 studies, evaluated the utility of different 
biomarkers of omega-3 FA intake and reported that eighteen different 
biomarkers had been used to measure the change in omega-3 FA level after 
taking supplements (191). Total plasma lipid DHA (used in six RCTs) and 
plasma phospholipid DHA (used as a biomarker in 21 studies) both reflected 
the supplement dose and were considered useful indicators of DHA status. 
Plasma triacylglycerol DHA, plasma cholesteryl ester DHA and plasma non-
esterified fatty acid DHA were also used in a small number of trials. Different 
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stages of red blood cell (RBC), platelet and peripheral blood mononuclear 
cell phospholipid DHA were also used in a small number of trials. 
Granulocyte, neutrophil, neutrophil phospholipid, peripheral blood 
mononuclear cell, LDL, and HDL were also used as sources of measurement 
of DHA in a small number of trials. Hence there is a range of useful 
biomarkers which can reflect omega-3 FA intake/supplementation. The most 
commonly used ones involve red blood cells (RBCs), plasma, and plasma 
phospholipids (PL). 
Given the long half-life of RBCs (about 120 days), it has been suggested that 
FA levels in RBC may better reflect long-term intake of particular FAs and 
therefore be a more appropriate biomarker to use to than plasma FA levels 
(192). DHA measurement in both plasma and RBC correlated with intake, but 
RBC DHA concentration was more strongly associated with long-term intake 
(193). To have a greater power and more reliable results, a biomarker with 
low biological variability would be preferred. Theoretically, RBC membrane 
omega-3 FA measures are likely to be relatively stable because of their 
esterified status in the membrane. Plasma contains lipoprotein-associated 
FAs (cholesteryl esters, triglycerides, and phospholipids) as well as non-
esterified FAs, and plasma FA composition may be more variable because of 
varying levels of types and amount of lipoproteins. A study was conducted 
which reported the rate and extent of which EPA and DHA were incorporated 
into RBC membranes in an 18 –month controlled trial (194). The proportion 
of EPA in RBC increased after just 3 days of supplementation. The 
incorporated half-life of EPA was reported as 28 days and the concentration 
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of EPA plateaued at 6 months, the RBC concentrations reflected the intake 
over the previous month. When supplementation was stopped, levels of FA 
came down at approximately the same rate at which they had risen and had 
fallen to about 50% of peak values after 1 month. 
A study which compared biological variability of omega-3 FA measurements 
in RBC, plasma and plasma phospholipids (PL), confirmed that RBC omega-
3 FA measurement showed the lowest with-in subject coefficient of variation 
(CV) (4.1 ±1.9%) compared with whole plasma (CV 15.0 ± 6.4%) or plasma 
PL (14.5 ± 8.4%) (192). A prior meal lowered the plasma EPA and DHA 
proportions (expressed as a percent of total FAs). The consumption of a 
meal that does not contain long-chain omega-3 FA (but does contain other 
FAs) will dilute the plasma FA pool with non-omega-3 FAs, lowering the 
relative content of omega-3 FA. But RBC omega-3 FA composition is not 
altered acutely by a meal, which is an advantage as a fasting sample is not 
required (192). Most of the FAs in RBCs are esterified in membrane PLs and 
are relatively stable in contrast with plasma which contains lipoprotein-
associated FAs and non-esterified FAs. Hence plasma FA composition is 
more variable than FAs in RBC since there are many FA carrier molecules. 
RBC omega-3 FA measurement showed the lowest biological variability and 
was unaffected by a prior meal, Hence it was possible to use nonfasting 
blood samples to obtain reliable RBC omega-3 FA concentration and this 
would be the preferred sample type in which to assess omega-3 FA status in 
ASCEND. The limitation of this study was that the composition of the meal or 
the exact timing of the blood collection after the meal were not critically 
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considered as their goal was to replicate the normal variability observed in 
clinical practice. 
A study looking at the adherence to nutritional advice to increase EPA and 
DHA showed that measurement of the percentage of DHA in RBCs 
characterizes adherence to EPA and DHA intakes in long-term intervention 
following the dietary advice, while plasma measurements of the percentage 
of EPA and DHA and dietary assessment reflect short-term increases in EPA 
and DHA intakes (195). Rapid incorporation of EPA into plasma and 
erythrocyte lipids, and DHA into plasma lipids makes measures of EPA and 
DHA susceptible to acute compensatory EPA and DHA intake just prior to 
blood collection during follow-up of long-term trials. The study excluded 
individuals with 4% Omega-3 FA index, existing CVD or diabetes mellitus 
and those consuming nutraceuticals containing EPA and DHA. The study 
was not blinded and knowing that blood samples would be measured at each 
study visit could have led to compensatory adherence immediately prior to 
the study visits.  
In the substudy of ASCEND, there was an option of measuring both plasma 
and RBC omega-3 index as a comparison of the two fractions. However, with 
a limited amount of blood collected (one ETDA tube) and the need to spare 
plasma for analysis of other laboratory tests that were pre-specified in the 
protocol, this option was not adopted. Moreover, based on the review of the 
literature, it appeared that measuring RBC omega-3 FA levels in ASCEND 
samples was the most appropriate method to use given the stability, reduced 
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variability and no requirement to use fasting samples for the purpose of long-
term adherence of study medication.  
The main challenge of collecting mailed based samples was the stability of 
analytes during postal shipment from the general practice to the laboratory at 
the CTSU. With the previous experience of collecting blood and urine 
samples at the baseline in the ASCEND, the CTSU laboratory team recorded 
of the majority of samples (>90%) arrived in the laboratory within 7 days at 
baseline sampling process. Hence the analytes to be measured needed to be 
stable at room temperature for at least 7 days. 
Red cell membrane omega-3 index 3.3.2
The omega-3 index is the EPA and DHA content of the red blood cells 
(RBCs) expressed as a percent of total identified RBCs FA (196) 
(OMEGAQUANT, 2009-2011 document). The omega-3 index is a biomarker 
of n-3 FA status and correlates with EPA and DHA supplementation in a 
dose-dependent manner (197). A randomised, placebo-controlled, double-
blind, parallel-group study in 125 people assessed 5 doses of EPA+DHA (0, 
300, 600, 900, 1800 mg) given daily for 5 months as fish oil supplements 
(Nordic Naturals). The omega-3 index was used to assess the level of FA 
uptake at baseline and at the end of the trial. The results showed that 
omega-3 FA supplements increased the omega-3 index in a dose-dependent 
manner. The omega-3 index increased by 121% (from 4.3% to 9.5%) for the 
1800 mg/day dose group, 75% for the 900 mg/day dose group, 59% for the 
600 mg/day dose group, and 44% for the 300 mg/day dose group (197).
104 
In the same trial, RBCs FA composition was analysed according to the HS-
Omega-3 index® methodology using dried blood spot preparation for easy 
transport to their laboratory in the USA. Briefly, fatty acid methyl esters were 
generated from RBCs by acid transesterification with boron trifluoride and 
analysed by gas chromatography using a GC2010 Gas Chromatograph 
(Shimadzu Corporation, Columbia, MD) equipped with an SP2560, 100-m 
column (Supelco, Bellefonte, PA). Fatty acids were identified by comparison 
with a standard mixture of fatty acids characteristic of RBCs. The omega-3  
index is the EPA+DHA content of RBCs expressed as a percentage of total 
identified fatty acids. The factors influencing the omega-3 index were 
investigated and independent determinants positively associated with the 
omega-3 index were age, a history of high cholesterol whilst negatively 
associated factors were being a current smoker and triglycerides (198): 
marine-derived n-3 FA supplementation explained two-thirds of the variability 
in response to RBCs EPA+DHA content, and several factors beyond dose 
(i.e., body weight, baseline omega-3 index, age, physical activity, and sex) 
added more precision to the predictive model (197). The CTSU Wolfson 
laboratory had no experience of measuring FAs and did not have gas 
chromatography machine on site and hence I set up a collaboration with 
Harris Laboratory at Sioux Falls, SD 57106, USA to analyse the omega-3 
index for collected samples. 
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Sample size calculation 3.3.3
Power calculation Formula 
The basic power formula for testing whether the difference in mean level 
between two treatment arms with equal numbers n per arm, is > dmin is: 
(d-dmin)  √(n / 2) / s > (za + zb), where d is the expected difference and s is 
the SD of a basic observation. 
The simplest basic observation is an individual observation, off treatment in 
one arm and on-treatment in the other.  However, depending on the 
reproducibility, it may be more powerful to make the basic observation a 
difference between an on-trial observation and a baseline observation off 
treatment. If r is the self-correlation, and s is the SD of an individual 
observation then the SD of the difference between two values is: s √ (2(1-r)). 
Given a fixed total number of samples n within each arm, which can be used 
either: (1) wholly for on-trial observations; or (2) as n/2 measurements of 
paired off and on-trial measurements for an individual, the standard errors of 
the means in an arm are: 
(1) sa=s/√n 
(2) sa=s √ (4(1-r)/n) 
(2) will give a lower standard error if 
√ (4(1-r)) <1 
which evaluates to r>0.75 
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Power formula with paired measurements 
Where “si” is the SD of the contribution from one individual, which may be 
either a single measurement or the difference between a pair of 
measurements at different times, and ni is the number of individuals within 
each arm: 
(d-dmin)  √(ni/ 2) / si > (za + zb) 
Thus, for the paired measurements, with this becomes 
(d-dmin)  √(ni / 2) / s √ (2(1-r)) > (za + zb) 
(d-dmin)  √ni / s √ (4(1-r)) > (za + zb) 
(so with r=0.75, this reduces back to the standard formula of (d-dmin)  √(n/ 2) 
/ s > (za + zb), with ni= n/2) 
Estimates from the literature: EPA+DHA measurement after 
supplementation of omega-3 FA 
EPA and DHA levels in red blood cells, whole plasma, and plasma 
phospholipids in 20 healthy volunteers were tested weekly over 6 weeks by 
Harris group. The within-subject coefficients of variation (Mean±SD) were 
4.1%±1.9%, 15.9%±6.4%, and 14.5%±8.4%, respectively (RBC vs. others, 
p<0.001). RBC omega-3 index showed the lowest biological variability and 
was not altered in the fed state (199) with the change in the red cell 
membrane omega-3 index of up to 46%. 
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The change in the red cell membrane omega-3 FA was also studied in the 
subset of the Framingham Offspring study (200). The RBC omega-3 index 
increased by 41% (95% CI: 31 to 52%) in 38 individuals who were taking fish 
oil supplements, but in 253 participants not taking fish oil, the proportion of 
RBC EPA+DHA did not change. The SD of measurements of pre and post-
supplementation with omega-3 FA calculated from the text and figure 1 of the 
published paper are given in Table 3.4 (200). 
Table 3.4: Sample size and study power calculation data for omega-3 FA 
Point  SE of log SD r 
On supplement-Baseline 
(n=38) 
0.042 0.26  
On supplement-post 
supplementation (n=38) 
0.036 0.22  
Diff, ratio of CI for on 
treatment to off treatment 
0.038 0.23 ~0.5 
No supplementation post 
randomisation, n=253 
0.0176 0.28  
It is expected, from the literature review, that there might be a 41% difference 
with an SD of log EPA+DHA of 0.28. Therefore with the funding allowance of 
analyzing the total number of 152 (38 in each of the treatment sub-groups), 
the study was powered to show a difference of at least 20% (with an 
expected 41% effect). This equates to the power to detect a non-zero effect 
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with a 21% (i.e. 41%-20%) expected effect. Stored samples were retrieved 
from the deep freezer using a unique sample identifiable code for each 
sample in a subgroup of 152 patients in the ASCEND study.  Dry blood spots 
were prepared from those blood samples and transported to the 
OmegaQuant laboratory, Bill Harris’s laboratory in South Dakota. Omega-3 
index was measured using the dried blood spot technology which was simple 
and easy for transport worldwide. In addition to EPA (20:5n-3) and DHA 
(22:6n-3), the other 22 fatty acids (by class as listed in the table below) are 
identified. The sum of these 24 fatty acids constituted the total fatty acid 
content of the blood. All of the FAs which were assayed are listed in Table 
3.5. Data in my thesis is presented as a percentage of the total fatty acid 
content, with the all fatty acids summing to 100% for all 152 samples. 
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Method of analysis 3.3.4
The results presented in this chapter considered EPA+DHA (the Omega-3 
Index) fatty acids only. Log values of each fatty acid were analysed as the 
results follow log-normal distributions. Pearson (Self) correlation coefficients 
between fatty acids at baseline and on trial were calculated in the placebo 
arm. Differences in log fatty acids between the active and placebo omega-3 
arms were investigated using generalised linear models. The means of the 
log variables were exponentiated to give geometric means. The modeled 
estimate of the effect of omega-3 FA was exponentiated and converted to 
give % difference. 
In summary, long-term omega-3 FA compliance in ASCEND was assessed 
using the omega-3 index. Samples were measured at two different time 
points; at baseline and during the trial in both trial arms (treatment and 
placebo arm). The results are presented in next chapter. 
3.4 Measurement of biochemical effects of aspirin 
Aspirin irreversibly acetylates platelet prostaglandin H-synthase-1 or 
cyclooxygenase-1 (COX 1) or H-synthase 2 (Cox-2) (as described earlier in 
figure 2.11). This results in a reduction in thromboxane A2 production (TxA2) 
which is a potent vasoconstrictor and promoter of platelet aggregation. The 
half-life of thromboxane A2 is very short (about 30 seconds). It is rapidly 
110 
converted to its stable metabolite, thromboxane B2 (TxB2) (137). Ideally, to 
measure whether aspirin is being taken and exerting its desired effect, we 
would measure aspirin blood levels. However, to date, there are no reliable 
assays to measure blood levels of aspirin.  
After decades of innovative attempts to assess aspirin response by 
measuring stable biochemical specific metabolite, thromboxane B2, there are 
now reliable methods which can be used for both serum and urine (201-203). 
However, in ASCEND, there are significant obstacles to measuring serum 
thromboxane as it requires careful sample collection, incubation at 37°C for 
about 1 hour, immediate centrifugation for 5 min (127), immediate separation 
and the storage of serum at least below -20°C. This requires a clinic setting 
with onsite facilities to process the sample after collection, which was not 
possible in ASCEND which is run mainly by mail. Urinary thromboxane B2 
(UTxB2) was therefore chosen as the preferred method for use in ASCEND 
despite some recognised limitations. UTxB2 has the advantage of being 
stable in urine over several days hence allowing collection of the sample and 
dispatch to the central laboratory by mail. Difficulties of assessing COX-1 
inhibition attributable to aspirin using UTxB2 include: the influence of body 
mass index (BMI) (145); smoking (204);  the possibility that individuals with 
diabetes behave differently from those without, physiological factors (age and 
renal function); pathological factors (kidney, liver and metabolic disorder, 
obesity, myeloproliferative neoplasm); genetic variants; drug-drug interaction 
(e.g. NSAIDs); development of resistance or tolerance; and compliance with 
the medication. Consequently, although not an ideal measure because of 
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these factors, measuring UTxB2 does provide an opportunity to assess the 
degree of platelet inhibition being seen in those randomised to aspirin 
compared to placebo in the ASCEND trial. The process of randomisation and 
the interpretation of means across the groups (rather than focusing on 
individual’s values) imply that despite the limitations useful information can 
be obtained.  For these reasons, other trials have also used UTxB2 as a 
biomarker of COX inhibition due to aspirin (138, 139, 145).  
Measurement of Urinary Thromboxane B2 in ASCEND 3.4.1
For the ASCEND trial, the AspirinWorks test kit was used to measure 
thromboxane B2 (UTxB2) in urine samples. The AspirinWorks test kit is an 
enzyme-linked immunoassay (ELIZA) to determine the level of 11-dehydro 
thromboxane B2 in the urine sample to see the platelet response to aspirin 
ingestion. Validation of the assays was done in the CTSU laboratory before 
being used to measure trial samples. 
Assay validation process for UTxB2 measurement 3.4.2
3.4.2.1 Accuracy  
In the absence of a certified reference material or an external quality 
assurance scheme, the kit quality control (QC) sample was used to test for 
accuracy. The three levels of kit QC were tested (four times) over two days 
and the results fell within the range supplied by the manufacturer when using 
the semi-Log processing method. For the Log-log processing method, the 
QC levels 2 and 3 fell within the range stated by the manufacturer, but one 
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individual result for level 1 fell outside of the manufacturer's range but the 
mean of the duplicates fell within the manufacturer's range. To improve 
accuracy based on these findings it was decided to run the samples in 
duplicate.  
3.4.2.2 Precision 
The precision test was carried out using the kit Quality Control (QC) material 
for both within-batch precision and between batch precision. The 
manufacturer states in the kit insert that the precision data has been obtained 
using the mean values of duplicate samples and was used 106 data points to 
gain the precision data. Both within-batch and between batch precision 
improved with duplicate samples as recommended compared to individual 
sample results. 
3.4.2.3 Reportable range (linearity) 
The detection range stated by the manufacturer was 300 – 4000 pg/mL and 
any sample with a result higher than 4000 pg/mL were retested with the 
appropriate dilution. Due to the limited space available on the plates, it was 
not possible to run six dilutions in triplicate. The linearity was checked by 
running a high sample (above the highest standard) diluted with the sample 
diluent (provided with the kit) to obtain a series of samples that were run in 
duplicate. The results were plotted and the percentage recovery calculated 
for each level (observed/expected x 100%). Limited data was produced for 
linearity due to the lack of plates available for the validation. The samples 
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were analysed in duplicate. The observed results were plotted against the 
expected results in Figure 3.4 (A- Semi-log and B-log-log). Both processing 
methods have been used.  All sample results were included in the graphs, 
but note that the 1 in 4 dilutions (M) were used to generate the expected 
results for both processing methods.  
Figure 3.4 (A) Linearity plot (Semi-Log) showing reportable range for UTxB2 
measurement in ASCEND 
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Figure 3.4 (B) Linearity plot (Log-Log) showing reportable range for UTxB2 
measurement in ASCEND 
The Semi-Log processing produced a recovery from between 88.6% to 
105.5%, while the Log-Log processing for the same samples produced a 
recovery from between 101% to 110.9%. The linearity was acceptable for 
both types of processing as they fall between 80% and 120%. 
3.4.2.4 Patient sample range 
The possible patient sample range was checked using sets of samples that 
have been obtained from healthy volunteers (n=11) in our trial centre as a 
pilot project to help understand UTxB2 behaviour after aspirin ingestion. The 
first sample was obtained at time zero (approximately 8 am) before taking 
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150 mg of aspirin (300 mg aspirin preparation was available for this pilot 
project and 150 mg (half of 300 mg) was used) a second sample was 
collected 12 hours (approximately 8 pm) after the aspirin was taken and a 
third sample was collected 24 hours (approximately 8 am the following day) 
after the aspirin was taken.  Some blank samples were also obtained from 
volunteers who had not taken aspirin in the 48 hours prior to giving the 
sample. The samples were placed at 4°C before being aliquoted and frozen 
at -80°C.  
It was expected that most samples corresponding to time 0 would give a 
result >1500pg UTxB2/mg creatinine (i.e. representing no suppression of 
TxA production so high UTxB2) and the subsequent time points would show 
suppression and a result of ≤1500pg UTxB2/mg creatinine, therefore, 
demonstrating the effect of the aspirin. All volunteers showed a change in the 
level of UTxB2, but three had anomalous results. One had a high UTxB2 
level, even after taking the aspirin with it not going below the 1500pg 
UTxB2/mg creatinine cut off, and two had levels below 1500pg UTxB2/mg 
creatinine at time zero, although they also decreased after taking aspirin. For 
these 2 individuals, the zero time point appeared to be from someone who 
had already taken aspirin but may have been due to other interfering 
substances (Table 3.6, Figure 3.5 A and B). 
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Table 3.6: Results of UTxB2 measurement in the pilot study (n=11) of 
ASCEND 







12Hrs v 0Hrs 
% change 
24Hrs v 0Hrs 
A1 1791.8 904.4 433.30 -49.5 -75.8 
A2 2638.9 831.0 606.47 -68.5 -77.0 
A3 2405.0   553.44   -77.0 
A4 2876.8 577.6 578.96 -79.9 -80.5 
A5 5297.6 2274.6 2067.13 -57.1 -61.0 
A6 2848.9 640.1 740.19 -77.5 -74.0 
A7 1743.0 480.0 500.37 -72.5 -71.3 
A8 866.1 339.9 359.56 -60.8 -58.5 
A9 2810.8 672.4 623.27 -76.1 -77.9 
A10 1275.7 450.5 497.89 -64.7 -60.97 
A11 2471.6 599.5 965.32 -75.7 -60.94 
 Overall 
Mean  
2456.9 777.0 720.54 -68.2 -70.44 
Overall SD 1159.3 552.6 474.86 10.0 8.35 
Overall CV 47.2 71.1 65.90 -14.7 -11.85 
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Figure 3.5 (A) The change in UTxB2 measurements after taking aspirin 
(Semi-Log data) 







































The overall mean reduction of UTxB2 at 12 hr after 150 mg of aspirin 
ingestion in the pilot study was 68.23% with SD 10.01, and of 70.44% with 
overall SD of 8.35 at 24 hr post-aspirin ingestion (Table 3.5). As a result of 
the pilot study, it was decided to analyse the samples at baseline and during 
the trial to better assess any changes due to treatment allocation. 
3.4.2.5 Comparing preserved and non-preserved samples  
After deciding to analyse samples from two-time points (i.e. baseline and in-
trial), we investigated whether using chlorostat preservative in the urine 
sample had any impact on the analysis. The aim was to assay an individual’s 
baseline and follow-up samples on the same plate (to minimise variation 
between runs) to assess changes in the level of UTxB2. The baseline urine 
sample had been collected without chlorostat preservative, therefore, a 
comparison between samples with and without preservative was required. 
The manufacturer recommends the use of preservatives as compulsory. 
However, after contacting the product specialist (personal communication) 
from the company, the reason of compulsory use was unclear and at Mayo 
Clinic, the non-preserved samples are routinely used. The use of 
preservative tablets for the collection of urine samples varied from different 
centres, for example, the Cleveland heart laboratory does not use 
preservatives for their sample collection. Samples from 3 volunteers were 
divided so that half the sample was in a tube without preservative and the 
other half had a preservative added. Each sample (both with and without 
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preservative) was then analysed and no significant differences on UTxB2 
measurement were observed between samples with or without preservative 
tablets. The results are displayed in Table 3.7 A and B. 






% Difference from 
Preserved sample 
1 2080.47 1980.87 4.79 
2 971.65 912.15 6.12 
3 859.51 738.22 14.11 






% Difference from 
Preserved sample 
1 1968.6 1889.34 4.03 
2 1077.04 1012.99 5.95 
3 949.54 813.05 14.37 
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3.4.2.6 Sample suitability 
The samples that were to be tested were mailed to the laboratory using the 
standard postal service, then aliquoted upon receipt and stored at ≤-80°C. 
The baseline samples were stored in liquid nitrogen tanks for several years 
before retrieval.  The follow-up samples were stored at ≤-80°C for less than 1 
year.  The follow-up samples had undergone a freeze/thaw cycle before 
being analysed for UTxB2. To check that this extra freeze/thaw did not have 
an effect on the samples, two aliquots (a and b) were taken and stored at -
80°C. The ‘b’ sample was removed and defrosted at room temperature for 3 
hours before being returned to the freezer. Then both the ‘a’ and ‘b’ aliquots 
were analysed on the same plate to compare the effects of the extra 
freeze/thaw on the sample. In total 28 samples were analysed but 6 required 
repeating at a different dilution, so only 22 sample results were used in the 
comparison. The results are displayed in Figures 3.6 A and B) below; the 
twice defrosted sample (b) plotted against the once defrosted sample (a). 
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Figure 3.6 (A) Semi-log plot showing freeze and thaw data for UTxB2 
measurements in ASCEND 
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Figure 3.6 (B) Semi-log plot showing freeze and thaw data for UTxB2 
measurements in ASCEND 
For the semi-Log processing method, there was a mean change of 1.81%. 
For the Log-Log processing method, there was a mean change of 2.43%. 
3.4.2.7 High Creatinine results 
From inspection of the raw data for samples that yielded unexpected results 
(false positive or false negative), there was some concern that a high level of 
creatinine in the sample might have interfered with the UTxB2 assay. As less 
than 2% of ASCEND patients had high creatinine levels at baseline this was 
not thought to have a material impact on the collected sample. 
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3.4.2.8 Stability in mail-based sample 
The experiments on the stability of UTxB2 for up to 7 days in 12 subjects, 
incubating the samples between 22 and 24 °C, e.g. in the 'worse' conditions 
of temperature during shipment of the samples was done in collaboration 
with Professor Carlo Patrono’s research laboratory in Italy and the results are 
shown below. The results indicate that there was no sign of degradation of 
the UTxB2 during this time frame at the set temperatures (Figure 3.7) and 
data from the manufacturer states that analytes were stable in samples 
stored at room temperature for 14 days (Table 3.8). 
Figure 3.7 Stability of sample with duration of storage at temperature 22-24’C 
(n=12) 
experiments of stability n=12 subjects
incubation time @ 22-24°C




























Table 3.8 Data from Manufacturer: Sample storage study at room 
temperature until 14 days. 
3.4.2.9 Method of collection 
Urinary albumin and creatinine ratio and UTxB2 were measured using a 
competitive enzyme-linked immunoassay (ELISA) method using Corgenix 
UTxB2 test kit AspirinWorks (Manufacturer’s CV 5-8%).  The baseline samples 
from the same subset of patients (which have been stored in liquid nitrogen) 
were analysed for UTxB2 and RBC membrane omega-3 index using the same 
methodology. The laboratory in Oxford used a number of internal and external 
quality control procedures and follows a standard operating procedure (in 
accordance with Good Laboratory Practice guidelines). Confirmed assay results 
were transferred to the central ASCEND database and linked to the patients’ 
other data. (Sample collection and processing have been described earlier in 
section 3.2.1) 
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Sample size calculation for UTxB2 3.4.3
The statistical power to detect differences between the randomised groups 
depends on the distribution of UTxB2, its reproducibility in samples taken 
some years apart from the same individual, and the effect of aspirin on it. 
Ames et al. (2012), reported UTxB2 post-aspirin [mean (± SD)] in people with 
diabetes of 996 ± 845 pg/mg creatinine; and at baseline of 3665 ± 2465 
(127). As the SDs were approximately proportional to the means, this 
suggests an approximately lognormal distribution. On this basis, these results 
lead to estimates for the SD of log (UTxB2 ) of 0.8 and 0.7 (127). These 
estimates were also corroborated by reports from Eikelboom group of the SD 
of log (UTxB2) of 0.7 to 0.8 (205). We assumed that the SD of the log-
transformed data was the same for both groups. We assumed a self-
correlation over the time period from baseline to follow-up of 0.75.  The Ames 
results suggest that aspirin reduces UTxB2 by 100 x (1-996/3665) i.e. ~70%.  
With 80% compliance in ASCEND, thus, a ~60% reduction might be 
expected.  However, there was considerable uncertainty around these 
estimates and so the power calculations also allowed for a smaller reduction 
in UTxB2 of 45%.  
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to detect  
Percent reduction 
to detect 











75 60% 25% -0.6 0.75 0.8 ~99% 
75 45% 25% -0.3 0.75 0.8 ~90% 
* Using the formula 
Zb=abs((d_del√n)/(s√(4(1-r))))-Za 
where Za=1.96 
As described in section 3.4.2, the overall mean reduction of UTxB2 at 12 hr 
after 150 mg of aspirin ingestion in the pilot study was 68.23% with SD 10.01, 
and of 70.44% with overall SD of 8.35 at 24 hr post-aspirin ingestion. With 75 
individuals per arm (assayed at two-time points), the power to detect a 
reduction of at least 25%, was >99% with a predicted reduction of 60% and 
about 90% with a predicted reduction of 45% (Table 3.9).  
Hence UTxB2 concentration (measured in pg/ml) at baseline and on trial in a 
subgroup of 152 patients in the ASCEND study were analysed with an 
attempt to answer the biochemical effectiveness of aspirin ingestion. Those 
randomly selected 152 samples were retrieved from storage after arriving 
back to the CTSU laboratory after sample collection. Patients were randomly 
selected within treatment arm from the group who had urine samples 
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available at both time points, to ensure equal numbers per randomised arm. 
Two duplicate samples per patient were to be analysed at each time point, 
thus giving four results per person.  
An additional research question was raised, as discussed earlier (section 
2.5), whether in diabetic patients the duration of platelet COX inhibition after 
aspirin ingestion is shorter than in people without diabetes. To investigate 
this a further sample (n=199) were selected from patients who were part of 
the mid-study sample and who reported taking aspirin either more than 12 
hours before their urine sample or between 0 and 12 hours earlier. These 
additional UTxB2 assays analyses were done only on samples from the mid-
study but not on baseline levels. In each case, duplicate samples were 
analysed on the same plate. 
3.4.3.1 Data completeness 
UTxB2 concentrations are given as pg/ml in the majority of cases. Low 
results are recorded as <150 pg/ml and high levels as above assay range or 
>10000 pg/ml. Of the 152 patients in the random sample, 144 (95%) had at 
least one in-trial result within assay range and 146 (96%) had at least one 
baseline result within assay range. The corresponding numbers for those 
with both results within assay range are 139 (91%) in-trial and 134 (88%) 
baseline, with 123 (81%) having all four possible results within the assay 
range. In 4 cases, one of the baseline results was unsuccessful due to a 
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plate error (all were on the same plate). Of the 199 patients in the additional 
sample, 193 (97%) had both on-trial results within assay range and the 
remaining 6 had both assay results reported as “above range”. 
 Method of analysis 3.4.4
The mean of the two duplicate UTxB2 concentrations was calculated at each 
time point. The Log of this value was analysed as the results followed a log-
normal distribution. Pearson (Self) correlation coefficients between duplicates 
of the same sample and between log UTxB2 at baseline and on trial were 
calculated. Differences in log UTxB2 between the active and placebo aspirin 
arms were investigated using generalised linear models. The means of the 
log variables were exponentiated to give geometric means. Differences in 
mean logs were exponentiated to give ratios of geometric means which were 
then converted to percentage differences. 
3.4.4.1 Correlations and choice of analysis 
The self-correlation between baseline and on-trial log UTxB2 in the 60 
placebo aspirin arm patients with all four results within the assay range is 
0.39 (p=0.002). As the self-correlation is <0.5, the analysis of on-trial values 
is more valid than analysing the change between baseline and on-trial. Log 
UTxB2 concentrations between the duplicates of the same sample (where 
both are within assay range) are highly correlated: 0.95 (p<0.0001, n=134) 
for baseline samples, 0.95 (p<0.0001, n=139) for on-trial samples in the 
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original dataset and 0.99 (p<0.0001, n=193) for on-trial samples in the 
additional dataset.  
3.5 Chapter summary 
The ASCEND trial is a large mail-based 2x2 factorial design randomised trial 
for diabetic patients who do not have established cardiovascular disease 
exploring the role of aspirin and/or omega-3 fatty acid for primary prevention 
of cardiovascular disease. The trial follow-up is mainly by self-reported 
follow-up questionnaires with backup telephone follow-up. 
To be able to interpret the trial results meaningfully, it is important to know 
the study medications are taken as self-reported compliance. Adherence to 
trial medication and hence biochemical confirmation of the effectiveness of 
study medication is vital to have meaningful study results. 
As ASCEND is mail-based without any study clinic visits, and because 
samples needed to withstand the postal service, this limited what was 
possible. This needed careful consideration while taking into account the 
most reliable measurement with limited sample collection.  Creating a sample 
collection kit was another challenge in order to have the right amount and 
type of stable sample posted in the mail. Working with the ASCEND team, I 
designed this sub-study, working closely with members of the CTSU 
laboratory on the assay validation, designing the mail-based sample 
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collection kit, collaborating with primary care physicians (GPs) to obtain 
sample collections and worked with a statistician to analyse the data when it 
arrived in the study database. I submitted an ethics committee application for 
the sub-study which was approved. With the findings from the laboratory 
investigations, into UTxB2, samples were analyzed in duplicate at each 
different time point (baseline and in-trial) to compare the percentage change 
in both treatment and placebo arm.  Omega-3 index was measured with a 
novel dried blood spot method at the Omegaquant laboratory.  
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4 Results  
4.1 Literature review and meta-analysis of the cardiovascular effects 
of omega-3 fatty acids 
Many trials assessing the effects of omega-3 FA on cardiovascular events 
have been conducted and reported conflicting results (153, 154, 180, 206-
212). As part of my study, I undertook a literature review and meta-analysis 
of published and some unpublished results from 10 RCTs of the effects of 
omega-3 fatty acid (FA) supplementation on risk of major vascular events 
(MVEs) (coronary heart disease, stroke and revascularisation), cancer and 
all-cause mortality, overall and on MVEs in pre-specified sub-groups.  
Ecological studies among the Inuit people prompted interest in research into 
the effects of omega-3 FA for prevention of cardiovascular disease, omega-3 
FA becomes the research of interest for its possible role in cardio protection 
for decades. Since 1985, results of many prospective cohort studies on fish 
consumption and cardiovascular disease have been published showing a 
protective effect on cardiovascular disease. In the Japan Public Health 
Center-based Study, the relative risk (RR) of non-fatal MI was 0.43 (95% CI 
0.23–0.81) in participants with a median fish consumption of 180 g per day 
compared with participants with a consumption of 23 g per day (213). In 
addition to the promising observational studies that are described in section 
2.5.3, many research groups around the world have undertaken RCTs to 
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assess if omega-3 FA supplementation had a beneficial effect on 
cardiovascular disease (Selective characteristic of RCTs are described in 
Table 4.7-4.9). Several systematic reviews and meta-analyses of these RCTs 
of the primary or secondary prevention of omega-3 FA on cardiovascular 
disease have also been reported. A summary of the published meta-analyses 
is shown in Table 4.1.  
A meta-analysis from 2002 included 11 RCTs (15,806 participants with 
coronary heart disease, minimum 6 months follow-up) published between 
1966 and 1999, concluded that dietary and supplementation of n-3 PUFA 
may decrease overall mortality, mortality due to myocardial infarction, and 
sudden death in patients with coronary heart disease; the risk reduction for 
mortality was statistically significant (214). The risk ratio (RR) of nonfatal 
myocardial infarction in patients who were on n-3 PUFA-enriched diets 
compared with control diets or placebo was 0.8 (95% confidence interval [CI]: 
0.5 to 1.2), and RR of fatal myocardial infarction was 0.7 (95% CI: 0.6 to 0.8). 
In 5 trials, sudden death was associated with a RR of 0.7 (95% CI: 0.6 to 
0.9), and RR of overall mortality was 0.8 (95% CI: 0.7 to 0.9) (214). However, 
several trials in this meta-analysis were small (N=59 to 600), the exceptions 
being The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto 
Miocardico (GISSI)-Prevenzione trial (N=11324 whereas total N=15608) and 
diet and reinfarction trial (DART) trial (N=2033), and many had re-stenosis as 
an endpoint (152, 153). These analyses did not differentiate between dietary 
omega-3 FA intake and supplements. This may be important as different 
forms of supplements may have different effects, for example, alpha-linolenic 
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acid (ALA) - a plant-derived omega-3 FA - is only poorly converted to EPA 
and DHA. 
In 2006, Lee Hooper published a meta-analyses which included 48 RCTs of 
omega 3 intake for ≥ 6 months in adults (with or without risk factors for 
cardiovascular disease) with data on a relevant outcome (36,913 participants 
with or without established cardiovascular disease) and 41 cohort studies in a 
systematic review of the effects of omega-3 FA on mortality, cardiovascular 
disease, cancer and bleeding events (215). The findings of this analyses 
differed from previous analysis (214) and found no strong evidence of a clear 
effect on total mortality or combined cardiovascular events. They reported 
non-significant reductions in the risk of total mortality (RR 0.87, 95% CI 0.73 
to 1.03) and combined cardiovascular events (0.95 CI, 0.82 to 1.12) in 
participants allocated additional omega-3 FA. The duration of intervention 
was only ≥ 6 months and this may not have been long enough to detect any 
effects of supplementation on clinical outcomes of interest. It also adopted a 
different methodology from the previous meta-analysis as cohort studies 
those estimated omega-3 intake and related this to clinical outcomes during 
at least 6 months were also included in this meta-analysis and studies with 
participants with or without risk factors for cardiovascular disease were also 
included. Hence differences in study design may explain the discrepant 
results between the results of previous meta-analyses. 
In 2009, Marik and Varon carried out a systematic review of RCTs assessing 
whether dietary supplements of EPA and DHA decrease cardiovascular 
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events. Placebo-controlled RCTs that evaluated effects of omega-3 FA on 
clinical cardiovascular end points (cardiovascular death, sudden death, and 
nonfatal cardiovascular events) and all-cause mortality were included in this 
meta-analysis (N=11 trials, 39 044 participants with recent myocardial 
infarction, those with an implanted cardioverter defibrillator, and those with 
heart failure, peripheral vascular disease, and hypercholesterolemia). It was 
prespecified that included trials used supplements of EPA/DHA for at least 1 
year and the primary end point was cardiovascular death (216) (Table 4.1). 
The average dose of EPA/DHA was 1.8 ± 1.2 g/day and the mean duration of 
follow-up was 2.2 ± 1.2 years. It was concluded that dietary supplementation 
with omega-3 FA for ≥ 1 year, reduced the risk of cardiovascular deaths 
(odds ratio [OR]: 0.87, 95% CI: 0.79–0.95) sudden cardiac death (OR: 0.87, 
95% CI: 0.76–0.99), all-cause mortality (OR: 0.92, 95% CI: 0.85–0.99), and 
nonfatal cardiovascular events (OR: 0.92, 95% CI:0.85–0.99). The results 
were similar to those of Hooper’s meta-analysis that was reported 3 years 
earlier using different methodology. Marik and Varon excluded a trial by Burr 
et al because treatment allocation was not blinded and the dose of omega-3 
FA was not standardized. Since then, several additional RCTs of omega-3 
FA supplements have been conducted (207-210, 217).   
In 2012, a further meta-analysis (14 RCTs, 20,485 participants with a history 
of cardiovascular disease) concluded that there was insufficient evidence for 
a secondary preventive effect of omega-3 FA supplements on cardiovascular 
events (218) and supplementation with omega-3 FA did not reduce the risk of 
overall cardiovascular events (RR, 0.99; 95% CI, 0.89-1.09). However, it 
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reported a small reduction in cardiovascular death (RR, 0.91; 95% CI, 0.84-
0.99) with omega-3 FA supplementation. This raised the question of whether 
there were differential effects of omega-3 FA on fatal versus non-fatal 
cardiovascular disease outcomes. The authors excluded two large open-label 
trials (the GISSI-Prevenzione study (N=11323) (153) and the Japan EPA 
Lipid Intervention study (JELIS) (N=18645) (206) which both suggested 
beneficial effects of omega-3 FA in the primary analysis. Hence, although a 
lot of research has focused on the role of omega-3 FA for the primary and 
secondary prevention of cardiovascular disease, there is still no clear 
evidence and some doubt persists about whether there are beneficial effects 
and some large trials are still on-going (183, 219, 220). Since starting the 
ASCEND trial, 8 large clinical trials have been completed and reported.  
To help resolve some of the uncertainty, the Omega-3 FA Treatment Trialists’ 
Collaboration (OTTC) was set up under the supervision of Professor Robert 
Clarke, to combine data from all the large randomised trials assessing the 
relevance of omega-3 FA for the prevention of CVD. The aims of the meta-
analysis were to assess the effects of omega-3 fatty acids on components of 
MVE, including coronary heart disease, stroke and revascularisation, cancer 
and all-cause mortality overall; and on MVE in pre-specified sub-groups. 
Summary (study-level) trial data from trials were sought from the 
investigators for this collaboration using a prespecified protocol and analysis 
plan.  A collaborative meta-analysis of these trials should ensure that reliable 
evidence emerges about the effects of omega-3 FA on the risk of 
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cardiovascular outcomes and help with the interpretation of results from 
ASCEND in due course. 
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The Omega-3 Treatment Trialists’ meta-analysis of large 4.1.1
randomised trials of omega-3 FA supplementation 
The Omega-3 FA Treatment Trialists’ Collaboration (OTTC) combined data from 
selected large RCTs (at least 500 patients randomised and duration at least 12 
months of supplementation) assessing the effect of omega-3 FA supplements for the 
prevention of CVD in adults (Detailed inclusion criteria described below Figure 4.1 
and Table 4.2).  The present analysis included the results from 10 large RCTs (153, 
154, 180, 206-212) (involving 77 906 individuals) completed and reported between 
1999 and 2016.  A collaborative meta-analysis of these trials should ensure that 
reliable evidence emerges about the effects of omega-3 FA on cardiovascular 
disease outcomes. The pre-specified aims of this meta-analysis were to assess the 
effects of supplementation with omega-3 FA on (i) fatal CHD, non-fatal MI, stroke, 
major vascular events, cancer and all-cause mortality; and (ii) major vascular events 
in various sub-groups.  
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Figure 4.1: Screening and selection of included trials for the OTTC meta-analysis 
629 reports remained after screening for 
omega-3 FA and cardiovascular disease and 
randomised trials as limits 
Excluded based on study 
duration of < 1 year (n= 548)
81 reports were reviewed for inclusion 
criteria for OTTC 
Excluded (n=74) because of :
sample size < 500,                                                             
major vascular outcomes  < 10 
events 
 10 RCTs included in OTTC  
3 trials (ORIGIN 2012, 
GISSI R&P 2013, 
AREDS-2 2014) were 
added after initial 
search 
41406 articles identified from database using the key words for omega-3 FA 
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4.1.1.1 Identification of trials 
The aim of the search was to identify all relevant RCTs assessing the effects 
of omega-3 FA supplementation on pre-specified vascular outcomes. 
Potentially eligible trials according to pre-specified eligibility criteria as per 
OTTC were identified by a range of methods, including computer-aided 
literature searches on electronic databases and scrutiny of the reference lists 
of trials. The search was done in March 2011. We reviewed the 
bibliographies of all selected articles and review articles that included 
information of omega-3 FA and cardiovascular disease. Summary of the 
literature search are provided in Figure 4.1 and search terms are described 
below. 
Step 1: The key words related to Omega-3 FA used for the search were 
omega, omega 3, omega 3 fatty, omega 3 fatty acids, omega-3 
polyunsaturated, omega-3 polyunsaturated fatty acid, omega-3 fish oil, 
omega fatty acid, eicosapentaenoic acid or EPA, docosahexaenoic acid or 
DHA (N=41406 articles were retrieved).  
Step 2: Search terms were restricted further to cardiovascular outcomes and 
for randomised trials (N=629 trials remained) 
Step 3: Limit to treatment duration minimum of 12 months after abstract 
review (N=81 trials remained) 
Step 4: 7 RCTs remaining after full-text review to include in OTTC 
Step 5: 3 trials added after the initial literature search those were published 
after March 2011 (Origin 2012, GISSI-R and P 2013 and ARDS-2 2014) 
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Full paper reviews were done to some trials included in the previous meta-
analysis but excluded in OTTC and the reason for exclusion was given in 
table 4.2. 














(2009) 38 1 + - - 
Sacks (1995) 59 2 + - - 
Gajos (2010) 63 0.1 + + - 
Leng (1999) 120 2 - + - 
Milner (1989) 194 0.5 + + - 
Raitt (2015) 200 2 + - + 
Svensson 
(2006) 206 2 + - - 
von Shacky 
(1999) 223 1 + - + 
Singh (1977) 230 1 + - - 
Grundt (2004) 300 2 + - - 
Leaf (2015) 402 1 + - + 
Johansen 
(1999) 500 0.5 - + - 
Eritsland (1995) 511 1 - - + 
Brower (2006) 546 1 - - + 
Holman (2008) 778 0.3 - + - 
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4.1.1.2 Trials assessing effects on vascular outcomes
After review of previously published meta-analysis results, 6 months 
intervention with omega-3 FA did not show any meaningful clinical outcome 
(215) however when this was increased to 1 year in subsequent analysis, 
variable results were reported (216). One of the aims for performing this 
meta-analysis was to examine the effects of completed large (N>500) RCTs 
where omega-3 FA supplementation was used as intervention similar to 
ASCEND (study duration >1 year with MVE outcomes). With this 
background, we prespecified strict eligibility criteria in order to identify RCTs 
with sufficient cardiovascular outcomes to include in OTTC. The endpoints 
for OTTC were adopted from ASCEND  outcomes and subgroups were 
predefined in the OTTC protocol before the start of the literature search. 
During the OTTC paper submission, subgroup analysis for statin use was 
requested from a reviewer. All eligible trials which fulfilled predetermined 
criteria were included in this meta-analysis without excluding whether they 
were primary or secondary cardiovascular prevention trials. However, the 
presence or absence of prior CHD was added in a prespecified subgroup. 
The results of the population-based case-control and prospective cohort 
studies suggest a protective effect of omega-3 FA  on fatal cardiac events 
(cardiac arrest and sudden death) and Zhao meta-analysis reported the 
possible beneficial effects of omega-3 FA on sudden death (Table 4.1 and 
anti-arrhythmic section of omega-3 FA section 2.5.3). Hence, the analysis 
also included prespecified assessment of separate effects on fatal and 
nonfatal events. 
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Randomised trials for prevention of CVD were eligible for inclusion in this 
collaborative meta-analysis if the trial had:  
(i) Sample size of at least 500 participants  
(ii) Study duration of at least 1 year  
(iii) MVE outcome of at least 10 events and  
(iv) Randomised to omega-3 FA supplements or control (open or 
control).   
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Table 4.3: Cardiovascular and non-vascular endpoints for meta-analysis 
Coronary Heart Disease (CHD) Non-fatal MI 
 Coronary death 
Sudden Death 
 Total CHD 
Stroke (and stroke sub-types) Fatal stroke 
 Non-fatal stroke 
 Total stroke* 
    Ischaemic stroke 
    Haemorrhagic stroke 
    Unclassified stroke 
Revascularisation Coronary 
 Non-coronary 
 Any revascularisation 
Any Major Vascular Events 
(MVEs) 
Total Cancer**  
Mortality Vascular death 
 Non-vascular death 
 All-cause mortality 
* excluding transient ischaemic attack (TIA) 
** excluding non-fatal non-melanoma skin cancer 
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Table 4.3 and 4.4 summarizes the vascular outcomes to be assessed in this 
meta-analysis. The primary comparisons were:  
(i) Coronary heart disease(CHD) (Non-fatal myocardial infarction, 
coronary death, total coronary heart disease)  
(ii) Stroke excluding transient ischaemic attack (TIA) (fatal or non-fatal 
stroke, total stroke with classification of ischaemic, haemorrhagic 
or unclassified )  
(iii) Revascularisation ( coronary, non-coronary or any vascularisation)  
(iv) Major Vascular Event (MVE) – 1st  occurrence of any major 
coronary event (MCE), stroke or coronary or non-coronary 
revascularization (coronary revascularization included coronary 
artery bypass grafting or coronary angioplasty (with or without stent 
insertion); and non-coronary revascularization includes carotid 
endarterectomy or carotid artery angioplasty, repair of an aortic 
aneurysm, peripheral arterial surgery, or angioplasty); 
(v) Total cancer, excluding non-fatal non-melanoma skin cancer and  
(vi) Mortality (vascular death, non-vascular death, all-cause mortality).  
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A composite of non-fatal myocardial 
infarction or coronary death; non-fatal or 
fatal stroke; or any revascularisation 
procedure (including coronary or non-
coronary angioplasty or grafting) 
Coronary 
Revascularisation
Coronary artery bypass graft, coronary 




Arterial surgery including leg artery 
bypass procedure, aortic  or other 
aneurysm repair or carotid surgery or 
stenting 
Stroke 
Fatal or non-fatal stroke (not including 
transient cerebral ischaemic attack).  I64 
(ICD 10 codes) 
Cancer 
Total cancer excluding non-fatal non-
melanoma skin cancer 
Myocardial 
Infarction 
I21 (ICD 10 code)  
Cardiac Death I46.9 (ICD 10 code) 
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Table 4.5: Prespecified subgroups for cardiovascular events 




Prior CHD Yes 
 No 
Prior stroke Yes 
 No 
Prior diabetes Yes 
 No 
Total cholesterol < 5.0 mmol/L 
 ≥ 5.0 mmol/L 
Triglycerides ≤ 1.7 mmol/L 
 > 1.7 mmol/L 
HDL-cholesterol ≥ 1.0 mmol/L 
 < 1.0 mmol/L 
LDLcholesterol* < 3.0 mmol/L 
 ≥ 3.0 mmol/L 
 * calculated or measured LDL-cholesterol 
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4.1.1.3 Statistical analysis 
In 1985, Peto and colleagues reported an alternative method to the usual 
Mantel-Haenszel method for pooling odds ratios across the strata of two-by-
two tables. The Peto odds ratio (POR) method is not mathematically equal to 
the classical odds ratio but is approximately equivalent (227). It uses an 
inverse variance approach and utilizes an approximate method of estimating 
the log odds ratio using different weights. An alternative way of viewing POR 
method is as a sum of ‘O – E’ statistics. Here, O is the observed number of 
events and E is an expected number of events in the experimental 
intervention group of each study. The approximation used in the computation 
of the log odds ratio works well when effects of the intervention are small (i.e. 
odds ratios close to one), events are not particularly common and the studies 
have similar numbers in experimental and control groups. (Cochrane 
handbook-5-1.cochrane.org/chapter_9/9_4_4). 
POR works well for rare events as it does not need correction for zero 
counts. Furthermore, POR is also employed with dichotomous events based 
on time-to-event analyses. For the calculation of relative measures such as 
risk ratio (RR) and odds ratio (OR) in a single study, additional approaches 
are required for zero counts in any group. Also, POR method can be used to 
combine studies with dichotomous outcomes in studies using time-to-event 
analyses where log-rank tests have been used In the case of zero counts in 
any one treatment arm, POR can be calculated without continuity correction, 
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and is currently the relative effect estimation method of choice for binary data 
with rare events (228).  
The Peto odds ratio can cause bias if there are substantial differences in the 
number of participants between the treatment and control groups or other 
unbalanced randomization (229, 230). The Mantel-Haenszel fixed-effects 
odds-ratio and logistic regression (standard, exact or Firth penalized 
likelihood logistic regression) provide reliable results for studies involving 
more common event rates. 
In OTTC, the included trials had randomised controlled designs and had 
approximately equal number of participants in the treatment and control 
groups and the effects of treatment were small. Hence after considering the 
available methods and detailed discussions with statisticians, POR was 
adopted instead of the Mantel-Haenszel fixed effects odds-ratio.  
The effect of treatment in each trial was analysed separately and summary 
statistics were calculated for each trial. For each trial, the “observed minus 
expected” statistic (O−E) and its variance (V) from the number of participants 
who developed the relevant endpoint, and the total number of participants in 
each treatment group were calculated, using standard formulae for 2×2 
contingency tables. These (O−E) values, one from each trial, were summed 
to produce a grand total (G), with variance (V) equal to the sum of their 
separate variances. The value exp (G/V) is Peto’s “one step” estimate of the 
rate ratio (RR), and its continuity corrected 95% confidence interval is given 
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by exp (G/V ± (0.5/V + 1.96/√V) (19). Rate ratios (RR) were given with 95% 
confidence intervals (CI) for the overall results and with 99% CI (replacing 
1.96 in the formula above by 2.58) for the results of individual trials or 
subgroups). Heterogeneity between the different subgroups was assessed by 
calculating S−(G2/V), where S is the sum of (O−E)2/V for each trial (or sub-
grouping), and testing this statistic against a χ2 distribution with degrees of 
freedom equal to one less than the number of sub-groups.  
Additional analyses of the primary outcomes assessed the effects of 
treatment on major vascular events in pre-defined subgroups, including age, 
sex, prior CHD, prior stroke, prior diabetes, blood lipids (total cholesterol, 
triglyceride, HDL-cholesterol, calculated or measured LDL-cholesterol), and 
design of trials (open-label or blinded trials). In interpreting subgroup results, 
the chief emphasis was placed on the overall results unless there was strong 
evidence of heterogeneity (p<0.001).  
Standardized data request forms were sent to principal investigators of 
selected trials (selected according to previously described eligibility criteria) 
After having secured the agreement for collaboration in this meta-analysis 
from the trials, the completed tabular data sets were then returned to central 
office at Clinical Trial Services Unit, the University of Oxford for data entry 
and analysis. 
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Results of the meta-analysis of omega-3 FA  4.1.2
4.1.2.1 Characteristics of individual trials 
Data were obtained on a total of 10 trials involving 77,906 participants (153, 
154, 181, 206-210, 231, 232) that met the inclusion criteria, ranging in size 
from 563 to 18,645 participants. The characteristic of each trial included in 
OTTC meta-analysis are described in table 4.7 and 4.8. The risk of bias 
assessment of included trials is listed in table 4.6. Eight trials had a double-
blind design and used placebo control and two trials had an open design 
(153, 206). Combinations of omega-3 FA (polyunsaturated fatty acid ethyl 
esters of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) 
were used in all except one trial (206) that tested 1.8 g daily of EPA alone. 
The daily dose of omega-3 FA supplements ranged from 0.4 to 2.4 g/day 
(weighted mean 1.1 g/day). The mean duration of treatment in individual 
trials varied from 1 to 6.2 years (weighted mean 4.4 years). About two-thirds 
of the participants were male and the mean age at entry was 64 years. About 
62% of participants had a prior history of CHD, 30% had a prior stroke, and 
38% had prior diabetes. Among 77,906 individuals, there was a total of 
11,088 major vascular events, (including 2276 with non-fatal MI, 1599 with 
CHD death, 1713 with stroke, and 6603 with revascularisation events. Data 
were available on the effect of treatment by prior use of statin therapy in 6 
trials involving 47 548 participants (207-209, 212, 231, 233). 
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Table 4.6: Risk of bias assessment of included trials in OTTC meta-analysis 
Selection 

















DOIT (2010) 0 0 0 0 0 
AREDS-2 (2014) 0 0 0 0 0 
SU-FOL-OM3 
(2010) 
0 0 0 0 0 
JELIS (2007) 0 1 1 0 0 
ALPHA OMEGA 
(2010) 
0 0 0 0 0 
GISSI-HF (2008) 0 0 0 0 0 
OMEGA (2010) 0 0 0 0 0 
GISSI R&P 
(2013) 
0 0 0 0 0 
ORIGIN (2012) 0 0 0 0 0 
GISSI-P (1999) 0 2 2 0 0 
Low risk of bias 0 
Unclear risk of bias 1 
High risk of bias 2 
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DOIT (2010) 563 Blind Y EPA+DHA 2.4 100 3 70 (3) 24 7 8 -
AREDS-2 (2014) 4203 Blind Y EPA+DHA 0.65 43 - 74 (-)   - - - -
SU-FOL-OM3 
(2010) 2501 Blind Y EPA+DHA 0.6 79 4.7 61 (-) 75 26 18 83
JELIS (2007) 18645 Open N EPA 1.8 31 4.6 61 (8) - - 16 100
ALPHA OMEGA 
(2010) 4837 Blind Y EPA+DHA 0.4 78 3.3 69 (6) 100 7 21 85
GISSI-HF (2008) 6975 Blind Y EPA+DHA 1 78 3.9 67 (11) 50 5 28 -
OMEGA (2010) 3818 Blind Y EPA+DHA 1 75 1 64 (-) 22 6 27 94
R&P (2013) 12505 Blind Y EPA+DHA 1 62 5 64 (-)   30 5 60 44
ORIGIN (2012) 12536 Blind Y EPA+DHA 1 65 6.2 64 (8) 65 87 88 54
GISSI-P (1999) 11323 Open N EPA+DHA 1 85 3.5 59 (11) 100 - 19 -
Total 77906 1.13 62 4.4 64       62 30 38
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563 Elderly men with long-
standing 
hypercholesterolemia with or 
without coronary heart 
disease 
Omega-3 FA  2.4 3 Measures of 
atherosclerosis 
progression: IMT, Pulse 







4203 Persons aged 50 to 85 with 
bilateral intermediate AMD 
or advanced AMD in 1 eye 
Factorial design, 
Omega-3 FA /macular 
xanthophylls  
0.65 4.8 Composite outcome of 
myocardial infarction, 







2501 individuals with a history of 
myocardial infarction, 
unstable angina, or 
ischaemic stroke 
 Factorial design, 
Omega-3 FA and 5-
methyltetrahydrofolate 
(560 μg), vitamin B-6 
(3 mg), and vitamin B-
12 (20 μg)  
0.6 4.7 Major cardiovascular 
events (composite of non-
fatal myocardial infarction, 





Japan Open 18645 Individuals with a total 
cholesterol of 6.5 mmol/L or 
greater  
 EPA  1.8 4.6 Major coronary events, 
(sudden cardiac death, fatal 
and non-fatal myocardial 
infarction, and other non-









4837 Individuals with History of a 






Omega-3 FA (EPA + 
DHA) and ALA 
0.4 3.3 Major cardiovascular 
events, (fatal and nonfatal 








6975 Individuals with chronic 
heart failure (New York 
Heart Association class II-
IV) 
EPA+DHA 1 3.9 Death or hospital admission 






3818 Survivors of acute 
myocardial infarction 





12505 High cardiovascular risk 
because of a cardiovascular 
disease other than 
myocardial infarction, or 
multiple risk factors (at least 
four major risk factors in 
non-diabetic patients and 
one in diabetics) 
EPA+DHA 1 5 Cardiovascular mortality 
(including sudden death) 







12536 Individuals with high risk for 
cardiovascular events and 
had impaired fasting 
glucose, impaired glucose 
tolerance, or diabetes 
Factorial design,  
Omega-3 FA and 
insulin glargine  





Italy Open 11323 Survivors of recent (< or = 3 
months) myocardial 
infarction 
Omega-3 FA and 
vitamin E  
1 3.5 Death, non-fatal myocardial 
infarction, and stroke 
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Table 4.9 Distribution of events in individual trials 
Trial Number randomised
Non-fatal 
MI CHD death Any CHD Stroke Revascularisation MVE
DOIT (2010) 563 12 11 23 17 24 64
AREDS-2 (2014) 4203 70 18 88 84 117 421
SU-FOL-OM3 (2010) 2501 61 18 78 67 351 427
JELIS (2007) 18645 145 60 201 328 413 586
ALPHA OMEGA 
(2010) 4837 115 138 248 101 408 663
GISSI-HF (2008) 6975 200 45 236 225 268 677
OMEGA (2010) 3818 141 57 208 35 975 1075
R&P (2013) 12505 476 158 634 37 - 1478
ORIGIN (2012) 12536 600 615 1215 650 1762 2571
GISSI-P (1999) 11323 456 479 893 169 2285 3102
All 77906 2276 1599 3824 1713 6603 11064
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4.1.2.2 Effects on CHD and on other major vascular events  
There were 5480 any major vascular events in the omega-3 FA treatment group 
and 5584 events in the control group in total. Figure 4.2 shows that allocation to 
omega-3 FA had no effect on the rate ratios for any coronary heart disease (CHD) 
(rate ratio 0.96; [95% CI 0.90-1.02]), including CHD death (0.94; 95% CI 0.82-
1.07) or non-fatal MI (0.97 [95% CI 0.87-1.08]). Allocation to omega-3 FA had no 
effect on the rate ratios (95% CI) for stroke (1.03 [0.93-1.13]) including ischaemic 
(1.03 [0.88-1.21]) or haemorrhagic stroke (1.07 [95% CI 0.76-1.51]). Likewise, 
allocation to omega-3 FA had no effect on the rate ratios (95% CI) for 
revascularisation events (0.99 [0.94-1.04]) including coronary (1.00 [0.93-1.07]) or 
non-coronary (0.92 [0.75-1.13]). Overall allocation to omega-3 FA had no effect on 
the rate ratios (95% CI) for major vascular events (0.97 [0.93–1.01]).   
This meta-analysis also showed no significant heterogeneity between the results 
of individual trials for non-fatal MI, CHD death, any CHD or major vascular events 
(Figure 4.3). A funnel plot for subtypes of CHD and for MVEs is shown in figure 
4.4. 
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Figure 4.2 Effects of supplementation with omega-3 fatty acid on major vascular 
events 
0.5 1.0 2.099% CI
95% CI
Number of events (%)





Coronary Heart Disease (CHD)
  Non-fatal MI 1121 (2.9) 1155 (3.0) 0.97 (0.87-1.08)
  CHD death 776 (2.0) 823 (2.1) 0.94 (0.82-1.07)
Any CHD 1877 (4.8) 1947 (5.0) 0.96 (0.90-1.02)
p = 0.2
Stroke
  Ischaemic 574 (1.9) 554 (1.8) 1.03 (0.88-1.21)
  Haemorrhagic 117 (0.4) 109 (0.4) 1.07 (0.76-1.51)
  Unclassified/Other 142 (0.4) 135 (0.3) 1.05 (0.77-1.43)
  Any stroke 870 (2.2) 843 (2.2) 1.03 (0.93-1.13)
p = 0.6
Revascularisation
  Coronary 3044 (9.3) 3040 (9.3) 1.00 (0.93-1.07)
  Non-coronary 305 (2.7) 330 (2.9) 0.92 (0.75-1.13)
  Any revascularisation 3290 (10.0) 3313 (10.2) 0.99 (0.94-1.04)
p = 0.6
  Any Major Vascular Event 5480 (14.0) 5584 (14.4) 0.97 (0.93-1.01)
p = 0.19
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Figure 4.3: Effects of supplementation with omega-3 fatty acid on subtypes of 
CHD and on major vascular events by trials 
0.25 1.0 4.099% CI
95% CI
Events (%)






  DOIT 8 (2.8) 4 (1.4) 1.97 (0.44-8.85)
  AREDS-2 30 (1.4) 40 (1.9) 0.72 (0.38-1.33)
  SU-FOL-OM3 32 (2.6) 29 (2.3) 1.10 (0.56-2.15)
  JELIS 62 (0.7) 83 (0.9) 0.75 (0.49-1.15)
  ALPHA OMEGA 56 (2.3) 59 (2.4) 0.96 (0.59-1.56)
  GISSI-HF 92 (2.6) 108 (3.1) 0.84 (0.58-1.22)
  OMEGA 74 (3.8) 67 (3.6) 1.08 (0.70-1.69)
  R&P 228 (3.7) 248 (4.0) 0.92 (0.72-1.17)
  ORIGIN 316 (5.0) 284 (4.5) 1.11 (0.90-1.38)
  GISSI-P 223 (3.9) 233 (4.1) 0.95 (0.75-1.22)
    ALL 1121 (2.9) 1155 (3.0) 0.97 (0.89-1.05)




  DOIT 3 (1.1) 8 (2.8) 0.39 (0.08-1.90)
  AREDS-2 9 (0.4) 9 (0.4) 0.96 (0.28-3.24)
  SU-FOL-OM3 5 (0.4) 13 (1.0) 0.41 (0.12-1.38)
  JELIS 29 (0.3) 31 (0.3) 0.93 (0.48-1.82)
  ALPHA OMEGA 67 (2.8) 71 (2.9) 0.95 (0.61-1.49)
  GISSI-HF 20 (0.6) 25 (0.7) 0.80 (0.37-1.72)
  OMEGA 28 (1.5) 29 (1.5) 0.95 (0.48-1.89)
  R&P 82 (1.3) 76 (1.2) 1.08 (0.72-1.64)
  ORIGIN 319 (5.1) 296 (4.7) 1.08 (0.87-1.33)
  GISSI-P 214 (3.8) 265 (4.7) 0.80 (0.63-1.02)
    ALL 776 (2.0) 823 (2.1) 0.94 (0.85-1.04)
p = 0.2 Heterogeneity : 92  11.99; p=0.21
Any CHD
  DOIT 11 (3.9) 12 (4.3) 0.91 (0.30-2.73)
  AREDS-2 39 (1.8) 49 (2.4) 0.76 (0.44-1.32)
  SU-FOL-OM3 37 (3.0) 41 (3.3) 0.90 (0.49-1.62)
  JELIS 88 (0.9) 113 (1.2) 0.78 (0.54-1.12)
  ALPHA OMEGA 120 (5.0) 128 (5.3) 0.95 (0.68-1.32)
  GISSI-HF 107 (3.1) 129 (3.7) 0.82 (0.58-1.16)
  OMEGA 112 (5.8) 96 (5.1) 1.16 (0.80-1.67)
  R&P 310 (5.0) 324 (5.2) 0.96 (0.78-1.18)
  ORIGIN 635 (10.1) 580 (9.3) 1.10 (0.94-1.29)
  GISSI-P 418 (7.4) 475 (8.4) 0.87 (0.73-1.04)
    ALL 1877 (4.8) 1947 (5.0) 0.96 (0.90-1.02)




  DOIT 29 (10.3) 35 (12.5) 0.81 (0.41-1.60)
  AREDS-2 213 (9.9) 208 (10.1) 0.98 (0.75-1.28)
  SU-FOL-OM3 216 (17.2) 211 (16.9) 1.02 (0.78-1.35)
  JELIS 262 (2.8) 324 (3.5) 0.80 (0.65-1.00)
  ALPHA OMEGA 332 (13.8) 331 (13.6) 1.02 (0.82-1.26)
  GISSI-HF 333 (9.5) 344 (9.9) 0.96 (0.78-1.18)
  OMEGA 534 (27.7) 541 (28.6) 0.96 (0.80-1.16)
  R&P 733 (11.7) 745 (11.9) 0.99 (0.86-1.14)
  ORIGIN 1276 (20.3) 1295 (20.7) 0.98 (0.87-1.09)
  GISSI-P 1552 (27.4) 1550 (27.4) 1.00 (0.90-1.11)
    ALL 5480 (14.0) 5584 (14.4) 0.97 (0.93-1.01)
p = 0.19 Heterogeneity : 92  6.8; p=0.66
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Figure 4.4: Funnel plots for subtypes of CHD and for major vascular events 
Figure 4.4 showed the funnel plot for subtypes of CHD and for major vascular 
events however with pre-specified eligibility criteria in the OTTC meta-analysis, 
this type of analysis has limited value for any meaningful explanation. Figure 4.5 
shows that allocation to omega-3 FA had no significant effect on major vascular 
events in any of the pre-specified subgroups, including those defined by sex, prior 
CHD, prior diabetes, pre-treatment levels of total cholesterol, HDL-cholesterol, 
LDL-cholesterol, triglycerides or prior use of statin therapy, albeit there was weak 
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evidence of heterogeneity in the effects of age (unadjusted p=0.03) and by prior 
stroke (p=0.03), respectively. While it was not possible to assess the effects of 
treatment by race, the results were unaltered after exclusion of the JELIS trial 
which was conducted in a Japanese population (Figure 4.6). 
162 
Figure 4.5 Effects of supplementation with omega-3 fatty acid on major vascular 
events in pre-specified subgroups 
0.5 1.0 2.099% CI
95% CI
Number of events (%)
Treatment Control






  Male 3619 (21.1) 3634 (21.3) 0.98 (0.92-1.05)
  Female 866 (13.8) 881 (14.2) 0.99 (0.86-1.13)
  Missing 995 (6.4) 1069 (6.9) 0.93 (0.82-1.04)
 Heterogeneity : 1
2  0.02; p=0.89
Age (years)
  <65 2411 (20.8) 2312 (20.2) 1.03 (0.95-1.13)
  65+ 2074 (17.7) 2203 (18.8) 0.93 (0.85-1.02)
  Missing 995 (6.4) 1069 (6.9) 0.93 (0.82-1.04)




  Yes 3159 (20.4) 3186 (20.7) 0.98 (0.91-1.05)
  No 1325 (17.0) 1325 (17.2) 0.99 (0.88-1.11)
  Missing 996 (6.4) 1073 (6.9) 0.92 (0.82-1.04)




  Yes 1299 (20.5) 1234 (19.5) 1.06 (0.95-1.19)
  No 1629 (14.6) 1726 (15.5) 0.93 (0.85-1.03)
  Missing 2552 (12.0) 2624 (12.3) 0.97 (0.89-1.05)




  Yes 1929 (21.1) 1935 (21.4) 0.99 (0.90-1.08)
  No 2554 (18.1) 2578 (18.3) 0.98 (0.90-1.06)
  Missing 997 (6.4) 1071 (6.9) 0.93 (0.82-1.04)




  <5 2045 (18.9) 2019 (18.8) 1.01 (0.92-1.10)
  5+ 2180 (21.2) 2255 (21.9) 0.96 (0.88-1.05)
  Missing 1255 (7.1) 1310 (7.4) 0.94 (0.84-1.05)




  <1.0 1392 (23.1) 1364 (22.3) 1.03 (0.92-1.16)
  1.0+ 2664 (18.6) 2719 (19.2) 0.96 (0.89-1.04)
  Missing 1424 (7.7) 1501 (8.1) 0.94 (0.85-1.04)




  <3.0 1867 (18.7) 1802 (18.1) 1.03 (0.94-1.13)
  3.0+ 2140 (21.0) 2233 (21.9) 0.95 (0.86-1.03)
  Missing 1473 (7.9) 1549 (8.3) 0.94 (0.85-1.04)




  <=1.7 2323 (18.9) 2309 (19.0) 0.99 (0.91-1.08)
  > 1.7 1854 (21.7) 1911 (22.0) 0.98 (0.89-1.08)
  Missing 1303 (7.3) 1364 (7.6) 0.94 (0.85-1.04)




  Yes 2824 (11.4) 2959 (11.9) 0.95 (0.88-1.02)
  No 742 (15.4) 696 (14.9) 1.05 (0.91-1.22)
  Missing 1914 (20.2) 1929 (20.4) 0.99 (0.90-1.09)
 Heterogeneity : 1
2
 2.55; p=0.11
ALL 5480 (14.0) 5584 (14.4) 0.97 (0.93-1.01)
p = 0.19
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Figure 4.6 Effects of supplementation with omega-3 fatty acid on CHD and MVE 
by trials excluding JELIS 
Figure 4.7 shows that allocation to omega-3 FA intervention had no significant 
effect on non-fatal MI, CHD death or overall CHD in the trials that used either an 
open and blind design. However, there was also some weak evidence of 
heterogeneity between the results from open versus blinded trials for all CHD (RR 
0.5 1.0 2.099% CI
95% CI
Number of events (%)





Coronary Heart Disease (CHD)
  Non-fatal MI 1059 (3.6) 1072 (3.6) 0.98 (0.88-1.10)
  CHD death 747 (2.5) 792 (2.7) 0.94 (0.82-1.07)
Any CHD 1789 (6.0) 1834 (6.2) 0.97 (0.91-1.04)
p = 0.4
Stroke
  Ischaemic 459 (2.2) 431 (2.0) 1.06 (0.89-1.26)
  Haemorrhagic 68 (0.3) 70 (0.3) 0.97 (0.62-1.50)
  Unclassified/Other 140 (0.5) 130 (0.4) 1.07 (0.78-1.47)
Any stroke 704 (2.4) 681 (2.3) 1.03 (0.92-1.15)
p = 0.6
Revascularisation
  Coronary 2853 (12.2) 2818 (12.1) 1.01 (0.94-1.09)
  Non-coronary 305 (2.7) 330 (2.9) 0.92 (0.75-1.13)
Any revascularisation 3099 (13.2) 3091 (13.3) 1.00 (0.94-1.05)
p = 0.9
Any Major Vascular Event 5218 (17.6) 5260 (17.8) 0.99 (0.94-1.03)
p = 0.5
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0.85 [95% CI 0.72-1.00] vs 1.01 [0.91-1.11]; unadjusted p=0.02), but not for either 
fatal CHD or non-fatal myocardial infarction, respectively. 
Figure 4.7 Effects of supplementation with Omega-3 fatty acid on fatal and non-
fatal vascular events by trial design (Open vs blinded) 
0.5 1.0 2.099% CI
95% CI
Number of events (%)






  Open 285 (1.9) 316 (2.1) 0.90 (0.72-1.11)
  Blind 836 (3.5) 839 (3.5) 0.99 (0.87-1.13)






  Open 243 (1.6) 296 (2.0) 0.81 (0.65-1.02)
  Blind 533 (2.2) 527 (2.2) 1.01 (0.86-1.19)






  Open 506 (3.4) 588 (3.9) 0.85 (0.72-1.00)
  Blind 1371 (5.7) 1359 (5.7) 1.01 (0.91-1.11)






Importantly, allocation to omega-3 FA intervention had no significant effects on the 
rate ratios (95% CI) for cancer (1.01 [0.94-1.08]) (Figure 4.8) or total mortality 
(0.96 [0.92-1.01]) (Figure 4.9).  











  DOIT 9 (3.2) 21 (7.5) 0.43 (0.16-1.13)
  AREDS-2 292 (13.6) 280 (13.6) 1.00 (0.79-1.26)
  SU-FOL-OM3 91 (7.3) 80 (6.4) 1.14 (0.76-1.72)
  JELIS 242 (2.6) 218 (2.3) 1.11 (0.87-1.42)
  ALPHA OMEGA 62 (2.6) 59 (2.4) 1.07 (0.66-1.71)
  GISSI-HF 184 (5.3) 190 (5.5) 0.96 (0.73-1.27)
  OMEGA 32 (1.7) 26 (1.4) 1.21 (0.61-2.40)
  R&P 129 (2.1) 118 (1.9) 1.10 (0.79-1.53)
  ORIGIN 463 (7.4) 489 (7.8) 0.94 (0.79-1.12)
  GISSI-P 146 (2.6) 140 (2.5) 1.04 (0.77-1.42)
ALL 1650 (4.2) 1621 (4.2) 1.01 (0.94-1.08)
p = 0.8
 Heterogeneity : 9
2  9.36; p=0.40
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Figure 4.9 Effects of supplementation with omega-3 fatty acid on total mortality  
0.25 1.0 4.099% CI
95% CI
Events (%)






  DOIT 14 (5.0) 24 (8.5) 0.57 (0.24-1.35)
  AREDS-2 30 (1.4) 27 (1.3) 1.06 (0.54-2.12)
  SU-FOL-OM3 72 (5.7) 69 (5.5) 1.04 (0.67-1.63)
  JELIS 286 (3.1) 265 (2.8) 1.08 (0.86-1.35)
  ALPHA OMEGA 186 (7.7) 184 (7.6) 1.02 (0.78-1.36)
  GISSI-HF 955 (27.3) 1014 (29.1) 0.92 (0.80-1.05)
  OMEGA 88 (4.6) 70 (3.7) 1.25 (0.82-1.90)
  R&P 348 (5.6) 337 (5.4) 1.04 (0.85-1.27)
  ORIGIN 951 (15.1) 964 (15.4) 0.98 (0.86-1.11)
  GISSI-P 477 (8.4) 554 (9.8) 0.85 (0.72-1.00)
ALL 3407 (8.7) 3508 (9.0) 0.96 (0.92-1.01)
p = 0.16




4.2 Results of biochemical effects of omega-3 FA  
In the ASCEND trial, blood spots from baseline and follow-up samples from 152 
participants were sent to the Harris laboratory in the USA for measurement of 
omega-3 FA index and results are given below. At baseline the geometric mean 
(95% CI) omega-3 FA index was 7.11 (6.79-7.45) among the 76 participants 
subsequently allocated active omega-3 FA and 6.59 (6.25-6.94) among the 76 
subsequently allocated placebo. These increased to 9.1 (8.79-9.41) during the trial 
(Table 4.10) in those allocated active omega-3 FA and were 6.54 (6.2-6.91) during 
the trial in those allocated placebo capsules.  This represented a 33% (26%-39%) 
increase compared to placebo among those allocated active omega-3 FA 
capsules and was highly statistically significant p <0.0001 (Table 4.10 and 4.11). 
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Table 4.10: Omega-3 Index (% of total fatty acids) on-trial allowing for baseline Omega-3 index (Overall) in ASCEND 
substudy 
Arm 
Active Omega-3 arm  Placebo Omega-3 arm  Percent increase on 
trial in Omega-3 arm 








Geometric mean (95% CI) 
N
Geometric mean (95% CI) 
Baseline On-trial Baseline On-trial 
Overall 76 7.11 (6.79 to 7.45) 9.10 (8.79 to 9.41) 76 6.59 (6.25 to 6.94) 6.54 (6.20 to 6.91) 33% (26% to 39%) <0.0001
Aspirin allocation 
Active aspirin 38 7.13 (6.71 to 7.57) 9.10 (8.71 to 9.50) 38 6.45 (5.96 to 6.98) 6.48 (6.00 to 7.00) 32% (23% to 41%) 0.8 
Placebo aspirin 38 7.10 (6.62 to 7.62) 9.09 (8.63 to 9.59) 38 6.73 (6.27 to 7.21) 6.61 (6.12 to 7.14) 33% (24% to 42%) 
Compliance with brown 
capsules 
No 1 7.77 6.79 3 6.60 (5.35 to 8.14) 7.07 (5.84 to 8.57) -13% (-38% to 20%) 0.01 
Yes 70 7.08 (6.74 to 7.43) 9.19 (8.87 to 9.52) 73 6.59 (6.24 to 6.95) 6.52 (6.17 to 6.90) 35% (28% to 41%) 
Baseline Omega-3 index 
High (8%+) 23 8.77 (8.40 to 9.16) 9.72 (9.09 to 10.40) 15 9.22 (8.70 to 9.78) 8.98 (8.36 to 9.65) 11% (1% to 22%) <0.0001
Low (<8%) 53 6.50 (6.21 to 6.80) 8.84 (8.52 to 9.17) 61 6.06 (5.81 to 6.33) 6.05 (5.77 to 6.35) 41% (33% to 48%) 
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Arm 
Active Omega-3 arm  Placebo Omega-3 arm  Percent increase on 
trial in Omega-3 arm 








Geometric mean (95% CI) 
N
Geometric mean (95% CI) 
Baseline On-trial Baseline On-trial 
Fatty acid supplement at 
baseline 
No 64 7.11 (6.74 to 7.49) 9.08 (8.75 to 9.41) 69 6.47 (6.13 to 6.84) 6.44 (6.08 to 6.81) 33% (27% to 40%) 0.4 
Yes 12 7.16 (6.58 to 7.80) 9.21 (8.33 to 10.18) 7 7.79 (6.92 to 8.77) 7.72 (6.78 to 8.79) 25% (9% to 44%) 
Type of fatty acid 
supplement at baseline 
Cod liver oil capsule 10 7.09 (6.40 to 7.84) 9.07 (8.06 to 10.22) 5 7.41 (6.89 to 7.97) 7.13 (6.52 to 7.79) 32% (15% to 50%) 0.5 
Omega-3/fish oil 
supplement 2 7.54 (7.17 to 7.93) 9.89 (9.47 to 10.33) 2 8.83 (5.95 to 13.10) 9.43 (7.38 to 12.04) 18% (-8% to 51%) 
Percent increase and p-values are from Generalised Linear Models and allow for baseline Omega-3 index 
Note: No patient had fatty acid supplements noted on their on-trial blood sample form 
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Allocation to aspirin had no significant effect on change in the omega-3 FA 
index with supplements (p for heterogeneity = 0.80).  Only 4 participants (1 
active and 3 on placebo) among those selected for omega-3 index measures 
reported non-compliance with their omega-3 FA capsules or placebo, 
providing limited power to assess differences. However, as expected, the 
omega-3 index did not rise significantly from baseline in the one non-
compliant participant. 
The effects on the omega-3 index were not significantly influenced by self-
reported omega-3 fatty acid supplement use at baseline (Table 4.10), but 
only 15 participants reported such use. For those reporting baseline use, 
there was still a 25% (9%-44%) increase in the index, but this was not 
significantly different from the overall results (p for heterogeneity 0.5). By 
contrast, those with a baseline omega-3 FA index >8% (i.e. a high baseline 
level), only increased by a 11% (1% to 22%) during the trial versus placebo 
compared with a 41% (33% to 48%) increase vs placebo in those with a low 
baseline omega-3 FA index <8% (p for heterogeneity <0.001).  
Tables 4.11 and 4.12 show the impact of accounting for baseline FA index 
and baseline use of omega-3 supplementation but does not change the 
overall message. 
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Table 4.11: Omega-3 Index on-trial allowing for baseline index (No fatty acid use reported at baseline) in ASCEND substudy 
Arm 
Active Omega-3 arm  Placebo Omega-3 arm  Percent increase 
on-trial in Omega-









Geometric mean (95% CI) 
N
Geometric mean (95% CI) 
Baseline On-trial Baseline On-trial 
Overall 64 7.11 (6.74 to 7.49) 9.08 (8.75 to 9.41) 69 6.47 (6.13 to 6.84) 6.44 (6.08 to 6.81) 33% (26% to 39%) <0.0001 
Aspirin allocation 
Active aspirin 33 7.12 (6.65 to 7.61) 9.04 (8.62 to 9.48) 35 6.35 (5.84 to 6.90) 6.37 (5.87 to 6.90) 33% (23% to 43%) 0.8 
Placebo aspirin 31 7.10 (6.54 to 7.70) 9.11 (8.62 to 9.63) 34 6.60 (6.14 to 7.10) 6.51 (6.00 to 7.06) 34% (25% to 45%) 
Compliance with brown 
capsules 
No 1 7.77 6.79 3 6.60 (5.35 to 8.14) 7.07 (5.84 to 8.57) -13% (-38% to 22%) 0.01 
Yes 59 7.04 (6.66 to 7.45) 9.17 (8.84 to 9.52) 66 6.47 (6.11 to 6.85) 6.41 (6.04 to 6.80) 36% (29% to 43%) 
Baseline Omega-3 index 
High (8%+) 21 8.75 (8.34 to 9.17) 9.57 (8.93 to 10.26) 13 9.20 (8.67 to 9.77) 8.95 (8.29 to 9.66) 10% (-1% to 21%) <0.0001 
Low (<8%) 43 6.42 (6.09 to 6.77) 8.84 (8.50 to 9.20) 56 5.97 (5.71 to 6.24) 5.96 (5.67 to 6.26) 43% (35% to 51%) 
Percent increase and p-values are from Generalised Linear Models and allow for baseline Omega-3 index Note: No patient had fatty acid supplements noted on their on-trial blood 
sample form. 
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Table 4.12: Omega-3 Index on-trial allowing for baseline index (fatty acid use reported at baseline) in ASCEND substudy 
Arm 
Active Omega-3 arm  Placebo Omega-3 arm  Percent increase 
on-trial in Omega-









Geometric mean (95% CI) 
N
Geometric mean (95% CI) 
Baseline On-trial Baseline On-trial 
Overall 12 7.16 (6.58 to 7.80) 9.21 (8.33 to 10.18) 7 7.79 (6.92 to 8.77) 7.72 (6.78 to 8.79) 33% (26% to 39%) <0.0001 
Aspirin allocation 
Active aspirin 5 7.21 (6.39 to 8.15) 9.48 (8.44 to 10.65) 3 7.72 (7.21 to 8.26) 8.01 (7.70 to 8.33) 25% (4% to 51%) 0.8 
Placebo aspirin 7 7.12 (6.29 to 8.07) 9.01 (7.71 to 10.54) 4 7.85 (6.33 to 9.73) 7.51 (5.93 to 9.52) 30% (11% to 53%) 
Compliance with brown 
capsules 
Yes 11 7.26 (6.64 to 7.93) 9.26 (8.31 to 10.33) 7 7.79 (6.92 to 8.77) 7.72 (6.78 to 8.79) 28% (13% to 44%) 
Baseline Omega-3 index 
High (8%+) 2 9.03 (8.49 to 9.59) 11.50 (10.78 to 12.27) 2 9.35 (7.06 to 12.40) 9.21 (6.89 to 12.31) 28% (-1% to 65%) 1.0 
Low (<8%) 10 6.84 (6.37 to 7.34) 8.80 (7.98 to 9.71) 5 7.24 (6.83 to 7.68) 7.20 (6.51 to 7.96) 27% (10% to 47%) 
Type of fatty acid supplement at 
baseline 
Cod liver oil capsule 10 7.09 (6.40 to 7.84) 9.07 (8.06 to 10.22) 5 7.41 (6.89 to 7.97) 7.13 (6.52 to 7.79) 32% (15% to 50%) 0.5 
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Arm 
Active Omega-3 arm  Placebo Omega-3 arm  Percent increase 
on-trial in Omega-









Geometric mean (95% CI) 
N
Geometric mean (95% CI) 
Baseline On-trial Baseline On-trial 
Omega-3/fish oil supplement 2 7.54 (7.17 to 7.93) 9.89 (9.47 to 10.33) 2 8.83 (5.95 to 13.10) 9.43 (7.38 to 12.04) 18% (-8% to 51%) 
Percent increase and p-values are from Generalised Linear Models and allow for baseline Omega-3 index 
Note: No patient had fatty acid supplements noted on their on-trial blood sample form. 
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4.3 Results of biochemical effects of aspirin  
Among the participants randomly sampled allocated to receive active aspirin, 
the geometric mean (95% CI) of UTxB2 concentration at baseline was 3453 
(3069-3895) pg/mg (n=70) which decreased to 1190 (1100-1287) pg/mg 
(n=167) during the trial (Table 4.10). Among those allocated the placebo 
white tablet, UTxB2 was 3499 (3114-3931) pg/mg (n=69) at baseline and 
3607 (3312-3929) pg/mg (n=170) during the trial. This represented 67% (63-
70%) decrease compared to placebo among those allocated active aspirin 
and was highly statistically significant with a p-value of <0.0001 (Table 4.10). 
Allocation to omega-3 FA in both active and placebo aspirin groups had no 
significant effect on change in UTxB2 concentrations (p for heterogeneity 
=0.80).  Only 14 participants (6 active aspirin and 8 on placebo) among those 
selected for UTxB2 measures reported non-compliance with aspirin or 
placebo providing limited power to say anything useful. However, as 
expected, UTxB2 did not reduce significantly from baseline in the 6 non-
compliant participants. The 8 non-compliant participants in placebo groups 
reduced UTxB2 indicating that they may have been on prescribed aspirin 
after they had stopped taking trial tablets. 
These results were not influenced by reported time since taking their aspirin 
or placebo tablet in compliant patients. In those who reported taking their 
tablet between 0-12 hours prior to the urine sample, the reduction in UTxB2 
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was 67% (63-72%) and in those who reported taking their treatment 12-24 
hours prior to sampling the reduction was 70% (64-74%) (Table 4.10) P =0.6. 
These results were not influenced by self-reported non-study NSAID use at 
baseline nor by on-trial supplement use or baseline UTxB2 results (high 
(>3000) and low (0-3000)) (Table 4.10)  
Figure 4.11 gives the results of creatinine-adjusted UTxB2 in-trial and at 
baseline by allocation to active vs placebo aspirin and non-study NSAID use.
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Table 4.13: Main results of measurement of urinary Thromboxane B2 in ASCEND substudy 
Arm 
Active Aspirin arm Placebo Aspirin arm Percent decrease 
on-trial in Aspirin 



















Overall 70 3453 (3061-3895) 167 1190 (1100-1287) 69 3499 (3114-3931) 170 3607 (3312-3929) 67% (63% to 70%) <0.0001 
Omega-3 allocation 
Active Omega 35 3294 (2750-3945) 77 1070 (967-1184) 36 3303 (2787-3914) 86 3337 (2957-3765) 68% (62% to 72%) 0.8 
Placebo Omega 35 3620 (3083-4252) 90 1303 (1163-1460) 33 3726 (3181-4364) 84 3907 (3468-4402) 67% (61% to 71%) 
Compliance with white tablets 
No 6 2344 (1108-4959) 6 2053 (998-4223) 8 3243 (2141-4912) 8 1449 (730-2874) -42% (-143% to 17%) <0.0001 
Yes 64 3581 (3205-4000) 161 1166 (1081-1257) 59 3465 (3067-3915) 160 3783 (3497-4091) 69% (65% to 72%) 
Time since white tablet last 
taken(in compliant patients) 
0-12 hours 49 3581 (3129-4097) 99 1127 (1024-1242) 43 3180 (2758-3667) 93 3489 (3166-3845) 67% (63% to 72%) 0.6 
12-24 hours 9 3669 (2887-4662) 56 1259 (1106-1432) 11 4283 (3451-5316) 62 4168 (3643-4769) 70% (64% to 74%) 
Baseline thromboxane 
(Original dataset only) 
High (>3000) 45 4534 (4153-4949) 45 1180 (997-1396) 46 4541 (4160-4957) 46 3574 (2999-4258) 67% (58% to 74%) 0.7 
Low (0-3000) 25 2115 (1770-2528) 25 761 (624-927) 23 2077 (1783-2419) 23 2472 (1945-3143) 69% (57% to 78%) 
Non-study NSAID at baseline 
No 64 3725 (3368-4120) 153 1191 (1096-1294) 62 3658 (3271-4091) 153 3699 (3384-4044) 68% (63% to 71%) 0.2 
Yes 6 1538 (804-2943) 14 1181 (939-1485) 7 2357 (1386-4009) 17 2877 (2176-3803) 59% (40% to 72%) 
Non-study NSAID on-trial 
No 67 3497 (3087-3962) 160 1194 (1101-1295) 62 3685 (3297-4119) 157 3780 (3473-4114) 68% (64% to 72%) 0.05 
Yes 3 2597 (2047-3295) 7 1094 (920-1301) 7 2208 (1340-3637) 13 2053 (1477-2853) 48% (16% to 68%) 
Compliance with white tablets 
and non-study NSAID on-trial 
Non-compliant and no NSAID 6 2344 (1108-4959) 6 2053 (998-4223) 7 3260 (2019-5264) 7 1603 (752-3418) -28% (-121% to 26%) <0.0001 
Non-compliant and NSAID 0 0 1 3131 1 713 
Compliant and no NSAID 61 3638 (3245-4079) 154 1169 (1081-1265) 53 3670 (3282-4105) 148 3946 (3652-4264) 70% (66% to 73%) 
Compliant and NSAID 3 2597 (2047-3295) 7 1094 (920-1301) 6 2083 (1172-3702) 12 2242 (1653-3040) 52% (23% to 70%) 
Unknown and no NSAID 0 0 2 6309 (4736-8407) 2 3117 (2439-3984) 
Non-study NSAID at baseline 
and/or on-trial 
Neither 63 3744 (3381-4146) 151 1193 (1097-1298) 59 3738 (3333-4192) 150 3765 (3449-4110) 68% (64% to 72%) 0.3 
Baseline only 4 1195 (494-2893) 9 1212 (858-1712) 3 2793 (1866-4178) 7 4105 (3033-5555) 70% (50% to 82%) 
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Arm 
Active Aspirin arm Placebo Aspirin arm Percent decrease 
on-trial in Aspirin 



















On-trial only 1 2700 2 1015 (690-1494) 3 2398 (2214-2596) 3 1528 (675-3460) 41% (-51% to 77%) 
Both 2 2547 (1695-3826) 5 1127 (911-1394) 4 2076 (822-5240) 10 2243 (1567-3211) 50% (12% to 71%) 
Percent decrease and p-values are from Generalised Linear Models (adjusted for original versus additional dataset) On-trial Creatinine Adjusted Urinary Thromboxane, Adjusted for 
original versus additional dataset, unadjusted for baseline Creatinine Adjusted Urinary Thromboxane. 
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179 
4.4 Summary of results 
The OTTC meta-analysis of tabular data from 10 large RCTs involving  
77,906 participants demonstrated that allocation to omega-3 FA supplements 
for an average duration of 4.4 years had no effect on fatal CHD, non-fatal MI, 
stroke, revascularisation events or any major vascular events. Importantly, 
this meta-analysis also showed no beneficial effect on major vascular events 
in any particular subgroups. Likewise, the present meta-analysis indicated no 
evidence of any hazards of omega-3 FA supplements on cancer or on all-
cause mortality. 
The biochemical effects of study medications were consistent with the 
expected effects. Allocation to omega-3 FA supplements was associated with 
a 33% increase in the omega-3 FA index (consistent with the previous report) 
with no effect among allocated placebo. Similarly, allocation to active aspirin 
was associated with the expected reduction in UTxB2 illustrating the 
suppression of TxA2 resulting from COX-1 inhibition.  Allocation to aspirin 
significantly reduced UTxB2 even up to 24 hours after ingestion with no 
evidence of any loss of effect.  There was no interference of allocation of 
aspirin on omega-3 FA biochemical effectiveness or vice visa. These effects 
were only apparent in participants who reported that they were compliant with 
their allocated treatments. 
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5 Discussion and Conclusion 
5.1 Discussion of findings from the Omega-3 Treatment Trialists’ 
meta-analysis of large randomised trials  
This meta-analysis of 10 large RCTs involving 77,906 participants 
demonstrated that allocation to omega-3 FA supplements for an average 
duration of 4.4 years had no effect on fatal CHD, non-fatal MI, stroke, 
revascularisation events or any major vascular events. Importantly, this meta-
analysis also showed no beneficial effect on major vascular events in any 
particular subgroups. Likewise, the present meta-analysis indicated no 
evidence of any hazards of omega-3 FA supplements on cancer or on all-
cause mortality. 
The chief strength of this study was the availability of tabular data extracted 
by the trial Principal Investigators for all trials included in this meta-analysis 
(with the exception of the JELIS trial (206), where published data were used). 
The definitions of events were more directly comparable than in previous 
meta-analyses of the published results (214, 218, 222). Secondly, this meta-
analysis had strict eligibility criteria for selection of trials, involving 
comparisons of omega-3 FA supplementation trials, involving 500 or more 
participants, and a treatment duration of at least one year. Thirdly, this meta-
analysis also examined effects of treatment in pre-specified subgroups of 
major vascular events.  
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The reasons for the discrepant results of the previous trials of omega-3 FA 
supplements on fatal and non-fatal CHD events are not fully understood. In 
contrast with the null findings for most recent trials e.g. the Alpha omega trial, 
the Omega trial and SU-FOL-OM3, the older GISSI-P trial (153) reported a 
14% reduction in major vascular events, chiefly due to a reduction in cardiac 
deaths and the JELIS trial reported a 19% (95% CI 5-31%) reduction in major 
CHD events, albeit based on only 586 events, chiefly due to a reduction in 
non-fatal CHD events. Both the GISSI-P and the JELIS trial used an open-
label design where placebo capsules were lacking. In the GISSI-P trial for 
patients surviving a recent MI, supplementation of omega-3 FA 900 mg per 
day reduced significantly fatal CVD by 30%, fatal CAD by 35%, and sudden 
death by 45%. In the GISSI-HF trial, where heart failure patients were 
included, fatal CVD was only reduced by 10%, sudden death non-
significantly by 7%, and first hospital admissions for ventricular arrhythmias 
significantly by 28% with the same dose of omega-3 FA supplementation. 
The JELIS trial showed the reduction of only major coronary events (fatal and 
non-fatal CAD, unstable angina, percutaneous coronary intervention, and 
coronary artery bypass grafting) with 1.8 g intake of EPA. Another possible 
explanation in addition to different study design could be that whether 
differences in prior disease, use of statins or other secondary prevention 
treatments may explain some of the conflicting results of individual trials 
(characteristic of included trials as described in section 4.1.2). Participants in 
the more recent trials were very well treated not only by antithrombotics but 
also by antihypertensives and statins. Compared with the recent trials, the 
treatment level with statins was low in the GISSI-P trial (29%). This could be 
182 
the reason for the high risk of fatal CAD and sudden death in the GISSI-P 
trial compared with the Alpha Omega Trial (85%), the omega trial (94%) and 
the SU-FOL-OM3 (83%). Previous reports suggested that the effects of 
omega-3 FA treatment may vary by prior use of statins (234, 235). For 
example, the Alpha Omega trial reported that low dose omega-3 FA reduced 
the risk of major vascular events in patients with prior MI not treated with 
statins (235). Importantly, the present meta-analysis demonstrated no 
heterogeneity of the effects of omega-3 FA on CHD death or non-fatal MI 
between the individual trials. The present meta-analysis also reported no 
differential effects of omega-3 FA on major vascular events by subgroups of 
those with or without prior cardiovascular disease or diabetes, or those with 
below or above average lipid levels or by prior use of statin therapy. The 
results of the present meta-analysis were unaltered with or without the 
inclusion of the JELIS trial (206), in which all were also treated with statins.  
Although several possible mechanisms of effects of omega-3 FA on fatal 
CHD have been suggested, including anti-arrhythmic effects, anti-thrombotic 
effects, anti-inflammatory effects, plaque stabilisation and vasodilatation or 
triglycerides lowering effects (234, 236), these trials were unable to evaluate 
any of these mechanisms. It is possible that the discrepant results of the 
observational studies of n-3 fatty acid biomarkers and fatal CHD (237),  and 
the effects on fatal CHD in this meta-analysis of the RCTs may reflect 
confounding by the healthy lifestyle of individuals with high versus low 
plasma levels of biomarkers of omega-3 FA intake in the observational 
studies. Results of observational prospective cohort studies and randomized 
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trials published before the year 2000 demonstrated that diets with higher 
amounts of omega-3 FA or supplements with omega-3 FA reduced 
cardiovascular mortality. The American Heart Association Guidelines, that 
people with established coronary arterial disease should be advised to take 
900–1000 mg of omega-3 FA (EPA–DHA combined) per day. Most recently 
reported RCTs with null findings of omega-3 FA supplementation on 
cardiovascular outcomes did not have dietary fish intake data to investigate 
whether dietary intake or therapeutic supplements are the best source of 
omega-3 fatty acids is yet to be determined. Alternatively, the absence of any 
beneficial effect of omega-3 FA on MVE may reflect an insufficient dose of 
omega-3 FA used in the existing trials. 
Previous meta-analyses of omega-3 FA trials (214, 218, 222, 238), were 
limited by being incomplete (214), including trials of dietary advice to 
increase fish consumption (214, 222) or by failing to distinguish effects of 
omega-3 FA on fatal versus non-fatal CHD outcomes (214, 218, 222, 238). 
Importantly, the results of the present meta-analysis differ from previous 
meta-analyses which suggested that omega-3 FA had a beneficial effect on 
fatal CHD (218, 222). In contrast, the present meta-analysis restricted to all 
eligible trials and tabular data supplied by individual trialists (except for the 
JELIS trial (206), reported no significant effect of omega-3 FA supplements 
on fatal CHD events. The present meta-analysis reported weak evidence of 
heterogeneity between the results of open and blinded trials for any CHD, 
which may reflect either chance or greater compliance in the open than in the 
blinded trials. An individual participant data meta-analysis (IPD) may have a 
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greater chance of detecting effects of omega-3 FA supplements on subtypes 
of fatal CHD (i.e. sudden death or ventricular arrhythmias) in a wider range of 
subgroups, but the overall null results of the present meta-analysis provide 
little encouragement for such an approach. Moreover, when I carried out 
OTTC as part of my MD project during my research time out of clinical 
training, I aimed to complete within the allocated time frame of 2 years and 
hence tabular meta-analysis methodology was adopted over IPD.  In contrast 
to the previous meta-analyses of these trials, the present meta-analysis, 
involving 5 years of treatment and 3271 incident cancer events, indicated no 
adverse effects of omega-3 FA on cancer incidence. While these findings 
confirmed the safety of omega-3 FA on overall risk of cancer, no data were 
available on site-specific cancer. An additional limitation of the present meta-
analysis involved the use of tabular rather than individual-level data. Hence, it 
was not possible to conduct additional analyses of the effects of omega-3 FA 
on major vascular events in subgroups by smoking or other cardiovascular 
risk factors. However, since the overall results and results in subtypes of 
disease were null, it is very unlikely that the results of a meta-analysis using 
individual-level data would differ from that using study-level data. Time-to-
event analyses require individual-level data, but the results of such analyses 
are also unlikely to differ from those obtained using the Peto observed minus 
expected statistic (O-E) and its variance methodology used in this meta-
analysis. 
The 95% CI in the present meta-analysis of 10 trials, involving 78,906 high-
risk individuals, including 11,000 major vascular events and 3824 CHD 
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events, cannot exclude a 7% lower risk of MVEs and a 10% lower risk of 
CHD for the effects of omega-3 FA supplements. Several ongoing large 
RCTs, involving a total of 64,000 participants (ASCEND: n=15,480; VITAL: 
n=25,874; STRENGTH: n=13,000 and REDUCE-IT: n=8000), should provide 
additional knowledge about the effects of omega-3 FA supplements on major 
vascular events, CHD and subtypes of CHD (124, 190, 220, 239). 
Importantly, the STRENGTH and REDUCE-IT trials will test the effects of 
major vascular events of much higher doses of omega-3 FA (3-4g/day) which 
will lower plasma levels of triglycerides without risk of bleeding or effect on 
blood glucose (detail discussion in section 2.5.3). These latter trials will also 
test the triglyceride-lowering hypothesis (with relatively higher dose 
compared to previous large RCTs in OTTC) in high-risk statin-treated 
patients with persistently elevated triglyceride levels.  
The 2016 ESC/EAS Guidelines for the Management of Dyslipidaemia state 
that more data on the efficacy of omega-3 FA supplements for prevention of 
clinical outcomes are needed to justify their prescription (124). The results of 
the present meta-analysis provide no support for the recommendations to 
use of about 1g/day of omega-3 FA supplements in high-risk individuals for 
prevention of vascular events, cancer or all-cause mortality. The results of 
the ongoing trials are required to assess if higher doses of omega-3 FA (3-
4g/day) have any beneficial effects on risk of MVEs.  
In conclusion, this meta-analysis of large RCTs is the largest such meta-
analysis carried out to date and has shown no significant effect of omega-3 
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FA supplementation on non-fatal MI, sudden death or on any major vascular 
events. No beneficial effect was also seen for stroke or revascularisation. 
The results of on-going large RCTs (ASCEND and VITAL) will provide 
additional evidence in a further 35,000 participants for the effects of omega-3 
FA for prevention of CHD.  The present results do not support 
recommendations to use omega-3 FA supplements in high-risk people for 
prevention of CHD (221). (OTTC paper is now published in JAMA 
Cardiology) 
5.2 Discussion of biochemical results 
In the ASCEND sub-study of the biochemical effectiveness of study 
medications, blood and urine samples were requested to 1500 participants at 
mid randomization phase, (10% of the total study population of randomly 
selected participants who returned samples at the baseline sample 
collection). In total 1288 samples were returned (1265 returned blood and 
urine samples, 6 blood only, 17 urine only, 512 did not return any samples). 
This selective randomisation method gave the opportunity to compare the 
analysis of biochemical measurement at two time-points for each individual, 
at baseline and post-randomisation. However, this approach may have a 
possible implication that those participants may tend to compliance more with 
study medication compared with non-responders to sample request in the 
first place. The percentage response rate of blood and urine sample 
collection for ASCEND on both time points was similar (around 78%-84%). 
About 98% of returned samples arrived to the central laboratory within the 
calculated time frame of 10 days from blood and urine collection at their local 
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surgery. Urine samples were frozen on arrival until measured. The impact of 
this was evaluated as part of the assays validation process (detail in section 
3.4.2) and showed no significant variation in the measurement of UTxB2. The 
methodology of adopting randomization between treatment group and 
placebo group for this sub-study should have given the reliable and 
meaningful results between groups. There was a plasma sparing effect by 
choosing red-cell membrane omega-3 index measurement by dried blood 
spots which allow stored plasma samples for future biochemical 
measurement in ASCEND.  
Biochemical results of Omega-3 index 5.2.1
Follow-up omega-3 index was increased by 33% (95% CI 26%-39%) from 
baseline in those allocated omega-3 FA compared to placebo. Our finding 
suggested that the increment was higher in patients with low omega-3 Index 
at baseline compared to a group of patients with high omega-3 index (>8%). 
Our findings are in agreement with a previously reported range of increase in 
measurement with omega-3 FA supplement. In a sub-study of the 
Framingham offspring cohort study for fish oil supplement, it was reported 
that omega-3 index increased by 41% (95% CI- 31-52%) in the active 
treatment group (200). The previously reported dose-response study 
reported that omega-3 index (mean +/-CI) increased from 4.7% (+/-0.9) to 
7.9% (+/-1.7) with 0.5 g/day omega-3 FA supplement, to 9.9% (+/-2.9) with 
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1g/day and to 11.6% (+/-2.4) with 2g/day. Supplementation of 1 g Omega-3 
FA in the ASCEND trial increased omega-3 FA index to 9.1% (8.79-9.41) in 
the active treatment group compared with placebo consistent with previously 
reported response of the omega-3 index after supplementation. 
The omega-3 index has been used in various trials in different populations. In 
a diabetic population, the mean level was reported as 3.47% (CI +/-1.20) in 
line with the baseline estimates in ASCEND. One US study reported results 
in patients with major depression in the USA showing the omega-3 index was 
very low at 2.9% (+/-1.5) (240). Trials of patients with end-stage renal failure 
having haemodialysis, peritoneal dialysis or renal transplant reported high 
omega-3 index level which was thought to be due to significant alterations in 
erythrocyte membrane FA by the dialysis method and the omega-3 FA 
supplementation (241). Fish consumption had a major effect on omega-3 
Index by 13% (p< 0.0001) increase for each serving level increase in oily fish 
intake (198). Diet was not included in the follow-up questionnaires in 
ASCEND, however, in this sub-study which measured omega-3 FA index at 
two time points (baseline and on-trial), the results indicate the desired 
increase in treatment group (follow-up omega-3 index was increased by 33% 
(95% CI 26%-39%) in those allocated omega-3 FA compared to placebo 
(p<0.0001, geometric mean 9.10% versus 6.54%).  
In the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto 
Miocardico-Heart Failure (GISSI-HF) study, the omega-3 index was 
measured in a subset of patients (n=461 out of 6975 randomised), at 
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baseline and after 3 months of omega-3 FA supplementation (1 g daily). After 
treatment, the omega-3 index increased from 4.8±1.7% to 6.7±1.9% in the 
treatment group but was unchanged in the placebo group (4.7±1.7 to 
4.8±1.5%) (P<.0001) (242). Previously omega-3 index has been suggested 
as a risk factor for cardiac death and was inversely associated with risk for 
CHD mortality coding >8% of the omega-3 index with the greatest 
cardioprotection (243). Based on this data the proposed cutoffs for healthy 
levels of the omega-3 index were thought to be in the range of desirable 
>8%, intermediate level 4%-8% and undesirable high-risk level of <4% for 
cardioprotective effect (243). Overall, in the ASCEND trial,  omega-3 Index 
(mean 95% CI) in the treatment group was 9.10% (8.79 to 9.41) compared to 
6.54% (6.20 to 6.91) in the placebo group in the trial. Biochemically the 
finding has confirmed that supplementation with 1g daily EPA+DHA 
increased the omega-3 index to a level believed to be cardioprotective. 
Previous omega-3 FA trials with null results were criticized for low 
bioavailability, and issues in study design (small sample size and insufficient 
duration). It was also assumed that with no difference in levels of omega-3 
FA between treatment and placebo groups, a difference in study outcome 
may not be possible (240). However, the large randomised ASCEND trial 
(N>15,000) with a mean duration of >7 years follow-up and biochemical 
confirmation of biochemical effectiveness measured by the omega-3 index, 
should provide reliable evidence for the effects of omega-3 FA 
supplementation on cardiovascular outcomes. 
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Discussion of the results of the Urinary Thromboxane 5.2.2
B2 measures 
Several groups have reported that the antiplatelet activity of aspirin in people 
with diabetes may be reduced or variable leading to aspirin resistance due to 
hyperglycaemia or rapid platelet turnover (138, 139, 143, 144, 244). In one 
study the prevalence of aspirin resistance was reported as being up to 18% 
in diabetic patients suggesting that such patients were at risk of arterial 
thrombotic events despite aspirin therapy (244). However, our results show a 
significant reduction in UTxB2 level (67% (95% CI 61%-74%)) reflecting 
suppression of TXA production due to COX 1 inhibition in diabetic patients 
with aspirin allocation compared to placebo group (p<0.0001) in the 
ASCEND trial. Our findings do not support the previously reported high 
prevalence of aspirin resistance in a diabetic population but show that aspirin 
has a similar biochemical effect in diabetes as seen in other populations. 
However, the limitation of this pilot study to add to consideration included a 
small number (n=337), randomly selected from those 1260 participants who 
sent their blood and urine samples at both time points (baseline and 3.5 
years follow-up) of sample collection. In addition, by being a mailed-based 
sample, aspirin ingestion was not witnessed and therefore the exact time 
difference between aspirin ingestion and sample collection was self-reported. 
It has also been suggested that diabetic patients require higher doses or 
more frequent dosing of aspirin to have the desired biochemical effect and 
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preventive effect on atherosclerotic events (136, 144, 245). In our study, in 
compliant participants, there was no evidence of a decrease in effect by time 
since ingestion of the active/placebo aspirin tablet (reductions 67% [95% CI 
63%-72%] at 0-12 hours and 70% [64%-74%] at 12-24 hours). Our results do 
not suggest rapid recovery of TxB2 generation with once a day dosing nor 
higher UTxB2 measurement after 12-hour post-aspirin intake.  
Measurement of serum thromboxane is regarded as the preferred method of 
assessment for COX inhibition by aspirin rather than UTxB2. However, we 
have shown that UTxB2 can also be used to reliably assess the biochemical 
effect of aspirin. Using measures of UTxB2 will allow trials to collect samples 
by mail or without any requirement for on-site sample preparation as it is a 
stable metabolite. One study has shown discrepancies between serum and 
urine thromboxane results and this may be related to a variety of factors (e.g.
BMI) but in the context of this randomised trial, it appears that UTxB2 levels 
were suppressed as expected (136). Although it was well recognized that 
UTxB2 level can be influenced by various factors, it has shown the 
percentage difference on a comparison between treatment group and 
placebo group in our pilot study. 
Another concern is that the preparation of aspirin with an enteric coating may 
lead to a failure to achieve complete inhibition of TxB2 generation due to 
incomplete absorption leading to possible aspirin resistance in diabetic 
patients (246). In ASCEND, the preparation was enteric coated aspirin and 
our results do not suggest less bioavailability as shown by the desired 
192 
significant reduction of UTxB2 after aspirin ingestion. Medication adherence 
might play a large role in aspirin resistance, and may, in fact, be the largest 
contributory factor and this should be fully investigated before “aspirin 
resistance” is invoked. 
Considering possible side effects of aspirin with bleeding risk, using higher or 
frequent dosing of aspirin should not be taken lightly especially with a recent 
report from The Japanese Primary Prevention Project (JPPP) for elderly 
people with multiple cardiovascular risk factors (N = 14,464, aged 60 to 85 
years) (247). The study was terminated early by the Data Monitoring 
Committee after a median follow-up of 5.02 years based on likely futility. The 
5-year cumulative primary outcome event rate was not significantly different 
between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% 
[95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-
1.15]; P = 0.54) (247). However, it showed significantly increased the risk of 
extracranial hemorrhage requiring transfusion or hospitalization (HR, 1.85 
[95% CI, 1.22-2.81]; P = 0.004). The ongoing, ASPREE (a double-blind, 
randomised, placebo-controlled trial of oral 100mg enteric-coated 
acetylsalicylic acid (ASA) or matching placebo being conducted in Australian 
and US populations), will examine whether the potential primary prevention 
benefits of low-dose aspirin outweigh the risks in healthy older individuals 
(248). ASCEND will complete and results will be available in 2018 to answer 
whether aspirin reduces the risk of cardiovascular events in individuals with 
diabetes who do not already have diagnosed occlusive arterial disease and 
whether such benefits outweigh any potential hazards from bleeding. A study 
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with n=>15,000 should have excellent power (95% Power 2p<0.01) to detect 
a 12-15% proportional reduction in the cardiovascular event rate among such 
patients with biochemical confirmation that aspirin inhibiting COX1 as shown 
by reduction in UTxB2. 
The work described in the present thesis has demonstrated the reliability of 
questionnaire-based, self-reported compliance with study medication for this 
large mail based trial. Whether the biochemical effects will translate into 
beneficial effects on clinical outcomes will become clear on completion of 
ASCEND in mid-2018. 
Aspirin: continuing clinical uncertainty  5.2.3
Substantial uncertainty still persists about whether or not aspirin should be 
recommended for the primary prevention of cardiovascular disease in people 
with diabetes. This uncertainty is reflected by the discrepant 
recommendations for use of aspirin in cardiovascular prevention guidelines. 
When ASCEND was designed, the American Diabetes Association 
recommended aspirin use for primary prevention in people with diabetes with 
one additional risk factor (249) but, at that time, the UK and European 
guidelines were more circumspect (250, 251). More recently, the UK National 
Institute for Health and Care Excellence (NICE) 2015 Guideline for Type 2 
Diabetes has included recommendations not to offer antiplatelet therapy for 
adults with type 2 diabetes without cardiovascular disease (252) and similarly 
the most recent European Guidelines (124). By contrast the U.S. Preventive 
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Services Task Force now recommends initiating low-dose aspirin use for the 
primary prevention of cardiovascular disease and colorectal cancer in adults 
aged 50 to 59 years who have a predicted risk for MI or stroke of at least 
10% over 10 years, are not at increased risk for bleeding, and are willing to 
take low-dose aspirin daily for at least 10 years, irrespective of their diabetes 
status (253) For the analogous group aged 60-69 the recommendation is 
“optional”.  
The ATTC meta-analyses have shown that the absolute risks for 
cardiovascular disease and for bleeding events are positively correlated. A 
diagnosis of diabetes increases an individuals’ risk both of occlusive vascular 
disease and of bleeding. Without direct evidence of the balance of benefits 
and harm of antiplatelet therapy in this population, it is difficult to make clear 
recommendations. Furthermore, since the ASCEND trial started, the potential 
role of aspirin for the prevention of cancer has emerged as an important 
additional factor to be considered.  
In addition to ASCEND, there are other ongoing trials in intermediate-risk 
populations which will provide further data. The Aspirin and Simvastatin 
Combination for Cardiovascular Events Prevention Trial in Diabetes 
(ACCEPT-D) study in Italy originally aimed to randomize 5170 diabetic 
patients aged over 50 years to aspirin 100mg daily versus open control, with 
follow-up until there have been 515 primary endpoints (CV death, MI, stroke 
or hospitalisation for vascular disease) (254) ACCEPT-D represented the 
only other major trial in diabetes but recruitment stopped at 2100 participants, 
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significantly reducing its ability to produce a reliable answer in the next few 
years. The ASPREE (ASPirin in Reducing Events in the Elderly) trial has 
randomized 19,000 healthy people over the age of 70 years from Australia 
and the USA to aspirin 100mg daily versus placebo but the proportion of 
patients with diabetes is likely to be under 10% (~1500); results are expected 
in 2018 (248). Finally, the ARRIVE study (Aspirin to Reduce the Risk of Initial 
Vascular Events) Study has recruited over 12,000 participants at moderate 
risk of major CHD events (estimated 10-20% 10 year CHD risk), but patients 
with diabetes at an estimated risk >20% over 10-year risk are excluded; the 
expected completion date is 2018. 
(https://clinicaltrials.gov/ct2/show/NCT00501059).  
Therefore, in the next 2-3 years, there should be substantially more data 
about the relevance of aspirin for primary prevention of cardiovascular 
disease. ASCEND will provide almost half of the available data in diabetes. In 
addition, there will be considerably more evidence in other intermediate-risk 
groups including healthy elderly people. It is likely that a meta-analysis of all 
of these trials will be needed to provide reliable evidence about the effects of 
aspirin in people with diabetes. It is, therefore, data from ASCEND will be 
combined with data from the other relevant trials in a further meta-analysis 
coordinated by the ATTC.  
Omega 3 fatty acids and OTTC results on ASCEND 5.2.4
Since ASCEND started, several large trials have reported their results with 
no clear evidence to support the use of omega-3 fatty acid supplementation 
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for the prevention of cardiovascular disease. Given OTTC data, it is unlikely 
that ASCEND will show benefits from allocation to omega-3 FA on risk. 
Nevertheless, it will provide additional randomised evidence on both efficacy 
and safety which may help elucidate whether there are particular groups who 
might benefit from omega-3 FA supplementation.  
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Impact of this thesis on current literature 
1. Trial methodology describing large randomised trial by mail (paper 
published in Trial in 2016 (190)). 
2. Design and baseline characteristics of the ASCEND trial (Published in 
AHJ (182)). 
3. Meta-analysis of omega 3 FA: no significant effects on the 
cardiovascular outcome (Paper published JAMA Cardiology (221)). 
4. Biochemical measurement supporting the compliance of trial 
medication in a mail-based trial (abstract submitted to ESC Congress 
2017 and presented in August 2017 at Barcelona). 
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Request for blood sample for the ASCEND trial
Your patient is participating in the ASCEND (A Study of Cardiovascular Events iN 
Diabetes), which is a nationwide study with over 15,000 men and women with 
diabetes taking part. It is a randomised trial assessing the benefits and risks of 
aspirin and/or omega-3 fatty acids in patients with diabetes with no previous history 
of cardiovascular disease. Further information about this study is available on 
www.ctsu.ox.ac.uk/ascend. 
An optional, but we believe valuable, part of the study involves obtaining blood and 
urine samples to measure glycaemic control, lipids, renal function and biochemical 
measurement of the effect of the study medications. 
We should be very grateful, therefore, if you would help us by collecting a blood 
sample and transferring the urine specimen brought by the participant to the two 
different containers. In addition, it would be most helpful if you could record both the 
time of the last dose of study aspirin/placebo and their current medication on the 
enclosed consent form. Detailed instructions are printed on the back of this letter. 
We apologise for troubling you with this request, but your collaboration would be 
extremely helpful. Many thanks. 
ASCEND
Clinical Trial Service Unit 
(CTSU) 
Richard Doll Building 
University of Oxford 




Office telephone: 01865 743888 
Office fax: 01865 743981 
Freefone: 0800 585323 
e-mail: ascend@ctsu.ox.ac.uk 
Website: www.ctsu.ox.ac.uk/ascend
ASCEND    
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Yours sincerely 
Professor Jane Armitage                                Dr Louise Bowman 
Study Coordinators 
Instructions for collecting and mailing of blood and urine samples
1. Please check that the name of the study participant corresponds to that on the 
enclosed barcode labels and consent form. 
2. Ensure that the consent form has been completely filled-in, signed and dated. 
(N.B. If the patient has not brought the consent form, please call the Freefone 
number below and ask for a copy to be faxed to you.) 
3. Please measure the patient's weight and record this on the consent form as 
indicated. Please fill in the list of medication the patient is currently taking. 
4. Collect 9ml of blood into the purple-topped vacuette [EDTA] and label this 
using one of the blood sample labels from the enclosed sheet. Please attach 
the label as straight as possible lengthways, and as close to the bung as 
possible. Then place the labelled vacuette (top upright) in one lined, green-
topped, opaque white plastic tube, ensuring that the cotton-wool bung 
provided is inserted into the green lid, before securing it tightly. 
 (N.B. If the vacuette fails or is broken we should be most grateful if you would 
use one of your own ETDA-containing vacutainers (9ml if possible, otherwise 
5ml). A spare blood sample barcode label is enclosed should you need it. 
5. Using the pipette, transfer 5ml of urine from the universal container brought by 
the participant to the small white topped tube and 10 ml of urine to the white 
top tube which contains small white tablet (a preservative), and label those 
using the urine sample labels from the enclosed sheet. Then place the 
labelled tubes (top upright) in the green-topped plastic tubes provided, again 
ensuring that the cotton-wool bungs are inserted into the green lids before 
securing those tightly. Then discard the universal container with remaining 
urine. 
6. Please indicate on the consent form that a blood and/or urine sample has 
been obtained and date the form. 
7. Put three green-topped mailing tubes in the cardboard box and secure the lid. 
(Please do not write on the box.) Put this, together with the completed 
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consent form, in the pre-addressed reinforced white envelope (no stamp 
required). 
8. Please mail the envelope today, as any delay will result in sample 
degradation. 
Please call the ASCEND study office on Freefone 0800 585323 if 
you have 
any queries regarding this. 
Many thanks for your collaboration.  
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[Date] 
[Our GP ref] 
[GP address] 
Dear Dr [GP name], 
[Patient name], [DOB], [address] 
ASCEND Study Ref: [100-1234] 
[Blood] [and] [urine] results from the ASCEND trial 
As you know [Mr Patient] [is participating in the ASCEND study. He recently provided 
[a non-fasting blood sample] [and] [a urine specimen] which was mailed to our central 
laboratory. Routine analysis of [this sample] [these samples] revealed the following 
results: 
Total cholesterol:     mmol/L  
HbA1C DCCT:    % 
HbA1C IFCC :    mmol/mol 
HDL-cholesterol:    mmol/L 
Urinary microalbumin/creatinine ratio*:   mg/mmol creatinine 
* NICE guidelines: microalbuminuria defined as ratio ≥ 2.5 mg/mmol [men] or 3.5 
mg/mmol [women] 
Please feel free to telephone Freefone 0800 585323 if you wish to discuss any 
aspect of the study. Many thanks for your help. 
ASCEND    
ASCEND
Clinical Trial Service Unit 
(CTSU) 
Richard Doll Building 
University of Oxford 




Office telephone: 01865 743888 
Office fax: 01865 743981 





Dr Jane Armitage                                        Dr Louise Bowman                             
Study Coordinators 
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Consent for additional blood and urine collection, storage, and analysis 
Please cross (      ) each of the following statements to which you agree: 
 I confirm that I have read and understood the information about blood and urine sampling. I understand 
that providing a blood and urine sample is optional, and I am free to continue taking part in the trial 
without agreeing to my blood or urine being taken. 
 I agree to my samples being used for immediate measurements of glucose control, lipids (cholesterol), 
kidney function and biochemical tests to assess the study treatment effects, and for relevant results to be 
provided to my general practitioner. 
 I agree that samples of my blood and urine may be stored for future biochemical tests to help understand 
the effects of the study treatment and the causes of diabetes and circulatory disease. This is the 
understanding that the investigations will be for medical research only and my results will be kept 
confidential. 
PRINTED name of participant  Signature  Date 
THANK YOU FOR YOUR HELP 
Current drug list 
Are you currently 
taking the study white 
tablets? 





Please give date and 
time last dose of 




or Stones lbs 
Has a blood sample 
been obtained? 
Is a urine 
sample 
provided? 
ASCEND    
To be completed by the practice nurse (in blue or black ink). If possible, please 
Yes          No 
Yes          No 




Day  Month  Year 
 0 4  2 0 0 3 2 0 1 0 4  2 0 0 3 
Yes          No 
Yes          No Yes          No 
Yes          No 
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Date and time blood 
sample was taken: 
Time 
Name of person 
taking blood sample 
Signature       
Contact Telephone 
No. 
Dear «Title» «Surname», 
Optional blood and urine tests for the ASCEND study 
Thank you for continuing to take part in ASCEND (A Study of Cardiovascular Events 
iN Diabetes). 
A worthwhile, but optional, part of this research study, involves the analysis of blood 
and urine samples from study participants. More information about this aspect of the 
study is included in the enclosed leaflet. Please read the leaflet carefully. If you are 
prepared to provide a sample of blood and urine for the ASCEND study, please do 
the following: 
1. Read, sign and date the consent form overleaf, remembering to cross (X) a 
“Yes” or “No” box for each statement.  
2. Make an appointment for a blood test either at your GP surgery, diabetes clinic 
or local hospital. (Some GP practices are unable to offer a blood test service. 
We would advise you to phone to check first.) Ideally, your appointment should 
be early in the week, i.e. on a Monday, Tuesday or Wednesday. N.B. This does 
not need to be a fasting blood sample. 
3. On the day of this appointment, fill the large clear plastic container (white screw-
top) with a specimen of urine. 
4. Hand this specimen to the nurse, along with the blood sampling kit, labels, letter 
with instruction sheet and completed consent form. 
Please ensure that the participant has read and signed the consent above and return the completed form with the blood and/or urine sample to the 
ASCEND coordinating centre in the Freepost envelope provided. Please mail it today as delays in the post can affect the measurements. If you require 
«MergeDate» ASCEND Document Ref: «Reference» 





Day  Month  Year 
 0 4  2 0 0 3 2 0 1 0 4  2 0 0 3 
222 
If you are willing, we would also like to obtain a measurement of your weight and a 
list of your current medications. In most cases, this can be done when you go to have 
your blood sample taken. 
The results of the blood and urine tests will be sent to your GP. We will also send you 
a copy of the signed consent form for you to keep. If you feel unable to provide either 
one or both samples you are still a valuable member of the study and are strongly 
encouraged to continue in ASCEND. 
Should you have any questions about this, or any other part of the study please call 
the ASCEND study office (Freefone 0800 585323) and speak to a study nurse or 
doctor. 
Thank you for your help. 
Yours sincerely 
Professor Jane Armitage Dr Louise Bowman 
Study Coordinators 
Enc: Sample kit, labels, instructions letter, sampling information leaflet
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[Date] 
[Our GP ref] 
[GP address] 
Dear Dr [GP name], 
[Patient name], [DOB], [address] 
ASCEND Study Ref: [100-1234] 
[Blood] [and] [urine] results from the ASCEND trial 
As you know [Mr Patient] [is participating in the ASCEND study. He recently provided 
[a non-fasting blood sample] [and] [a urine specimen] which was mailed to our central 
laboratory. Routine analysis of [this sample] [these samples] revealed the following 
results: 
Total cholesterol:     mmol/L  
HbA1C DCCT:     % 
HbA1C IFCC :    mmol/mol 
HDL-cholesterol:    mmol/L 
Urinary microalbumin/creatinine ratio*:   mg/mmol creatinine 
Please feel free to telephone Freefone 0800 585323 if you wish to discuss any 
aspect of the study. Many thanks for your help. 
Yours sincerely 
Dr Jane Armitage                                        Dr Louise Bowman                             
Study Coordinators 
ASCEND    
ASCEND
Clinical Trial Service Unit 
(CTSU) 
Richard Doll Building 
University of Oxford 




Office telephone: 01865 743888 
Office fax: 01865 743981 




Appendix 2: ASCEND study protocol 
ASCEND (A Study of Cardiovascular Events iN 
Diabetes): 
A randomised 2x2 factorial design study of aspirin versus placebo, 
and of omega-3 fatty acid supplementation versus placebo, for the 
primary prevention of cardiovascular events in people with diabetes 
Should aspirin be used routinely in people with diabetes but no vascular 
disease? 
The role of antiplatelet therapy (chiefly aspirin) for the secondary prevention of 
cardiovascular disease is firmly established for many high-risk groups with diagnosed 
occlusive arterial disease, and the proportional reductions in heart attacks and 
strokes appear to be similar whether or not these patients have diabetes. But, most 
younger and middle-aged people with diabetes do not have manifest arterial disease 
– although they are still at significant cardiovascular risk – and yet the available 
randomised evidence for the use of antiplatelet therapy in such individuals is sparse. 
As a result, there is major uncertainty about the role of antiplatelet therapy for the 
primary prevention of cardiovascular events among people with diabetes, and only a 
small minority receives it. 
ASCEND aims to demonstrate whether aspirin reduces the risk of cardiovascular 
events in individuals with diabetes who do not already have diagnosed occlusive 
arterial disease and whether such benefits outweigh any potential hazards from 
bleeding. In order to do this reliably, at least 15,000 patients with diabetes and no 
clinical evidence of occlusive arterial disease will be randomly allocated to receive 
100mg aspirin daily or matching placebo tablets for at least 7 years. A study of this 
size should have excellent power to detect a 12-15% proportional reduction in the 
cardiovascular event rate among such patients. 
Do omega-3 fatty acids (fish oils) reduce cardiovascular risk in people with 
diabetes?  
There is consistent evidence from observational studies of lower rates of 
cardiovascular disease (particularly cardiac and sudden death) in people with higher 
intakes, or higher blood levels, of omega-3 fatty acids (FA). Randomised evidence
among people who have survived a heart attack suggests modest, but potentially 
worthwhile, reductions in coronary events of 15-20%. There is, however, no large-
scale randomised evidence for the use of omega-3 fatty acids in the primary 
prevention of vascular events. People with diabetes are at increased cardiovascular 
risk, and may gain particular benefit from the effects of omega-3 fatty acid 
supplementation on platelet aggregation and dyslipidaemia. Hence, participants in 
ASCEND will also be randomly allocated in a 2x2 factorial design to receive 1g 
omega-3 FA daily or matching placebo capsules for at least 7 years. Such a study 
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design allows all randomised patients to contribute fully to the assessment of the 
separate effects of aspirin therapy and of omega-3 fatty acids.  
ASCEND: A streamlined, mail-based trial collecting only essential data 
The reliable assessment of the important questions that ASCEND is addressing 
requires the randomisation of a very large number of people with diabetes, and their 
long-term treatment and follow-up. In order to be able to study 15,000 people with 
diabetes for at least 7 years at low cost, ASCEND is streamlined and being 
undertaken predominantly by mail (supplemented by central records). If it can reliably 
demonstrate that aspirin and/or omega-3 fatty acids safely reduces the risk of 
cardiovascular events and deaths in patients with diabetes who do not have pre-
existing occlusive arterial disease, then this would be relevant to some tens of 
millions of people world-wide (who are currently not receiving such therapy) and 
could save tens of thousands of lives each year. Consequently the British Heart 
Foundation is supporting this large streamlined trial. 
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1. BACKGROUND AND RATIONALE 
1.1 Reliable assessment of the effects of aspirin for primary prevention of 
cardiovascular events in diabetes mellitus 
1.1.1 Diabetes mellitus: An increasingly common cause of cardiovascular disease
Diabetes mellitus affects about 150 million individuals worldwide, with at least 40 million cases 
in the Established Market Economies and over one million diagnosed cases in the UK.1
Moreover, the prevalence is increasing rapidly, and it is estimated that there will be 300 million 
people worldwide with type 2 diabetes mellitus by 2025, and a further 30 million with type 1 
disease.2 Patients with diabetes of either type are at substantially increased risk of 
cardiovascular events and death, and the majority (60-70%) of deaths in both types of diabetes 
are attributed to vascular causes.3,4 However, among prevalent cases of diabetes in younger 
and middle age, the majority will not have a history of vascular disease.5,6
1.1.2 Lack of reliable evidence for benefit with antiplatelet therapy in patients with  
diabetes 
In the “secondary” prevention of cardiovascular disease, there is reliable randomised evidence 
that antiplatelet therapy (chiefly aspirin) reduces the risk of further cardiovascular events by 
about one-quarter among a wide range of different high-risk groups with occlusive arterial 
disease,7,8 and the benefits appear to be similar whether or not such patients also had diabetes 
(Figure 1). As a consequence, most patients with diabetes who have diagnosed vascular 
disease are currently receiving antiplatelet therapy9,10 and its use is widely included in 
guidelines for secondary prevention.11,12
Figure 1: Absolute effects of antiplatelet therapy on vascular events among patients with 
occlusive arterial disease in the absence and presence of diabetes7
However, the majority of people with diabetes do not have manifest occlusive arterial disease5,6
(at least 0.5 million in Britain and several tens of million worldwide), and for them there is no 
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direct evidence of benefit with aspirin or any other antiplatelet agent. The main randomised 
evidence currently available on the effects of antiplatelet therapy in such patients with diabetes 
comes from 9 trials involving a total of about 5000 patients, and a meta-analysis of their results 
indicates a much smaller proportional reduction in cardiovascular events than has been found 
in the secondary prevention setting (just 7% compared with about 20-25%: Figure 2).8 Even in 
aggregate, however, those studies in people with diabetes involved relatively few events, and 
the confidence interval for the estimated effect is wide, ranging from a 23% risk reduction to an 
8% hazard.  
Given the consistency of the beneficial effect in other high-risk settings (including patients with 
diabetes with arterial disease: Figure 1), it seems likely that the true effect of antiplatelet 
therapy in people with diabetes alone is similar to the reduction of about one-quarter seen 
overall in high-risk patients as, for example, has been shown with cholesterol-lowering13 and 
anti-hypertensive therapies14). 
Figure 2:  Proportional effects of antiplatelet therapy on vascular events in 195 trials 
among high-risk patients subdivided by disease category8 
1.1.3 Aspirin increases the risk of major bleeding (but appears to be relatively safe in 
diabetes) 
In the meta-analysis of previous trials among people with occlusive arterial disease, antiplatelet 
therapy was found to increase the risk of cerebral haemorrhage by about 25% and the risk of 
major extracranial bleeds by about 60%, with similar proportional increases in the different 
types of patient studied.8 Among such high-risk patients, the absolute reductions in heart 
attacks and ischaemic strokes with antiplatelet therapy substantially outweighed the relatively 
small absolute risks of cerebral haemorrhage and major extracranial bleeds. There is also good 
evidence from the previous trials that antiplatelet therapy is not associated with any special 















12 20000 13.5 17.0 25(4)
Acute myocardial
infarction
15 19300 10.4 14.2 30(4)
Previous stroke/TIA 21 12000 17.8 21.4 22(4)
Coronary artery
disease
55 17500 6.2 8.9 37(5)
High risk of embolism 14 5200 13.5 16.8 26(7)
Peripheral arterial
disease
42 9700 5.8 7.1 23(8)
Other vascular conditions 20 3400 4.2 6.4 32(13)
Diabetes mellitus 9 5100 15.7 16.7 7(8)
ALL TRIALS 195 144100 10.7 13.2 22(2)
Antiplatelet better Antiplatelet worse
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risks in patients with diabetes. In particular, the Early Treatment Diabetic Retinopathy Study 
(ETDRS) of 650 mg aspirin daily versus placebo among 3700 people with diabetes indicated 
that aspirin did not increase the risk of retinal or vitreous haemorrhage.15 Nevertheless, there is 
a lack of reliable direct evidence that the balance of benefits and risks of antiplatelet therapy 
among patients with diabetes alone is favourable. 
1.1.4 Large-scale randomised evidence is required to demonstrate directly that the 
benefits of aspirin outweigh any risks in people with diabetes 
The emergence of reliable evidence about the substantial net benefits produced by aspirin in 
people with occlusive arterial disease has rapidly lead to its widespread use in such patients 
(with, for example, over 80% of those with a history of previous heart attacks or strokes 
receiving some form of antiplatelet therapy).10 Based on extrapolation from the evidence in 
these other high-risk settings, the American Diabetes Association (ADA) has recommended the 
use of aspirin in people with type 2 diabetes and at least one additional risk factor (e.g. 
hypertension or hypercholesterolaemia).16 By contrast, UK and European guidelines are more 
circumspect in their recommendations about aspirin use for people with diabetes alone.11,12 
Presumably as a result of the current uncertainties about the net benefit of antiplatelet therapy 
in this setting, surveys in the US and UK indicate that only about 10-20% of patients with 
diabetes without diagnosed occlusive arterial disease are taking antiplatelet therapy 
regularly.17,18 Similarly, less than 20% of diabetic patients without vascular disease were taking 
aspirin regularly in the United Kingdom Prospective Diabetes Study (UKPDS) and the 
MRC/BHF Heart Protection Study19 (HPS) conducted in Britain, as well as in the ongoing FIELD 
trial conducted in Australia, New Zealand and continental Europe. Data from the Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT) also indicate that less than 20% of the 
hypertensive patients with diabetes and no occlusive vascular disease were taking aspirin in the 
last 6 months of the study in Sweden, Denmark and Norway (personal communication). 
Currently, the only ongoing comparison of antiplatelet therapy versus no antiplatelet therapy in 
patients with diabetes without pre-existing occlusive arterial disease involves 2000 of the 
participants in the Women’s Health Study (WHS), which is too few to assess the effects of 
treatment in such individuals reliably (see below). The Prevention of Progression of 
Asymptomatic Diabetic Arterial Disease (POPADAD)20 study involves the assessment of aspirin 
among a further 1600 patients with diabetes, but all of the participants in that trial have 
diagnosed peripheral arterial disease. Further information about the effects of antiplatelet 
therapy among diabetic patients without pre-existing arterial disease will emerge from a 
collaborative meta-analysis of individual participant data from all of the previous “primary” 
prevention aspirin trials. But, preliminary results among the 3000 low-risk diabetic participants 
involved in that analysis indicate only a non-significant 25% (SD 16) reduction in coronary 
events (59 [3.9%] aspirin-allocated versus 71 [4.9%] placebo-allocated events; 2P=0.1) during 
median follow-up of 5 years (personal communication). Hence, there is a real need to initiate a 
much larger randomised trial of antiplatelet therapy in people with diabetes without occlusive 
arterial disease for whom there is not considered to be any clear indication for such treatment.
1.1.5 Aspirin 100mg (enteric coated) daily: an effective and well-tolerated antiplatelet 
regimen 
The Anti-Thrombotic Trialists’ (ATT) collaborative meta-analysis of previous trials found that 
high doses of 500-1500mg aspirin daily (which are more gastrotoxic21) are no more effective 
than lower doses of 75-100mg/day either in direct comparisons or in indirect comparisons 
(Figure 3).7 As a consequence, daily doses of 75-150mg are generally preferred for long-term 
treatment as protection against serious vascular events in high-risk patients. The use of enteric-
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coating delays the dissolution of the contents of the tablet until the higher pH of the duodenum 
is reached, and so may reduce gastric injury and symptoms.22 Hence, a regimen of 100mg daily 
enteric-coated aspirin is to be used in this study. 
1.2 Reliable assessment of the effects of dietary supplementation with  
omega-3 fatty acids 
1.2.1 Higher intake of omega-3 fatty acids is associated with less coronary heart 
disease
Omega-3 fatty acids are long-chained polyunsaturated fatty acids (PUFA) with their first double-
bond found at the third carbon atom from the methyl group (which is why they are referred to as 
n-3 or omega-3 fatty acids). Man is unable to manufacture these omega-3 fatty acids (FA) and 
is reliant upon intake from plants and animals. The richest dietary sources of the two principal 
omega-3 fatty acids, eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 
22:6n-3), are marine animals.23 Consumption of oily fish 2-3 times per week provides about 
500mg daily of EPA and DHA combined, but consumption is less than about 50mg per day in 
people who do not eat fish regularly.24
The possible link between high intake of omega-3 FA and prevention of coronary heart disease 
was first noted in the 1940s when the diets of Greenland Eskimos, among whom coronary 
disease was rare, were compared with those of Danes living in Denmark where coronary heart 
disease (CHD) rates were about 10 times higher.25 Despite similar total fat intake (about 40% of 
total calories), eskimo diets contained significantly greater proportions of omega-3 FA (>4%) 
compared with the Danes (<0.1%). These observations stimulated a large number of 
observational studies of omega-3 FA intake and heart disease risk in different populations. A 
1999 systematic review of all of the observational data concluded that in high-risk populations 
consumption of the equivalent of 40-60 grams of fish per day (providing about 0.2-1g daily of 
omega-3 FA depending on the type of fish) is associated with 40-60% lower rate of cardiac 
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Figure 3: Proportional effects of different 
doses of aspirin on vascular events in 
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fish consumption and incidence of CHD,27-29 (including among 5000 women with diabetes 
followed for about 9 years30) and stroke.24
1.2.2 Randomised trials of omega-3 FA supplementation in post-MI patients suggest  
15-20% reductions in cardiovascular events but there is no information in diabetes 
In the only large randomised trial of omega-3 FA supplementation that has been conducted to 
date, 11,000 heart attack survivors in Italy were allocated to receive 1g daily of n-3 PUFA 
(containing 0.4g of EPA and 0.3g of DHA) versus no PUFA treatment for 3.5 years.31 Marginally 
significant reductions of 13% (95% CI 1-24%, p=0.04) in coronary events (i.e. non-fatal 
myocardial infarction [MI] or coronary death) and of 17% (95% CI 3-29%, p=0.02) in 
cardiovascular deaths, were observed among those allocated PUFA capsules in this GISSI-
Prevenzione trial. This was despite 80-90% of patients in both groups eating fish at least once a 
week, and high use of cardioprotective drugs (including aspirin). In another randomised trial, 
2000 men with a history of myocardial infarction in Wales were allocated to a recommended 
intake of at least 2 portions of fatty fish per week (or 1.5g Maxepa capsules daily, which contain 
about 0.5g EPA) versus no change in fish intake for 2 years.32 There was a non-significant trend 
towards 17% fewer (95% CI 35% reduction to 8% excess) coronary events among patients 
allocated increased fish intake, and cardiac deaths were by 35% (95% CI 13-52%, p=0.004). 
Background intake of fish in that Welsh population was low, and only about 10% of the patients 
were taking aspirin. In a meta-analysis of all of the available unconfounded randomised 
evidence for increased omega-3 FA intake from these two trials and 9 much smaller trials33,34
(which tested doses of EPA and DHA in the range 1-6g per day among a total of about 2000 
patients), there was a highly significant reduction in coronary events of 18% (95% CI 8-27%, 
p=0.0008). Based on these studies – which were conducted chiefly among people with vascular 
disease – it would seem plausible that omega-3 FA supplementation might produce a 15-20% 
reduction in coronary and other occlusive vascular events among high or intermediate risk 
populations, including people with diabetes. 
1.2.3 Cardioprotective effects of omega-3 fatty acids may be additional to those of 
aspirin 
Aspirin irreversibly inhibits platelet cyclo-oxygenase, the enzyme that controls the conversion of 
arachidonic acid to prostaglandins and thromboxanes, which reduces the formation of 
thromboxane A2 in platelets and produces a potent anti-aggregatory effect.21 But, aspirin also 
reduces the formation of prostacyclin, which is a potent vasodilator, and so may lead to 
vasoconstriction. Omega-3 FA (particularly EPA) compete with arachidonic acid for cyclo-
oxygenase,23 and so reduce thromboxane A2 production in platelets (albeit to a lesser extent 
than aspirin). Unlike aspirin, however, omega-3 FA enhance prostacyclin production in 
endothelial cells. Moreover, when aspirin and omega-3 FA are given together, there is a shift 
towards increased prostacyclin formation in endothelial cells and vasodilatation.35
Consequently, any beneficial effects of aspirin and omega-3 FA on vascular disease that are 
mediated through these effects on prostaglandins and thromboxanes should be 
complementary.35 Omega-3 FA might also have other cardioprotective effects, including: 
reducing myocardial susceptibility to ventricular arrhythmias;36 increasing the stability of 
atherosclerotic plaques through anti-inflammatory effects that are mediated by prostaglandins 
and leukotrienes;37 reducing blood pressure;38 and reducing plasma concentrations of 
triglycerides (TG) and very-low-density lipoproteins, and inhibiting post-prandial lipaemia.39-41
These effects of omega-3 FA on lipoproteins are seen both in the presence, and in the 
absence, of statin therapy.34 As cardiovascular disease in diabetes derives both from platelet 
activation42 and from disordered triglyceride metabolism,3 omega-3 FA may be particularly 
worthwhile for people with diabetes. 
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1.2.4 Omega-3 fatty acids are considered safe and well tolerated 
The Food and Drug Administration (FDA) consider omega-3 FA doses of up to at least 3g daily 
to be safe,23 with no significant risk of bleeding. In the large GISSI Prevenzione trial,31 90% of 
participants were taking aspirin, but no excess of bleeding was observed with the addition of 1g 
omega-3 FA daily. The only side-effects reported in that open-label study were a slight fishy 
after-taste and some gastrointestinal disturbances, but only 3.8% of participants stopped their 
omega-3 FA supplements because of these side effects. Omega-3 FA have no effect on 
glycaemic control in diabetes40,43 and their small, potentially adverse, effects on plasma 
concentrations of LDL-cholesterol may be offset by beneficial changes in lipoprotein particle 
size.39,41 For the present trial, a daily dose of approximately 1g of omega-3 FA  (0.4g EPA and 
0.3g DHA is to be used (as in GISSI), which can be conveniently provided in 1 capsule of the 
concentrated preparation (with matching placebo capsules containing olive oil). 
1.2.5 Need for a large-scale study of omega-3 FA supplementation in people with 
diabetes
As discussed above, diabetes is associated with a 2-4 fold increase in the risk of cardiovascular 
disease and the incidence of diabetes worldwide is increasing rapidly. Consequently, the 
demonstration that an inexpensive and readily available food supplement – such as omega-3 
FA – reduces cardiovascular risk in patients with diabetes would have important public health 
consequences. By adopting a 2x2 factorial design within this large streamlined study, it will be 
possible to assess the separate and combined effects of both aspirin and omega-3 FA 
supplementation in a particularly cost-effective manner. 
1.3 Mail-based studies for efficiency and cost-effectiveness 
1.3.1 Previous successful experience of conducting cost-effective randomised trials by 
mail 
Both aspirin and omega-3 FA are widely available and used, the hazards are low and well 
characterised, and neither requires biochemical monitoring. Several large randomised trials 
have been conducted using mailed drug supply and follow-up, including the CTSU-coordinated 
British Doctors’ Study44 and the (first) US Physicians Health Study45 of aspirin for the prevention 
of myocardial infarction. Currently, there are 3 large studies46-48 of either aspirin or various 
supplements being conducted entirely by mail in the US: the (second) US Physicians’ Health 
Study ll, the Women’s Antioxidant Study (WACS) and the Women’s Health Study (WHS). The 
latter study includes 40,000 American women from a wide range of educational and social 
backgrounds randomised to aspirin or matching placebo, and in a factorial design to different 
vitamin and mineral combinations. Experience from these studies shows that - with appropriate 
attention to the wording of information leaflets, consent forms and questionnaires, - good 
response rates and compliance can be achieved and reliable information about medical events 
gathered.49 In addition, the 24-hour Freefone service established by CTSU for other large heart 
disease trials will allow study participants to discuss any aspects of the study with experienced 
clinical staff, and so help ensure good compliance and the early identification of serious 
problems. 
2. PLAN OF INVESTIGATION 
2.1 Study aims: assessment of outcomes 
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The aim of ASCEND is to determine whether 100mg daily aspirin and/or supplementation with 1 
gram capsules containing 90% omega-3 fatty acids (0.41g EPA, 0.34g DHA) daily prevents 
cardiovascular events in patients with diabetes who do not already have clinically manifest 
arterial disease (without leading to significant bleeding or other adverse events). 
2.1.1 Primary assessments 
Aspirin therapy: The primary comparison will involve “logrank” analyses54 of “serious vascular 
events” (defined as the combination of non-fatal myocardial infarction, non-fatal stroke or 
transient ischaemic attack, or vascular death excluding confirmed cerebral haemorrhage during 
the scheduled treatment period among all those allocated aspirin tablets versus all those 
allocated placebo tablets (i.e. “intention-to-treat” comparisons). (Vascular death includes ICD 
I00-I52 and I63-99 in the 10th International Classification of Diseases.) 
Omega-3 fatty acid supplementation: The primary comparison will involve “logrank” analyses 
of “serious vascular events” during the scheduled treatment period among all those allocated 
omega-3 fatty acid capsules versus all those allocated placebo capsules. 
2.1.2 Secondary assessments 
The principal subsidiary comparisons will be of the effect of allocation to aspirin versus 
allocation to placebo tablets and, separately, of allocation to omega-3 FA versus allocation to 
placebo capsules on: 
(i) The incidence of serious vascular events, and the combined endpoint of “serious 
vascular events or revascularisations” (i.e. serious vascular event, or coronary or 
non-coronary revascularisation) in various prognostic subgroups (e.g. older 
versus younger, men versus women, longer versus shorter duration diabetes); 
and in the presence and absence of the other study treatments 
(ii) The incidence of confirmed cerebral haemorrhage and, separately of other “major 
haemorrhage” (defined as any other bleeding episode that requires hospitalisation 
or transfusion, or is fatal or disabling). 
2.1.3 Tertiary assessments 
In addition, comparisons will be made of the effects during the scheduled treatment period of 
each of the study treatment allocations on: total and cause-specific mortality (coronary, other 
vascular and non-vascular death separately); total coronary events (ie. non-fatal myocardial 
infarction, coronary death or coronary revascularisations [i.e. CABG and PTCA]); non-
haemorrhagic strokes or transient ischaemic attacks; venous thromboembolism; total and site-
specific cancers; and hospitalisations for various other causes. Allowance for multiple 
hypothesis testing in these analyses will be made using the “Bonferroni” correction. 
2.2 Sample size and predicted number of events 
 2.2.1 Random allocation of at least 15,000 patients with diabetes without arterial 
disease should provide good statistical power to detect plausible effects 
One particular cohort of people with diabetes and no evident cardiovascular disease had a 
coronary event rate of around 3% per annum.55 However, although that study is widely quoted, 
event rates may not be as high in diabetic populations with lower levels of other risk factors. For 
example, among the 5000 men and women with newly diagnosed type 2 diabetes (mean age 
53 years) randomised in the UKPDS,56 annual rates were 1.6% for coronary events and 1.1% 
for death due to macrovascular disease (i.e. fatal MI, stroke or sudden death). Similarly, among 
about 3000 people with diabetes (mean age 63) without diagnosed occlusive arterial disease 
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randomised in HPS,13,57 the annual overall rate of cardiovascular events (fatal or non-fatal 
myocardial infarction or stroke) was 2.2%. Hence, it would seem prudent to base sample size 
calculations for any randomised trials in patients with diabetes and no arterial disease on 
serious vascular event rates of no more than about 2% per annum.  
Aspirin has been shown to reduce cardiovascular event rates by about one quarter in a wide 
range of high-risk groups with arterial disease, with similar proportional reductions irrespective 
of whether or not diabetes is present (see Figure 1).7 Hence, as in other high-risk populations, it 
seems plausible that aspirin might reduce the risk of serious vascular events by around one-
quarter in patients with diabetes who do not have clinical evidence of arterial disease. Similarly 
omega-3 FA have reduced risk of cardiovascular events by 15-20% in high-risk populations. 
Proportional reductions of 15-20% among people with diabetes without diagnosed arterial 
disease would still correspond to substantial absolute benefits (see Table 1). But, even if such 
benefits do exist, at least 10,000 patients with diabetes would need to be randomised and 
followed for 5 years to detect these effects reliably. During the trial it is intended that blinded 
event rates (i.e. active and placebo groups combined) will be monitored and, if they are 
substantially lower than anticipated, the Steering Committee will have the option of increasing 
the sample size or prolonging the scheduled treatment period (see below)  
Table 1: Statistical power to detect 15-20% proportional reductions in serious vascular 
events among 10,000 randomised patients (based on 10% 5 year control group event 












1000 over 5 years
25% 500 375 >95% >95% 25 
20% 500 400 80% >90% 20 
15% 500 425 60% 70% 15 
Protocol addition January 2011: Accumulating evidence from within ASCEND, suggests that 
the overall (i.e. blinded) annual event rate (including transient ischaemic attacks) is likely to be 
about 1.2%, i.e. somewhat lower than the initial estimate of 2% pa in the control group. In 
addition, a recent meta-analysis of primary prevention trials of aspirin suggests that reductions 
in serious vascular events of 12-15% may be more likely than reductions of 20-25%.58 Table 2 
indicates that, with an annual event rate of 1.2% in the control group, randomisation of 15,000 
patients with follow-up of 7.5 years would provide robust statistical power to detect plausible 
risk reductions of 12-15%. Hence, the Steering Committee agreed during 2010 to increase the 
sample size to 15,000 and the duration of follow-up to at least 7 years. 
Table 2: Statistical power to detect plausible effect sizes with 15,000 participants 
followed for up to 7.5 years at 1.2% per annum serious vascular event rate in the control 
group. 





Number of events (%) Power  




over 7.5 years 
10% 5 450   (6%) 405   (5.4%) 60% 36%  
7.5 675   (9%) 608   (8.1%) 79% 58% 9 
12% 5 450   (6%) 398   (5.3%)  76% 54%  
7.5 675   (9%) 593   (7.9%) 92% 78% 11 
15% 5 450   (6%) 383   (5.1%) 92 79%  
7.5 675   (9%) 570   (7.6%) 99 95% 14 
2.2.2 Full efficiency of a 2 x 2 factorial design: separate assessment of both study 
questions without any material effect on non-drug cost or sample size requirements. 
A factorial design will be used, with at least 7500 patients being randomly allocated to receive 
aspirin tablets versus 7500 patients allocated to receive matching placebo tablets (see Figure 
4). Similarly, at least 7500 patients will be separately randomised to receive omega-3 FA 
capsules versus 7500 patients allocated to receive placebo capsules. The primary analyses will 
involve two-way comparisons of all those allocated aspirin versus all those allocated matching 
placebo tablets, irrespective of the omega-3 FA allocation (Figure 4: subtotal A versus subtotal 
B), and of all those allocated omega-3 FA versus all those allocated matching placebo capsules 
irrespective of the aspirin allocation (i.e. subtotal 1 versus subtotal 2). Hence, reliable 
assessment of the effects of aspirin will not interfere with reliable assessment of omega-3 FA 
(or vice versa), as outcomes among all those allocated active aspirin can still be compared with 
those among all those allocated placebo aspirin (even though half of each group will have 
received omega-3 FA). Use of such a factorial design instead of a simple 2-way design has little 
or no effect on the statistical sensitivity with which the overall effects can be assessed, or on the 
total number of patients required in the study.53
































2.3 Data and safety monitoring 
2.3.1 Interim analyses: role of the Data Monitoring Committee and Steering Committee 
During the study, the independent Data Monitoring Committee will review unblinded interim 
analyses, at least annually, of mortality, of cardiovascular events and of other serious adverse 
events, along with any other analyses requested. In the light of these analyses and the results 
of any other relevant trials or meta-analyses of trials, the Data Monitoring Committee will advise 
the Steering Committee if, in their view, the randomised comparisons in the study have 
provided both (a) "proof beyond reasonable doubt"* that for all patients, or for some specific 
types, aspirin therapy is clearly indicated or clearly contraindicated in terms of a net difference 
in mortality, and (b) evidence that might reasonably be expected to influence materially the 
patient management of many clinicians who are already aware of any other main trial results. 
The Steering Committee can then decide whether to end or modify the study (or to seek extra 
data). Unless this happens, the Steering Committee, the collaborators and the coordinating 
centre staff (except those who supply the confidential analyses) will remain ignorant of the 
interim results on mortality and morbidity until the study is terminated. Collaborators, and all 
others associated with the study, may write (preferably through the Oxford coordinating centre) 
to the chairman of the Data Monitoring Committee, drawing attention to any worries they may 
have about the possibility of particular side-effects, or about particular categories of patient 
requiring special consideration, or about any other matters that may be relevant. 
2.3.2 Monitoring of any serious adverse events believed to be due to the study 
treatment  
Throughout the trial, all serious adverse events believed with a reasonable probability to be due 
to study treatment are to be reported immediately by telephoning the 24-hour telephone service 
(see Section 3.6). A “serious” adverse event is defined as any untoward medical occurrence 
which results in death, is life-threatening, requires hospitalisation or the prolongation of existing 
hospitalisation, results in persistent or significant disability or incapacity, or is a congenital 
anomaly or birth defect. During this telephone call, standard information (i.e. identity of the 
patient and of the person reporting the event, nature and date of event, and reasons for 
attribution to study treatment) will be recorded directly on the coordinating centre computer. 
These reports will be reviewed immediately, blind to treatment allocation, by the clinical 
coordinators, and any further information required sought urgently. Confirmed reports will then 
be promptly forwarded “unblinded” to the chairman of the Data Monitoring Committee. and to 
Bayer Healthcare AG or to Abbott Products Operations AG, as appropriate and included in the 
Annual Safety Report sent to the Research Ethics Committee (REC). Any such serious adverse 
events that are also unexpected will be reported in an expedited fashion to the REC and 
relevant drug regulatory agencies.  
2.4 Central Coordination 
2.4.1 Central coordination and local collaboration 
The Clinical Trial Service Unit (CTSU) at Oxford University is coordinating this study and will 
have overall responsibility for the administration and coordination of the study. There will be a 
* Appropriate criteria of proof beyond reasonable doubt cannot be specified precisely, but in general a difference of at least
3 standard deviations in an interim analysis of a major endpoint would be needed to justify halting, or modifying, such a 
study prematurely, especially if the comparison was based on relatively few events (e.g. less than 100). If this criterion were 
to be adopted, it would have the practical advantage that the exact number of interim analyses would be of little 
importance, and so no fixed schedule is proposed 53. 
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Steering Committee to oversee the trial conduct (back page). CTSU is responsible for obtaining 
Multicentre Research Ethics Committee approval; for the training and monitoring of all staff 
directly involved in the study; for the supply of conveniently packaged study drugs and other 
study materials; for the identification, with the assistance of the local medical collaborators, of 
potentially eligible participants; for obtaining any relevant permissions to invite suitable patients 
to participate; for the initial invitation of participants and subsequent randomisation and follow-
up by mail; for the provision of a 24-hour Freefone telephone service (for queries from 
participants or medical staff, for unblinding when medically necessary, and reporting of any 
serious adverse events believed to be due to study treatment); and for the collection and 
analysis of data, and blood samples. The medical collaborators around the UK are responsible, 
with the help of the Oxford coordinating centre, for obtaining local ethics committee approval 
and for assisting in the identification of potentially eligible individuals with diabetes (including 
liaison with hospital medical records staff). (This is summarised below, and is described in 
detail in the coordinating centre standard operating procedures [SOP].)
2.4.2 Training and monitoring 
The administrative and nursing staff in the Oxford coordinating centre will be trained in correct 
study procedures (as summarised in Section 3 of the protocol and described in detail in the 
SOPs). The coordinating centre staff will also arrange regular meetings of all the collaborators 
to discuss the progress of the study and other general issues, and to provide an update on the 
results of any other relevant studies. Collaborators will be encouraged to contact the 
coordinating centre office (or 24-hour telephone service for urgent queries) if they wish to 
discuss some problem or other issue related to the study. 
2.4.3 Supply of study materials
Aspirin and matching placebo tablets are to be manufactured and provided by Bayer Healthcare 
AG. Omega-3 FA capsules and matching placebo capsules are to be provided by Abbott 
Products Operations AG (formerly Solvay Pharmaceuticals). Both treatments are to be 
delivered in bulk to Brecon Pharmaceuticals for packaging and labeling prior to dispatch to 
participants. All study medication will be supplied in convenient treatment packs appropriate for 
mailing which contain the appropriate number of blister-strips for each period of the study. An 
inventory of study drug supply will be maintained on the coordinating centre computer, and any 
study drug not required by participants is to be returned to the coordinating centre for disposal. 
2.4.4 Data handling 
Lists of potentially eligible people with diabetes will be sought, preferably in computerized 
format, by the Oxford coordinating centre from medical collaborators who have access to 
diabetes registers, from trial databases and from general practitioners (GPs). This information 
will be used by the coordinating centre to generate invitations, in the name of the local medical 
collaborator, for patients to join the study (see Section 3.3). Hospital collaborators, general 
practitioners or practice nurses will also be able to offer a standard “invitation pack” (containing 
patient information leaflet, screening questionnaire and freepost envelope) to potentially eligible 
participants when they are seen for routine care in their clinic. In addition, randomised 
participants will have the option to recommend any friend or relative they think may be eligible 
and interested in participating in the study and potential participants can volunteer themselves if 
they hear about the study from any source. Responses from participants will be collected on 
questionnaires which are to be returned to the coordinating centre either on paper or 
electronically. Any coding that is required will be undertaken and data will then be entered into 
the coordinating centre computer (following an operating procedure for data handling). Any 
failure by participants to return Follow-up questionnaires will result in two mailed reminders 
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being sent. Subsequently, when necessary, study coordinating staff will undertake a telephone 
follow-up. 
Errors or omissions in the completion of study forms will result, if appropriate, in computer-
generated correction requests being sent to participants for completion. All such corrections to 
the data will be entered on the central computer with an appropriate audit trail. The coordinating 
centre is also responsible for seeking confirmation and additional information about any 
relevant clinical events reported during follow-up, and for obtaining details from national 
registries of any deaths, non-fatal cancers or other relevant events available among study 
participants (see Section 3.7). 
2.4.5 Laboratory measurements and sample storage 
Blood and urine samples taken at GP practices from those patients who agree to start Run-in 
treatment (Section 3.3.2) and samples taken from a randomly selected group of patients during 
follow up (Section 3.3.1) will be mailed to the coordinating centre laboratory in Oxford. The 
central laboratory will use part of each blood sample for immediate assays, with the remainder 
being frozen for subsequent assays. The laboratory uses a number of internal and external 
quality control procedures and follows a standard operating procedure (in accordance with 
Good Laboratory Practice guidelines). Checked assay results will be transferred to the central 
computer and linked to the patients’ other data.  
2.4.6 Source documents and archiving 
The lists of potentially eligible patients provided to the Oxford coordinating centre by 
collaborators, the returned questionnaires from these patients, the additional information 
obtained on reported outcome measures and other relevant events, the death certificates, the 
blood assay results and the drug supply records constitute the “source documents” for the 
study. The coordinating centre will retain these data and records for at least 15 years. 
Regulatory agencies and the companies providing the study medications will have the right, in 
accordance with Good Clinical Practice guidelines, to commission a confidential audit of such 
records kept in the coordinating centre, as long as this does not result in unblinding of the 
interim results while the study is still in progress. 
2.4.7 Source of support and non-negligent liability cover 
Funding has been obtained from the British Heart Foundation to cover the administrative and 
coordination costs of the trial. A supply of aspirin and matching placebo is to be provided by 
Bayer Healthcare AG, and a supply of omega-3 FA and matching placebo capsules by Abbott 
Products Operations AG (formerly Solvay Pharmaceuticals), with some funding from each 
company to cover drug packaging.  
The trial is to be conducted, analysed and interpreted by CTSU entirely independently of the 
funding sources, which have no representation in its organisation and will, like the Steering 
Committee, remain blind to the main results as they accumulate. This arrangement is intended 
to ensure that no suggestions of lack of objectivity of the findings can be justified.  
2.4.8 Publication in the names of all the collaborators  
The success of this study depends on the wholehearted collaboration of a large number of 
doctors, nurses and patients. For this reason, chief credit for the main results will be given not 
to the central organizers, but to all those who have collaborated in the study. Draft copies of any 
manuscripts will be provided to all collaborators for review prior to their publication and will be 
published in the name of the collaboration. 
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3. SUMMARY OF PRACTICAL PROCEDURES  
POTENTIALLY ELIGIBLE
 Diabetes mellitus (type 1 or 2) 
 Male or female 
 No diagnosed occlusive arterial disease 
 Aged ≥ 40 years 
____________________________________________________________________ 
IDENTIFICATION AND INVITATION
 Potentially eligible patients identified from existing diabetes registers or databases 
and other sources 
 Invited by GP, diabetologist or study coordinators, either in person or by mail. 
Invitation includes Information Leaflet, Consent Form and brief Screening 
Questionnaire  
 Central Freefone number for any questions 
____________________________________________________________________ 
SCREENING PROCESS (-2 months) 
 Screening Questionnaire returned, which identifies eligible and consenting patients 
 Run-in pack with 2-month supply of placebo treatment mailed to patient 
 GP informed of patient's possible participation, and asked to return form if patient 
not to be randomised 
 Blood and urine samples (optional) collected locally and mailed to central laboratory 
 Freefone number (0800 585323) for medical advice and any questions 
____________________________________________________________________ 
RANDOMISATION (0 months) 
 Randomisation Questionnaire sent to re-confirm eligibility, and to characterize the 
patient more fully 
 Randomisation Questionnaire returned, and eligible patient randomised by central 
computer 
 Allocated treatment pack mailed to patient: 100 mg aspirin daily or matching 
placebo tablet, and 1g omega-3 FA daily or matching placebo capsule 
 GP informed of patient's randomisation 
___________________________________________________________________ 
FOLLOW-UP QUESTIONNAIRES (6-monthly)
 Follow-up Questionnaires and treatment packs sent 6-monthly  
 Freefone number (0800 585323) for medical advice and any questions 
 Further details sought from responsible clinicians about any relevant events 
reported on Follow-up questionnaires  
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 Flagging for mortality and cancer at central registries
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3.1  Eligibility for ASCEND 
Men or women aged at least 40 years at the time of invitation for Screening are eligible for the 
study, provided they fulfil all of the following criteria: 
 Clinical diagnosis of diabetes mellitus: The participant’s own doctor considers them 
to have type 1 or type 2 diabetes (based on standard WHO or ADA diagnostic 
criteria50,51); 
 No clear indication for aspirin: The participant has no diagnosed occlusive arterial 
disease (i.e. a history of myocardial infarction, angina pectoris, coronary or non-coronary 
revascularisation procedure [i.e. peripheral arterial bypass surgery or angioplasty], stroke 
or transient ischaemic attack); 
 No clear contra-indication to aspirin: The participant is not at high risk of bleeding due 
to: gastrointestinal haemorrhage or peptic ulcer within the previous 6 months; active 
hepatic disease such as cirrhosis or active hepatitis; use of warfarin, or other anti-
coagulant therapy; or has a history of aspirin allergy; 
 Substantial uncertainty about whether antiplatelet or omega-3 FA therapy confers 
worthwhile benefit: Neither the participant nor the participant’s own doctor considers 
there to be a definite need for the patient to take aspirin or omega-3 FA supplements 
regularly (or a definite need not to do so);
 No other predominant life-threatening medical problem: The participant does not 
have some condition (other than diabetes) that might limit compliance with 5 years of 
study treatment, such as cancer (other than non-melanoma skin cancer).
3.2 Identification of participants 
3.2.1 Large numbers of potentially eligible patients can be identified through diabetes 
registers, trial databases and general practice 
Based on our previous experience, large numbers of potentially suitable individuals may need 
to be approached to randomise at least 15,000 eligible patients into this long-term trial. People 
with diabetes will be sought from 3 main sources: diabetes registers, trial databases and 
general practice. Diabetologists from around the UK will be invited to collaborate and allow 
invitation of potentially suitable individuals from locally held diabetes registers (such as those 
held for retinopathy screening or for service provision). Such registers vary in size from a few 
thousand to many thousands and at least one third of participants are expected to be recruited 
from these sources. Other people with diabetes will be identified from among the populations 
taking part in HPS and other diabetes trials. In order to streamline the invitation process, the 
contact details of potentially eligible people will be sought electronically whenever possible to 
allow central mailings in the name of the local doctor. This approach has allowed large numbers 
to be recruited by CTSU into the HPS and SEARCH trials, and is more efficient and cost-
effective than mailings sent from individual centres or practices. It also allows over-selection of 
certain groups (e.g. older individuals) to ensure an appropriate balance of different types of 
participant. The third source will be directly from general practice. Diabetologists and other 
collaborators will be asked to identify 20-30 local general practices with computerized diabetes 
registers, and to seek their agreement to mailing a single batch of letters to potentially eligible 
individuals. Experience of screening notes in general practice indicates that ~3.5% of patients 
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aged 50-65 have diabetes without diagnosed arterial disease. Hence, a typical group practice of 
about 10,000 registered patients may have 100-150 potentially eligible individuals. To 
complement these 3 main methods of recruitment, hospital collaborators, general practitioners 
or practice nurses will also be able to offer a standard “invitation pack” (containing patient 
information leaflet, screening questionnaire and freepost envelope) to potentially eligible 
participants when they are seen for routine care in their clinic, or directly by mail if they have 
previously agreed to be approached for research. In addition, randomised participants will have 
the option to recommend any friend or relative they think may be eligible and interested in 
participating in the study and potential participants may volunteer themselves if they hear about 
the study from any source. 
3.3 Screening (- 2 months) 
3.3.1 Establishing eligibility 
Patients with diabetes that are identified from any source as being possibly suitable will be 
invited by letter to take part. An invitation letter will be sent enclosing an information leaflet 
(Appendix 1) and a brief one-page Screening questionnaire to determine eligibility and to seek 
consent (Appendix 2), along with a Freepost envelope. Preliminary eligibility for the pre-
randomisation Run-in phase will be based on information provided on the completed Screening 
questionnaire (i.e. diagnosis of diabetes, no history of diagnosed occlusive arterial disease, no 
contraindication to regular aspirin and signed consent to participate). 
3.3.2 Pre-randomisation Run-in treatment and optional blood and urine sampling 
Eligible patients will be sent a Run-in pack of medication (containing placebo tablets and 
placebo capsules) and asked to take one tablet and one capsule daily for 2 months. An 
information sheet about the medication will be provided and a copy of their signed agreement to 
participate will also be sent to them. About 2-4 weeks later, participants will be sent an optional 
blood and urine sampling kit, and asked to take this kit to their general practice for sample 
collection (and for measurement of blood pressure, height and weight), with this sample then 
mailed to the central laboratory in the containers provided. A supplementary information leaflet 
is to be provided and separate consent sought for this 5-10ml blood and urine collection which 
will allow baseline stratification by important biochemical prognostic variables (such as blood 
HbA1C, lipids and markers of renal function, and urinary albumin/creatinine ratio).  
During the Run-in period, the participant's general practitioner will be informed by letter of their 
patient's possible involvement in the study and asked to return a form if they consider there to 
be any reason not to randomise their patient (in which case the patient would be informed of 
their GP’s decision and withdrawn before randomisation). Patients are to be randomised only if, 
at the end of the Run-in period, they seem likely to comply with the study protocol for several 
more years. By this process, many potential drop-outs should be excluded before becoming 
part of the randomised comparison, with a consequent improvement in statistical sensitivity of 
the “intention-to-treat” analyses.52 Patients who are not eligible will be thanked for completing 
the questionnaire, but will not proceed further. 
3.4 Randomisation (0 months) 
3.4.1 Final check of eligibility and compliance before randomisation 
About 2 months after they have been sent their Run-in pack, participants will be sent a further 
more detailed Randomisation questionnaire asking about any significant problems (including 
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any cardiovascular events) and their compliance with the study treatments during the Run-in 
period. Details of their diabetes history (in particular to allow classification as type 1 or 2), 
current medication, ethnic group, and smoking history will be sought to allow baseline risk 
stratification.59 Participants will be asked to reiterate their commitment to a 7-year study and 
also, if willing, to provide details of a friend or relative living at a different address who may be 
contacted in the event of loss of contact with the participant. 
3.4.2 Random allocation of aspirin 100mg daily versus placebo, and of 1g daily 
capsules containing omega-3 fatty acids versus placebo 
Participants who indicate on the randomisation questionnaire that they remain eligible and 
willing to continue into the long-term part if the study will be randomised by the central computer 
in CTSU, using a minimisation algorithm to ensure balance by important baseline variables.60
Eligible patients will be randomised in a 2 x 2 factorial blinded design between:  
 Aspirin 100mg daily versus matching placebo  
 Omega-3 fatty acid capsules 1 daily versus placebo 
One aspirin tablet and one capsule are to be taken each day for about 7 years unless some 
clear reason to stop develops.  
They will then be mailed a pack containing a 24-week supply of their allocated study treatment, 
along with relevant information about the medication and the CTSU Freefone number for any 
trial-related queries. The patient's general practitioner will be informed by letter of their patient's 
randomisation into the trial and the results of any relevant blood tests taken during Run-in (e.g. 
lipid profile and HbA1C). 
3.5 Post-randomisation Follow-up 
 3.5.1  6-Monthly follow-up questionnaires sent by mail (with telephone 
back-up) 
Follow-up questionnaires asking about cardiovascular events, other serious adverse events 
(including bleeding episodes), compliance with study treatment and use of relevant non-study 
treatments will be sent 6-monthly with a further supply of the participant’s allocated study 
treatment. All randomised patients - irrespective of whether or not they continue to take study 
treatments - are to be encouraged to return their questionnaire with up to 2 mailed reminders 
sent routinely. Failure to return a questionnaire will result in a study administrator telephoning 
the patient in order to complete the Follow-up questionnaire. Those who do not agree to being 
contacted in this way will be followed via their GPs and central registries. 
3.5.2 Modifying study treatment 
The aspirin component of the study treatment will be discontinued if a patient starts to use 
regular non-study aspirin or warfarin or is considered to have developed some other clear 
contraindication to the study aspirin (e.g. high risk of bleeding or aspirin allergy). 
(N.B. Patients who stop the aspirin component of the study will be encouraged to continue the 
omega-3 FA component, unless this is thought to be clearly contraindicated.) 
The study treatments will also be stopped if a serious adverse experience believed with a 
reasonable probability to be due to study treatment is reported (see Section 3.6). Patients may 
also stop either study treatment at their own request, or at the request of their own doctors. But, 
any patient who stops the study medications would still be encouraged to continue returning 
their Follow-up questionnaires and, if appropriate, to continue taking either study treatment 
alone if the other is to be stopped. 
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 3.5.3 Follow-up of deaths and of non-fatal cancers through central registries 
All randomised patients will be flagged through the Office for National Statistics and other 
central registries for death, cancer and other relevant events. Consequently, unbiased cause-
specific mortality and site-specific cancer incidence data for all patients can be obtained, 
independent of whether they are still complying with study medication or responding to 
questionnaires. 
3.6  Reporting serious adverse events 
3.6.1 Immediate reporting of expected and unexpected serious adverse events believed 
with a reasonable probability to be due to study treatment 
To fulfil regulatory authority requirements, serious adverse events believed with a reasonable 
probability to be due to study treatment are to be reported immediately by telephoning the 24-
hour Freefone service, where a few brief details will be recorded. For the purposes of this study, 
the only adverse events that need to be reported in this way are those that are both: 
 (i) serious (defined as any untoward medical occurrence which results in death is life-
threatening, requires hospitalisation or the prolongation of existing hospitalisation, results 
in persistent or significant disability or incapacity, congenital abnormality, or the result of 
an overdose); and
 (ii) believed with a reasonable probability to be due to study treatment. 
All such serious drug related adverse events (whether expected or not) will be reported 
(unblinded) to the Chairman of the independent Data Monitoring Committee, and included in the 
Annual Safety Report for the Research Ethics Committee, to Bayer Healthcare AG and to 
Abbott Products Operations AG (formerly Solvay Pharmaceuticals). Any such serious drug 
related adverse events which are unexpected (SUSARs) will be reported, unblinded in an 
expedited fashion to the Medicines and Healthcare products Regulatory Agency (MHRA) and to 
the companies. Expected aspirin related serious adverse events might include those due to 
bleeding, gastro-intestinal perforation, broncho-spasm or other recognised side-effects of 
aspirin; there are no expected omega-3 fatty acid related serious adverse events.  
3.6.2 Reporting of other serious adverse events on routine follow-up questionnaires 
Any serious adverse events that are not thought to be due to study treatment, including study 
endpoints, should not be reported in this way. Such events are, however, to be routinely 
recorded on the Follow-up questionnaires (see Section 3.5) for central analysis and regular 
review by the Data Monitoring Committee (see Section 2.3). 
3.6.3 Unblinding of study treatment allocation 
Unblinding of study treatment allocation is available via the 24-hour Freefone service, where all 
such unblindings are logged. In general, unblinding of patients is only likely to be necessary if 
knowledge of treatment allocation will influence immediate patient management or for onward 
reporting of serious drug related adverse events (see Section 3.6.1). 
3.7 Central ascertainment of biochemical effects and confirmation of 
reported vascular events, cancers and death 
3.7.1 Assessing biochemical efficacy of study treatments by random sampling 
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As well as asking all participants routinely about their compliance with allocated study 
treatments, compliance will be assessed in a random sample of participants at intervals during 
the study. A randomly selected sub-set of randomised participants (5-10%) will be sent a kit for 
blood collection by their GP and mailing to the coordinating centre. Assays of serum or urine 
thromboxane levels to assess aspirin effects61 and blood markers of omega-3 FA intake,62 will 
be measured to estimate compliance with study treatments. At least once during follow-up 
assessments will be made in a random sample of participants of the effects of study treatments 
on blood HbA1c, lipids and markers of renal function, and on urinary albumin/creatinine ratio. 
3.7.2 Confirmation of patient reported cardiovascular and other significant serious 
adverse events using mail-based systems 
The coordinating centre will seek confirmation and additional information (including, if 
necessary, any relevant hospital discharge records) from the participant’s GPs about each 
suspected myocardial infarction, stroke, coronary or non-coronary angioplasty, arterial surgery, 
cancer, or other relevant hospitalisation or serious adverse event recorded on Follow-up 
questionnaires or reported by participants during telephone calls or other contact. Similarly, 
further information will be sought from participant’s GPs and other relevant sources about all 
cancers and deaths identified from national registries. All such information will then be 
reviewed, blind to treatment allocation, by coordinating centre clinical staff and coded in 
accordance with pre-specified criteria. The diagnosis of myocardial infarction (MI) requires 
information about either: (i) the presence of two or more of: (a) typical ischaemic chest pain, 
pulmonary oedema, syncope or shock; (b) development of pathological Q-waves and/or 
appearance or disappearance of localised ST-elevation followed by T-wave inversion in two or 
more of twelve standard electrocardiograph leads; and (c) increase in concentration of 
biochemical markers consistent with MI (e.g. CK >2xULN, or elevated troponins); or (ii) 
necropsy findings of MI of an age corresponding to time of onset of symptoms. (Silent 
myocardial infarctions are not to be included.) Stroke is defined as rapid (or uncertain) onset of 
focal or global neurological deficit lasting >24 hours or leading to death and transient ischaemic 
attack is defined by the same symptoms lasting <24 hours. Information (e.g. CT/MRI scan 
results) will be sought to ascertain the likely aetiology of the stroke (i.e. haemorrhagic or not). 
These procedures for reviewing reports from patients and other sources of possible study 
outcomes was developed by CTSU for the MRC/BHF Heart Protection Study, and allowed over 
98% of such reports to be successfully confirmed or refuted. 
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Appendix 1: Information leaflet for potentially eligible patients 
 ASCEND: Invitation to join a large medical research project 
A randomised study of aspirin and of natural oils for the primary prevention of cardiovascular 
events in diabetes 
You are being invited to take part in a research study. Before you decide whether to participate, it is 
important for you to understand why the research is being done and what is involved. Please take 
time to read the following information carefully and discuss it with friends or relatives if you wish. You 
are entirely free to decide whether or not to take part in this trial. If you choose not to take part, the 
standard of care you are given by your own doctors will not be affected. If there is anything that is not 
clear, or if you would like more information, please telephone the ASCEND Freefone number (0800 
585323) and speak to a study nurse or doctor. The study is to be conducted mainly by mail, so no 
extra clinic visits will be required. 
 Aspirin, heart disease and strokes 
Patients with diabetes may be at increased risk of developing heart disease or suffering a stroke. 
Aspirin prevents heart attacks and strokes in people who have existing problems with their heart or 
blood circulation. But it is not known whether aspirin would be helpful in people with diabetes who 
have not yet been diagnosed with heart or circulatory problems. Serious (but uncommon) 
complications from the regular use of aspirin are bleeding in the stomach or intestinal tract. Typically 
this might happen in only about 1 per 1000 people taking aspirin regularly each year. Extremely 
rarely, aspirin may cause bleeding in the brain (about 1-2 per 10,000 people taking aspirin each 
year). Previous studies in people with known circulatory problems have shown that about 10 times as 
many people given aspirin have avoided a heart attack or stroke as have experienced a serious 
complication. However, in people with diabetes and no circulatory problems, it is not known whether 
the benefits of aspirin will outweigh the possible risks. 
Omega-3 fatty acids and diabetes 
Naturally occurring oils that are rich in omega-3 fatty acids (such as fish oils) may reduce the 
chances of a recurrent heart attack among people who have survived at least one heart attack. 
These oils have not been widely tested in people with diabetes, but there are reasons to hope that 
they may be helpful (although this is unproven). Taking regular supplements of such oils may have 
little or no beneficial effect among people living in a country (such as Britain) where most people eat 
a balanced diet. It is also possible that the long term use of these oils could, on balance, be slightly 
harmful – but this too is unknown.
What the study hopes to answer 
The main purpose of the ASCEND study, is to find out whether long-term treatment with aspirin in 
people with diabetes who are not already known to have heart or circulatory problems, produces 
benefits by preventing heart attacks and strokes which outweigh the possible risks of bleeding. 
ASCEND will also help establish whether oils rich in omega-3 fatty acids are of any importance in 
reducing the chances of having a heart attack in people with diabetes who have not yet got 
circulatory problems. 
Why have I been chosen? 
ASCEND will involve at least ten thousand men and women from around Britain, who like you, are 
being invited to take part because they have diabetes. This invitation has come from either your own 
GP or a local Specialist because they think you might be suitable for the study. Alternatively you may 
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have been recommended by a friend or relative who is already taking part in the study or volunteered 
yourself having read about the study. It is up to you to decide whether or not to take part in this study. 
If you do decide to take part, you would, of course, be free to withdraw from the study treatment at 
any time without necessarily giving any reason (and without adversely affecting the medical care you 
can expect from your own doctors). In particular, at the end of the first 2 months, when you finish your 
first box of treatment, you will have the chance to withdraw if you have any second thoughts or 
problems with study treatment. 
What taking part in ASCEND involves
Everyone taking part will have agreed to do so voluntarily, knowing that it may involve them in taking 
study treatment for at least 7 years. The daily study treatments (which would be sent to you by mail) 
will be a single white tablet and a single brown capsule taken from a blister pack. The white tablets 
will contain either active aspirin (100mg) or a similar looking inactive substance called a “placebo”. 
Whether or not a participant receives active or placebo tablets will be determined randomly (like 
tossing a coin). Each participant will have a 50% chance of receiving active aspirin and a 50% 
chance of receiving placebo (“dummy”) tablets. The brown capsules will each contain 1 gram of a 
naturally occurring oil, either mainly omega-3 fatty acids or mainly olive oil. Each participant will have 
a 50% chance of receiving the omega-3 containing capsules and a 50% chance of receiving olive oil 
capsules. The type of study treatment being taken will not generally be known by you or your doctor. 
This information will be known only by certain staff at the coordinating centre in Oxford, but it would 
be made available to your doctor if this were ever medically necessary. This design helps ensure that 
reliable information will be obtained about the effects of these potentially important treatments. 
 What you have to do to join the study 
If you might like to participate in this study you should complete the brief Screening Questionnaire on 
the inside of the letter, sign the Agreement to Participate and return them both in the enclosed 
Freepost envelope. We will use your answers on the questionnaire to check that you are suitable for 
the study. If you are suitable, then we will send a box of conveniently packaged study treatments, and 
ask you to start taking one tablet and one capsule each day by mouth for the next 2 months. We shall 
also inform your general practitioner of your involvement in the study and check that they are happy 
for you to continue in the study. 
Within a few weeks of receiving this first pack of study treatment, you will also be sent an optional
blood and urine sampling kit. If it is convenient for you to do so, you would be asked to attend your 
local surgery to have a small blood sample taken (about 2 teaspoons full) and to provide a urine 
specimen. Measurements of your height, weight and blood pressure would also be recorded at the 
surgery and this information, along with the sample, would then be mailed to the ASCEND 
coordinating centre.  
Long-term commitment to the study 
Towards the end of the 2 months you will be sent a second study questionnaire. This will allow you to 
indicate whether or not you would be willing to continue taking the study treatments long-term. 
Participation in the study does require a commitment to take the study treatments regularly for at 
least 7 years and to complete questionnaires regularly. If you do not think that you would be 
willing or able to do this then it would be better not to join in the first place.
If you decide to continue you would then be sent further supplies of the study treatments and asked 
to take one tablet (which would be active or dummy aspirin) and one capsule (containing one or other 
naturally-occurring oil) every day for the next several years. Further questionnaires would be sent out 
at 6-monthly intervals. We would ask you to tell us about your current medication and any changes to 
CTSU, University of Oxford                                                                   Protocol 
[V9.0_140111] 
251
your health since your last questionnaire. Additional supplies of study treatment would be sent to you 
6-monthly if you were willing to continue taking it. If you do stop during the first 2 months then no 
further enquiries will be made of you. But, if you decide to continue, we would like to remain in 
contact with you for the next several years – even if you stop taking the study treatment during this 
period. Throughout the study, your own doctors would remain fully responsible for all your 
other medical care as usual. However, if you develop any unexpected symptoms which you believe 
may be due to study treatment you should contact a study doctor on the 24-hour Freefone service: 
0800 585323. 
What are the side-effects and risks of taking part?
A low dose of aspirin is being used in this study in order to minimise any stomach upset or other 
gastrointestinal problems. Some minor bleeding (e.g. after having blood taken) and bruising may be 
experienced by some people, but serious bleeding is likely to be rare. We shall monitor whether 
aspirin causes an unacceptable level of bleeding during the study. Bleeding risks with aspirin may be 
somewhat greater among those who are taking warfarin (Marevan) or other blood thinning drugs (e.g. 
Acenocoumarol (Nicoumalone, Sinthrome) or Phenindione).  So, if you are taking any of these blood 
thinning drugs you would not be suitable to join the study, and if you are prescribed them later we 
recommend stopping the study aspirin/placebo tablets. People who join the study would be asked to 
avoid taking aspirin-containing painkillers, and to take an alternative, (such as paracetamol), 
whenever pain relief is necessary. All other prescribed treatments can be taken as usual. There are 
no other lifestyle or dietary restrictions required.  The doses of the naturally occurring oils being 
tested in ASCEND are not known to cause any particular problems, although some people may 
experience gastro-intestinal (“tummy”) disturbances. If you did experience any symptoms that you 
thought were related to either of the study treatments, medical advice is available at all times through 
the 24-hour Freefone service: 0800 585323. 
What are the possible benefits of taking part? 
We hope that both the study treatments may help you. However, this cannot be guaranteed. The 
information we get from this study may help us to treat future patients with diabetes better and may 
help to prevent many thousands of heart attacks and strokes. 
What if new information becomes available? 
Sometimes during the course of a research project, relevant new information becomes available 
about the treatment that is being studied. If this happens we will tell you and your general practitioner 
about it and you can discuss whether you want to continue in the study. A study doctor is available 
through the 24-hour Freefone service if either you or your GP need to discuss any new information.  
What happens at the end of the study? 
When the research study finishes, we will inform you and your GP of the study results. You will then 
be able to decide whether or not you should take aspirin and/or omega-3 fatty acids. After the study 
finishes we will no longer continue to provide study medication for you. But, if the study results 
suggest possible benefit, you could discuss with your GP whether you should take either of these 
treatments routinely. We will also publish the study results in a professional medical journal as soon 
as possible after the study finishes. You would not be identified individually in any published report. 
What if something goes wrong? 
In the unlikely event of you being harmed as a result of taking part in the ASCEND study, the 
University of Oxford provides insurance cover and you would retain the same rights of care as any 
other patient treated in the National Health Service. 
Will my taking part in this study be kept confidential? 
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The coordinating centre would seek information from participants’ own doctors and from NHS and 
other central registries about any serious illnesses (such as heart attacks, strokes, cancers etc) that 
occur. All such information would be used, in confidence, only for medical research purposes and for 
routine regulatory and audit purposes. 
Study organisation 
The ASCEND study has been designed, and is coordinated, by Oxford University’s Clinical Trial 
Service Unit. It involves the collaboration of many doctors and nurses around the country. The study 
design has been reviewed and agreed by independent Research Ethics Committees, which include 
people from outside the medical profession. The British Heart Foundation has provided a grant to 
conduct this research study, and packaged study treatment has been provided free by Bayer (makers 
of the aspirin/placebo) and Abbott (who are providing the natural oils).  An independent Data 
Monitoring Committee will review various outcomes among participants during the study, and will 
inform the organisers if any important new information has emerged that needs to be provided to 
participants and their doctors.  Any questions about the study should be directed to the coordinating 
centre in Oxford either by telephone (24-hour Freefone service: 0800 585323) or by mail to: ASCEND 
Study, CTSU, Richard Doll Building, University of Oxford, Old Road Campus, Oxford, OX3 7LF.  
Alternatively you can e-mail us on ascend@ctsu.ox.ac.uk. 

 ASCEND: Summary of invitation to join a large medical research project 
 Having diabetes may increase the risk of heart attacks and strokes 
Aspirin and omega-3 fatty acids benefit people who have survived a heart attack  
 It is not clear whether people with diabetes who have not shown signs of circulatory 
problems should take aspirin or omega-3 supplements regularly 
 Most people with diabetes and no circulatory problems do not take aspirin or 
omega-3 supplements regularly 
 Low-dose aspirin is generally very safe, but does increase the risk of bleeding 
 Omega-3 fatty acids at the doses being taken in ASCEND are also considered safe 
 The purpose of ASCEND is to find out whether aspirin and/or omega-3 fatty acid 
supplementation prevents heart attacks and strokes in people with diabetes who 
have not shown signs of circulatory problems 
 If these treatments are shown to be safe and effective for people with diabetes, then 
their widespread use could lead to the prevention of many thousands of heart 
attacks and strokes and the saving of many lives 
 With your help we can answer these questions reliably with the ASCEND study
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If you have any questions about the study then please feel free to contact the 
coordinating centre on Freefone: 0800 585323 
If you think you might be interested in joining this research study please 
complete and return the attached questionnaire and agreement to participate. 
A copy of your signed agreement to participate will be returned to you when 
your first pack of study treatment is sent out. 
Please keep this information sheet for your own records. 
THANK YOU FOR YOUR HELP
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Cost-effective recruitment methods for a
large randomised trial in people with
diabetes: A Study of Cardiovascular Events
iN Diabetes (ASCEND)
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Abstract
Background: Clinical trials require cost-effective methods for identifying, randomising, and following large
numbers of people in order to generate reliable evidence. ASCEND (A Study of Cardiovascular Events iN Diabetes)
is a randomised ‘2 × 2 factorial design’ study of aspirin and omega-3 fatty acid supplements for the primary
prevention of cardiovascular events in people with diabetes; this study used central disease registers and a mail-
based approach to identify, randomise, and follow 15,000 people. In collaboration with UK consultants and general
practitioners (GPs), researchers identified potentially eligible people with diabetes from centrally held registers
(e.g. for retinopathy screening) and GP-held disease registers. Permission was obtained under section 251 of the
National Health Service Act 2006 (previously section 60 of the NHS act 2001) to allow invitation letters to be
generated centrally in the name of the holder of the register. In addition, with the collaboration of the National
Institutes for Health Research (NIHR) Diabetes and Primary Care Research Networks (DRN and PCRN), general
practices sent pre-assembled invitation packs to people with a diagnosis of diabetes. Invitation packs included a cover
letter, screening questionnaire (with consent form), information leaflet, and a Freepost envelope. Eligible patients
entered a 2-month, pre-randomisation, run-in phase on placebo tablets and were only randomised if they completed a
randomisation form and remained willing and eligible at the end of the run-in. Follow-up is ongoing, using mail-based
approaches that are being supplemented by central registry data.
Results: Information on approximately 600,000 people listed on 58 centrally held diabetes registers was obtained, and
300,188 potentially eligible patients were invited to join the study. In addition, 785 GP practices mailed invitations to
120,875 patients. A further 2,340 potential study participants were identified via other routes. In total, 423,403 people
with diabetes were invited to take part; 26,462 entered the 2-month, pre-randomisation, run-in phase; and 15,480 were
randomised.
Conclusion: If sufficient numbers of potentially eligible patients can be identified centrally and the trial treatments do
not require participants to attend clinics, the recruitment and follow-up of patients by mail is feasible and cost-effective.
Wider use of these methods could allow more, large, randomised trials to be undertaken successfully and cost-effectively.
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Background
Randomised controlled trials are the cornerstone for reli-
ably evaluating the safety and efficacy of therapeutic strat-
egies [1]. For chronic conditions, where many treatments
are expected to have only moderate effects, trials need to
be large in size and long in duration to achieve sufficient
statistical power and ensure a robust result. The regula-
tions surrounding clinical trials are becoming increasingly
burdensome [2, 3], and as a result, the cost and complex-
ity of a standard approach to evaluating therapies is pro-
hibitive (typically at least £3–400 M for large clinical
outcome trials), and the model is unsustainable [4]. The
development of potentially effective drugs is often stopped
prematurely on financial, rather than scientific grounds,
and it has become more difficult to do academic trials of
important scientific questions; this difficulty has resulted
in the distortion of the scientific agenda.
Clinical trials are typically undertaken in a clinic-based
setting either in primary or secondary care, and the re-
cruitment of large numbers of participants may require
many sites, resulting in organisational complexity and
very substantial costs [4]. However, for interventions
that require no ongoing physical or laboratory safety
monitoring, conducting the trial by mail offers a cost-
effective alternative. Several large, successful, rando-
mised trials have been conducted using both a mailed
drug supply and follow-up [5–8]. Experience from these
studies shows that, with appropriate attention to the
wording of the information leaflets, consent forms and
questionnaires, good response rates and compliance can be
achieved, and reliable information about medical events,
gathered. However, previous trials had been conducted
among healthcare professionals (i.e. doctors or nurses), and
it was not known if such mail-based approaches to clinical
trials would be feasible and acceptable in people without
such a background.
ASCEND (A Study of Cardiovascular Events iN Dia-
betes) is a 2 × 2 factorial design randomised study to as-
sess whether aspirin 100 mg daily versus placebo and
separately, omega-3 fatty acids 1 g daily versus placebo,
reduce the risk of cardiovascular events in individuals
with diabetes who do not already have diagnosed occlu-
sive arterial disease, and whether any such benefits out-
weigh any hazards from bleeding. To minimise costs
sufficiently to allow ASCEND to be funded by non-
commercial sources, the study was designed to be run
mainly by mail with back-up from a 24-hour Freefone
service. The rationale and design are available on the
study website (http://www.ctsu.ox.ac.uk/ascend/further_-
pro.htm). This report describes the highly cost-effective
mail-based-recruitment methods, which allowed the ran-
domisation of 15,480 people with diabetes from around
the UK into ASCEND, making it one of the largest ever
trials in this patient group.
Methods
Trial coordination and approvals
The University of Oxford’s Clinical Trial Service Unit &
Epidemiological Studies Unit (CTSU) is coordinating the
study and has overall responsibility for the administration
and management of the study under the guidance of a
Trial Steering Committee. The University of Oxford is the
regulatory sponsor of the trial. After the study had secured
initial funding from the British Heart Foundation and a
commitment to provide packaged aspirin and matching
placebo tablets from Bayer Pharmaceuticals and omega-3
fatty acid capsules and matching placebo capsules from
Solvay Pharmaceuticals (subsequently Abbott and now
Mylan), Multi-centre Research Ethics Committee (MREC)
approval was obtained in 2003 (North West REC, ref 03/
8/087) for the study protocol and, in particular, to use cen-
trally held diabetes registers to identify potential partici-
pants. Since local doctors were not directly involved in
recruitment, the MREC approval indicated that local
ethics committees need only be informed of the study,
and site-specific approval was not required. Regulatory ap-
proval was obtained from the Medicines and Healthcare
Products Regulatory Agency (MHRA), and permission to
obtain identifiable details of people with diabetes without
their explicit consent (in order to invite them to partici-
pate in the trial) was obtained from the Patient Informa-
tion Advisory Group (PIAG), constituted under Section
60 of the NHS Act 2001 (subsequently the National Infor-
mation Governance Board under section 251 of the
National Health Service Act 2006, and more recently the
Confidentiality Advisory Group). The coordinating centre
ensured that the necessary Research Governance approvals
were also in place for the invitations to be sent from gen-
eral practices.
Identification of participants
People with diabetes were identified from two main
sources: (1) centrally held diabetes registers and (2) gen-
eral practice diabetes registers. Once potentially eligible
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individuals had responded to their invitation, subsequent
processes were identical for each route of identification
(Fig. 1).
Centrally held registers
Consultant diabetologist physicians and other relevant doc-
tors from around the UK were invited to collaborate with
the investigators in Oxford in order to allow invitation of
potentially suitable individuals with diabetes from their lo-
cally held diabetes registers (such as those held for retinop-
athy screening). To streamline the invitation process, and
in accordance with the PIAG approval, the individuals’
contact details, date of birth, and GP details were sought
electronically, and lists were sent to the coordinating
centre. Prior to contacting anyone, lists of potential invitees
were sent to the relevant GP asking that they inform the
coordinating centre if they did not wish their patients (ei-
ther specific individuals or all potentially eligible patients)
to be contacted about the study. No response from the GP
after a reminder letter was taken as agreement to contact
the patients. Immediately prior to the invitation being sent,
the vital status of the person was checked with the Office
for National Statistics (subsequently Health and Social
Care Information Centre), to help avoid inadvertent invita-
tion of people who had died (although delays in the avail-
ability of up-to-date information could not prevent this
entirely). Large-scale, automated, mailing systems were
used to generate individualised invitation letters, which
Fig. 1 Main routes of identification and invitation of potential study participants. * At the time of recruitment for ASCEND, PIAG/NIGB approval was a
separate application process. More recently it has become integrated with the central IRAS system.** ASCEND sought local R&D from every primary care
trust (PCT) in England, health board in Scotland and local health board in Wales [13]. NRES: National Research Ethics Service (now part of the Health
Research Authority); PIAG: Patient Information Advisory Group; NIGB: National Information Governance Board; ONS: Office for National Statistics; HSCIC:
Health and Social Care Information Centre
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were sent with the computer-generated signature of the
designated holder of the diabetes register. The invitation
pack included the signed cover letter, a screening question-
naire (including the consent form), the study patient infor-
mation leaflet and a Freepost return envelope addressed to
the coordinating centre (see Additional files 1 and 2). A
24-hour Freefone telephone service was available for trial-
related enquiries from both potential participants and
medical staff.
General practice registers
Consultants and other collaborators were also asked to
identify 20–30 local GPs with computerised disease reg-
isters and to seek their agreement to mail invitations to
potentially eligible individuals. In addition, the National
Institutes for Health Research (NIHR) Diabetes Research
Network (DRN) and the NIHR Primary Care Research
Network (PCRN) identified other interested general
practices and provided support for practice staff in the
recruitment process. Staff in collaborating practices per-
formed an electronic search on their practice database
for potentially eligible patients. Having reviewed the list
generated by this search to remove anyone considered
unsuitable for the trial, they informed the coordinating
centre of the number of invitation packs required, and
these were sent to the practice. At the practice, an ap-
proved invitation letter was mail-merged with the pa-
tient’s name and address onto practice headed paper,
and these invitation letters were added to the invitation
packs provided by the coordinating centre and mailed. For
practices identified via the DRN and PCRN, local network
support funding was available to help with these adminis-
trative tasks.
Other identification routes
Other potentially eligible patients with diabetes were
identified from among participants in the Medical
Research Council/British Heart Foundation (MRC/
BHF) Heart Protection Study (HPS) [9], and they were
sent similar invitation packs, with the cover letter
adapted accordingly. In addition hospital-based collab-
orators were sent pre-assembled invitation packs that
they could hand to potentially eligible patients seen in
their outpatient clinics, and randomised participants
had the option of recommending a friend or relative
they thought might be eligible and interested in partici-
pating in the study. With their friend’s or relative’s per-
mission, their contact details were sent to the
coordinating centre, and an invitation pack was mailed
directly to the individual. The study website also facili-
tated the registration of potential volunteer partici-
pants. Diabetes UK, the UK patient, healthcare
professional, and research charity, published a brief
article about the study in their patient magazine
‘Balance’, which resulted in a number of ‘self-referrals’.
Method of recruitment
People were potentially eligible if aged over 40 years,
had type 1 or 2 diabetes, and were not thought to have
occlusive vascular disease. Preliminary eligibility was
based on information provided on the completed screen-
ing questionnaire (i.e. confirmation of diabetes diagnosis,
no reported history of diagnosed occlusive arterial dis-
ease, no contraindication to regular aspirin, and signed
consent to participate – see Additional file 1). Com-
pleted screening questionnaires were returned (Freepost)
to the coordinating centre where they were logged and
then scanned using optical character recognition soft-
ware to facilitate the efficient transfer of information
into the study databases. Bespoke computer programs
were used to validate the data, with study administra-
tors, nurses, or clinicians performing additional checks
where needed or contacting participants for clarification
of responses if necessary.
Consent and pre-randomisation run-in
The screening questionnaire included specific questions
related to consent (Additional file 1), which the partici-
pants had to sign to confirm that they had understood,
and that if they had any questions, these had been ad-
dressed by study staff. The 24-hour Freefone service was
available if they had any questions about the trial or
wished to speak to a doctor about their involvement.
During the day, this was manned by the study team, and
outside working hours, a clinician was available via a
radio pager. Based on the screening questionnaire re-
sponses, willing and eligible patients, all of whom had
provided signed informed consent, entered a 2-month,
placebo, run-in phase (single-blind) and were mailed a
pre-randomisation ‘run-in’ pack of medication, which
contained 8-weeks of placebo aspirin and placebo
omega-3 fatty acids (Fig. 2). An information sheet about
the medication was provided (including a list of contra-
indicated medications – see Additional file 3), along with
a copy of the scanned image of their signed agreement
to participate.
The purpose of the run-in was to check that patients
would take the study medication and return the question-
naires regularly, thereby aiming to increase the chance
that, if randomised, they would remain compliant and
complete follow-up [10]. The run-in also provided the
time and opportunity for the coordinating centre to in-
form the GP of their patient’s provisional agreement to
enter the study, with an option for the GP to advise
against it if they wished, and for the coordinating centre
to send a blood and urine kit (see below) to the participant
to obtain baseline biological samples.
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During the run-in phase, a blood and urine sampling kit
was sent with a supplementary information leaflet and
consent form (Fig. 3 and Additional file 4). Participants
were asked to take this kit to their general practice for
sample collection and the samples were then mailed to the
central laboratory in the containers provided. With the
exception of those practices in which phlebotomy services
were very limited, this approach was widely accepted, and
most practices agreed to provide this service without
requesting additional payment. The practice nurse was also
asked to record the patient’s blood pressure and height and
weight on the form provided. This allowed minimised
Fig. 2 Packaged study drugs for mail-based trial
Fig. 3 Blood and urine sampling kit for mail-based trial
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randomisation by relevant biochemical prognostic variables
(e.g. lipids, HbA1c) as well as the collection of samples for
long-term storage and future analyses (including DNA).
Approximately 2 months after entering the run-in, the
participants were sent a randomisation questionnaire to
confirm their eligibility, collect more detail about their
diabetes and current medications, and check their com-
pliance with the study treatments during the run-in
period (Additional file 5). Participants were randomised
if they completed and returned a randomisation form
and remained willing and eligible to participate.
Results
A total of 423,403 potentially eligible individuals were
invited via the different routes, of which, 29 % (121,254
people) returned the screening questionnaires to the co-
ordinating centre (Table 1). Approximately one-third of
those returning the questionnaire agreed to join the trial.
After review of the questionnaire data, 26,462 partici-
pants (6 % of those originally invited) were willing and
eligible to join ASCEND and entered the 2-month run-
in period.
Randomisation questionnaires were sent to 22,579 pa-
tients. Of these, 15,480 people returned a completed ques-
tionnaire, remained willing and eligible to participate, and
were randomised into ASCEND using a computer-based
minimisation algorithm. Approximately 40 % of all patients
who entered the run-in dropped out before randomisation,
and half of these (approximately 5500 participants) had no
clinical reason to stop the trial but simply declined to con-
tinue. Overall, 4 % of those invited were randomised: 3 %
from centrally held registers (9013 patients) and 5 % from
GP registers (6037 patients).
The recruitment process took longer than expected
(Fig. 4) but accelerated after mid-2009 due to both the in-
creased availability of the large central registry data (re-
gional retinopathy registers) and to the support from the
DRN and PCRN. More than 700 general practices helped
with recruitment for the study, from which approximately
6000 of the randomised patients were identified. The ma-
jority of practices were identified with the help of the net-
works, whose support of ASCEND resulted in more than
5000 participants being recruited into the study (Table 2).
If a completed screening questionnaire was not received
within approximately 2 weeks of the initial invitation from
a centrally held register, a reminder questionnaire was
sent. Approximately one-fifth (38,785 of 203,083) of those
who received a reminder returned either the original or
the reminder screening questionnaire. Similarly, a re-
minder was sent if a randomisation questionnaire was not
returned within 2 weeks. Approximately two-thirds (3110
of 5101) of those to whom randomisation questionnaire
reminders were sent, replied, and this led to 2183 patients
being randomised. Overall, nearly half (4111 of 9013) of
all randomised patients recruited via the centrally held
register route were sent a reminder for at least one of the
questionnaires.
The availability of information (e.g. sex, date of birth,
and post code) from the centrally held registers allows
the response rate to the invitation to be compared
among the different types of people (Table 3). Younger
invitees were more likely to express an interest in par-
ticipating in the study, even if they were not eligible
based on their returned screening form (14 % of those <
50 years old vs 7 % of those ≥ 70 years old, trend p value
< 0.0001). However, amongst people who were eligible
for the trial and entered the run-in phase, the percent
randomised did not vary substantially according to age.
There was also a slightly better initial response from
men than women (11 % vs 8 %, chi-square p < 0.0001),
but when those who were ineligible at screening are taken
into account, the proportion randomised of those entering
run-in was similar by sex (56.2 % men vs 55.5 % women,
chi-square p = 0.4) (Table 3).
A particular advantage of the mail-based trial method-
ology used in ASCEND is that with no requirement to at-
tend study clinics, participation is not limited by
geographical proximity to a study centre. Figure 5 shows
the location of the home addresses of the randomised par-
ticipants in ASCEND, with recruitment covering both
rural and urban areas across the UK. The response to invi-
tation was slightly greater from those living in rural areas
compared with those in cities (10.9 % vs 9.7 %, p < 0.0001,
Table 3). This is likely to be in part due to differences in
the Townsend index (a measure of material deprivation
based on the subject’s home post code), in which a
Table 1 Recruitment by route of identification
Central registers General practitioner (GP) registers Othersa Total (% of those invited)
Invited 300,188 120,875b 2340 423,403
Returned valid screening form 100,563 19,478 1213 121,254 (29 %)
Entered run-in 16,091 9739 632 26,462 (6 %)
Sent randomisation form 13,481 8541 557 22,579 (5 %)
Randomised (% of those invited) 9013 (3 %) 6037 (5 %) 430 (18 %) 15,480 (4 %)
aMRC/BHF Heart Protection Study/self-referral/Friends & Family referral/consultant clinic invitations
bBased on number of screening forms sent by coordinating centre to GP practices to be mailed to participants
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substantial variation is observed from 12 % among those
in the least deprived areas to 8 % from the most deprived
areas (trend p value < 0.0001, Table 3). However, a highly
significant rural vs urban effect still persists after allowing
for Townsend index (p < 0.0001).
The number of days between mailing a study invitation
and receipt of the response could be recorded for screen-
ing questionnaires sent by the coordinating centre and for
all randomisation questionnaires. The mean (SD) time
from original invitation to response was 24 (27) days and
14 (15) days for the screening and randomisation
questionnaires, respectively. To keep study costs down,
second class postage was used for all routine mailings, so
the minimum achievable response time was, therefore,
4 days. Ninety-five percent of responses to the screening
and randomisation questionnaires were received within
approximately 2 months and 1 month, respectively.
A 24-hour Freefone telephone service for queries from
participants or their doctors was available to support the
recruitment process. Over the 6-year recruitment phase,
8800 telephone calls were logged to this service: 3500
were incoming calls with enquiries from participants or
Fig. 4 Cumulative recruitment of study participants by year
Table 2 Number of GP practices identified and participant recruitment via the Primary Care Research Network (PCRN), Diabetes
Research Network (DRN) and other routes
Number of practices recruited Number of patients invited Number of patients
entered run-in
Number of patients randomised
(% of those invited)
PCRN 512 79,471 6733 4207 (5 %)
DRN 156 24,420 1772 1065 (4 %)
Other 117 16,984 1234 765 (5 %)
Total 785 120,875 9739 6037 (5 %)
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their carers/relatives or doctors, and 5300 were outgoing
calls made by study staff, typically to clarify information
that had been written on the screening and randomisa-
tion questionnaires. Approximately half of all telephone
calls (both outgoing and incoming) related to partici-
pants who were not subsequently randomised.
Blood and urine kits were sent to 22,858 patients who
entered the pre-randomisation phase and who had not
informed the coordinating centre that they wished to
withdraw before the kits were due to be sent. Samples
(either blood or urine or both) were received by the
laboratory from 13,270 individuals, among whom 11,685
were subsequently randomised. The average delay be-
tween sample collection and receipt at the coordinating
centre laboratory (sent by first class post to limit sample
delays) was 2 days.
Discussion
ASCEND is one of the largest ever randomised trials
among people with diabetes. It achieved its recruitment
target of 15,000 participants by means of central and local
diabetes registers to identify patients who might be suitable
and by using highly cost-effective mail-based systems to
send screening and randomisation questionnaires, provide
study drugs, and collect biological samples. The trial is
funded by a grant to the University of Oxford from the
British Heart Foundation (£3.7 million), which covers the
costs of running the study over a 15-year period (to include
planning, recruitment, follow-up, and study close-out and
reporting activities). Within this budget, the costs of print-
ing and postage for the mail-based recruitment process
were less than £0.5 million, which is substantially less than
the clinic staff costs that would be required for a standard
clinic-based approach at this large scale. Study drug and
additional funding for drug packaging (£3.6 million) was
provided by Bayer and Solvay Pharmaceuticals (subse-
quently Abbott, and now Mylan). In addition, the 668 prac-
tices identified via the DRN and PCRN were eligible for
local network support funding (typically around £500 per
practice) to help with recruitment activities. Overall, the
total costs of this major trial are therefore an order of mag-
nitude lower than those of a typical commercial clinic-
based study (generally at least £3–400 M for large clinical
outcome trials [4]).
Table 3 Response to invitation; entering pre-randomisation run-in phase; and randomised by age, sex, and Townsend Index (central
register route only)






Percent of those entering run-in
who are subsequently randomised
Age (years)b
<50 12,753 1,729 (14 %) 1,262 (10 %) 694 (5 %) 55 %
≥50, < 60 59,635 7,580 (13 %) 4,914 (8 %) 2,801 (5 %) 57 %
≥60, < 70 93,526 11,040 (12 %) 6,103 (7 %) 3,543 (4 %) 58 %
≥70 134,274 9,508 (7 %) 3,812 (3 %) 1,975 (1 %) 52 %
Sex
F 130,889 10,642 (8 %) 5,931 (5 %) 3,297 (3 %) 56 %
M 169,299 19,215 (11 %) 10,160 (6 %) 5,716 (3 %) 56 %
Townsend Indexc
< -3 64,054 7,635 (12 %) 4,649 (7 %) 2,781 (4 %) 60 %
≥ -3 < 0 100,057 10,544 (11 %) 6,022 (6 %) 3,467 (3 %) 58 %
≥0 < 2 47,597 4,207 (9 %) 2,179 (5 %) 1,201 (3 %) 55 %
≥2 < 4 41,932 3,576 (9 %) 1,697 (4 %) 838 (2 %) 49 %
≥4 < 6 30,637 2,466 (8 %) 1,009 (3 %) 496 (2 %) 49 %
≥6 15,354 1,287 (8 %) 458 (3 %) 195 (1 %) 43 %
Urban/rural locationd
Urban 244,718 23,729 (10 %) 12,590 (5 %) 6,960 (3 %) 55 %
Rural 54,116 5,923 (11 %) 3,397 (6 %) 2,004 (4 %) 59 %
Unknown 1,354 205 (15 %) 104 (8 %) 49 (4 %) 47 %
Total
300,188 29,857(10 %) 16,091 (5 %) 9,013 (3 %) 56 %
aIncludes willing but ineligible responses. Eligibility likely to vary in subgroups due to differing incidence of prior vascular disease
bBased on age on the date screening invitation generated
cBased on postcode at screening (lower values indicate least deprived). Score unknown for 557 of those invited
dBased on postcode at screening (using ONS 2011 Rural-Urban Classification for Small Area Geographies)
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Detailed baseline characterisation of the randomised par-
ticipants has been possible from the information collected
on the mailed screening and randomisation questionnaires
and from mailed blood and urine samples. ASCEND illus-
trates that if large enough numbers of potentially eligible
patients can be identified, and automated methods can be
adopted, it is possible to recruit a large study population
successfully by mail.
Access to centrally held registers of potentially eligible
patients was crucial to the success of recruitment into
ASCEND. Although this required the transfer of patient-
identifiable information from the register holder to the
coordinating centre without the patient’s prior consent,
existing legislation allows this to be done within a strict
legal framework. Without access to these registries, more
than 2000 GP practices would need to have been identified
and, even if this had been possible, such an approach would
have increased the costs and time to recruit significantly.
Previous patient volunteer focus group work conducted by
CTSU for other studies has confirmed that most patients
find this approach acceptable, as long as robust information
governance standards are adhered to.
In ASCEND, a small number of complaints were re-
ceived about the transfer of data without consent. In
the majority of cases, the complainant was unaware of
the relevant legislation, and a simple verbal explanation
of the process was sufficient to clarify any concerns,
with many such individuals subsequently agreeing to
join the trial. The complainant remained dissatisfied in
only 28 cases (0.01 % of 300,188 people invited from
centrally held registers) and requested removal of per-
sonal data from the study database. The coordinating
Fig. 5 Location of randomised participants in the UK (postcode of home address)
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centre had a standard operating procedure for such re-
quests, which were acted on promptly. Whereas previ-
ous mail-based trials had successfully recruited from
populations of healthcare professionals [5–8], ASCEND
has demonstrated the acceptability of this approach in
a general diabetic population.
Overall, less than one-third of those invited replied to
the invitation to take part, and the majority of those who
did reply declined to join the study. Other groups have
reviewed possible methods to improve the response to
postal and electronic questionnaires in order to identify
effective strategies to improve recruitment to trials and
epidemiological studies. A Cochrane review reported sub-
stantial heterogeneity among trials, evaluating more than
100 different approaches to increasing the response to
postal questionnaires (typically for epidemiological stud-
ies) [11]. Strategies involving monetary incentives and the
use of recorded delivery of the questionnaire appeared to
be successful, approximately doubling the response rate to
postal questionnaires. However, such approaches would
add substantially to the cost of a large trial such as
ASCEND. Furthermore, those recruited by means of fi-
nancial incentives might not remain adequately compliant
with follow-up and study treatment in longer-term stud-
ies. Sending reminders in ASCEND was an effective strat-
egy, which substantially improved the response rate,
without which, an additional 140,000 potentially eligible
people would have needed to be invited.
Follow-up in ASCEND is ongoing, using mail-based ap-
proaches supplemented by central registry data. Study par-
ticipants receive requests every 6 months for follow-up
information. This can be provided either by means of a
paper questionnaire, by telephone to the coordinating
centre, or using a web-based interface via an internet
browser, according to the individual’s preference. For par-
ticipants who are no longer able or willing to complete
questionnaires, follow-up information is obtained from
their GP. Overall, good rates of follow-up are being
achieved using these cost-effective methods. At present,
approximately 95 % of all live study participants have
follow-up information available from within the last
12 months, and efforts are ongoing to contact those par-
ticipants for whom follow-up is due.
The currently observed compliance (blinded) with the
aspirin/placebo study treatment at the end of the first
year post-randomisation is approximately 85 %, with a
further 5–7 % decline in compliance annually thereafter.
Despite participants having no routine direct contact
with the study team, this is comparable to clinic-based
trials in similar populations [12]. However, notably, the
compliance with study treatments is somewhat lower
among those who were sent a reminder randomisation
form compared with those who replied to the initial
mailing. For example, at the study mid-point (45 months
after randomisation), 61 % of those sent a randomisation
reminder were compliant with their aspirin/placebo
study tablets versus 68 % of those where no reminder
was sent (p < 0.0001). This reduction in compliance became
apparent within the first 6 months after randomisation and,
although reminders were essential for the completion of
recruitment, the implications for reduced compliance in
those who do not readily respond to questionnaire mailings
is an important consideration.
On the other hand, the use of a pre-randomisation
run-in is a valuable methodological tool to enhance
compliance, especially in the early phase of a long-term
study [10]. Of those who entered the single-blind pla-
cebo run-in period in ASCEND, approximately 40 %
dropped out of the study before randomisation. Had
there been no run-in, these withdrawals would probably
have occurred after randomisation (most likely in the
first 6–12 months), thereby substantially reducing the
statistical power of the study.
Recruitment into ASCEND took longer than initially
hoped as a result of a variety of factors, including research
governance delays [13], the time taken to obtain the elec-
tronic records from the diabetes registers, establishing ro-
bust IT systems to monitor the study, and an increase in
the original recruitment target. However the involvement
of the former local NIHR Diabetes and Primary Care Re-
search Networks across England and Scotland provided a
valuable extra resource, which boosted recruitment and,
had they been established sooner, might have shortened the
recruitment period. A substantial infrastructure for pa-
tient recruitment to research studies continues to be
available through the NIHR Clinical Research Network.
The response to invitation was higher among those
identified from general practice compared with those in
central registries (5 % vs 3 % of those invited were
eventually randomised). This may have been partly due
to the ability to pre-screen potential participants to ex-
clude those with established vascular disease but also
because participants were more likely to respond posi-
tively to a GP whom they knew.
The design of ASCEND included an optional baseline
blood and urine sample collection during the pre-
randomisation run-in phase. This exercise was funded
by a separate project grant from the British Heart Foun-
dation (£140 k). Previous transport studies have demon-
strated that a wide range of analytes (including HbA1c
lipids and cystatin C as a measure of renal function) and
genetic polymorphisms can be reliably measured in
whole blood samples with delayed separation [14, 15].
During the past few years, extensive experience has been
gained with obtaining cardiovascular risk factor mea-
surements from mailed blood samples [16]. In ASCEND,
this approach has allowed measured baseline risk factor
information to be obtained from 75 % of those
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randomised at very low cost, which will allow the effects
of the study treatments to be assessed within subgroups
defined by biological measures.
Conclusions
ASCEND is designed to be streamlined and highly cost-
effective. When completed, the trial will have cost < £10
million overall. This includes both the NHS service sup-
port costs provided to general practices and the substan-
tial costs of drug packaging and distribution (which are
typically covered by the pharmaceutical industry and not
usually included in the budget quoted for many large-
scale outcome studies). Using the methods described,
ASCEND has randomised nearly 15,500 people with dia-
betes, making it one of the largest ever randomised trials
in this patient group. The questions it aims to address are
clinically relevant for the hundreds of millions of people
worldwide with diabetes and, with good follow-up and
compliance, will add valuable information on the balance
of benefits and risks of these treatments, including im-
portant data on the use of aspirin for cancer prevention.
The strategies which helped make recruitment successful
include (1) simple inclusion and exclusion criteria, (2) the
central coordination of recruitment, (3) the ability to iden-
tify a large pool of potentially eligible people, and (4) the
involvement of local research networks. The success of
these methods in ASCEND show that, with good plan-
ning, mail-based methodology is cost-effective and could
be more widely adopted for the assessment of interven-
tions that require little monitoring.
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ASCEND: A Study of Cardiovascular Events iN
Diabetes: Characteristics of a randomized
trial of aspirin and of omega-3 fatty acid
supplementation in 15,480 people
with diabetes
Louise Bowman,MBBS, FRCP, a,b MarionMafham,MRCP,MD, a,bWilliamStevens, PhD, a,b RichardHaynes,DM, FRCP, a,b
Theingi Aung, MRCP, c Fang Chen, PhD, MBBS, a,b Georgina Buck, MSc, a,b Rory Collins, FRCP, FRS, a,b and
Jane Armitage, FRCP, FFPH a,b, The ASCEND Study Collaborative Group Headington, Oxford; Reading, UK
Objectives The use of aspirin for the secondary prevention of cardiovascular disease (CVD) is firmly established, and the
proportional reductions in heart attacks and strokes appear to be similar in people with and without diabetes. Uncertainty
remains about the role of antiplatelet treatments for primary prevention of CVD, and guidelines vary in their recommendations.
It has also been hypothesized that long-term aspirin can prevent gastro-intestinal and other cancers.
Observational studies suggest associations between higher intakes of omega-3 fatty acids (FA) and lower rates of CVD, but
there is no large-scale randomized evidence to support using prophylactic omega-3 FA supplementation in primary prevention.
ASCEND is a randomized trial assessing whether 100 mg daily aspirin safely prevents CVD and cancer in patients with
diabetes without known arterial disease. It is also assessing whether supplementation with 1 g omega-3 FA daily prevents
CVD. This paper describes the methods and baseline characteristics of the randomized participants.
Methods and results Between 2005 and 2011, using mail-based methods, 15,480 people with diabetes were
randomized to aspirin versus placebo and, in a factorial design, to omega-3 FA supplementation versus placebo. Blood and
urine samples were collected to allow baseline stratification by biochemical prognostic variables (e.g. HbA1c, blood lipids).
Follow-up is for a median of at least 7 years.
Conclusions Demonstrating that prophylactic aspirin safely reduces the risk of CVD or cancer in the primary prevention
setting, or that omega-3 FA supplementation prevents CVD, would be relevant to hundreds of millions of people worldwide who
are currently not receiving such therapies. The results of ASCEND will be reported in 2018. (Am Heart J 2018;198:135-144.)
ASCEND is a randomized placebo-controlled trial
aiming to determine whether 100 mg daily aspirin
prevents cardiovascular events or cancer in 15,480 UK
patients with diabetes who are not already known to have
occlusive arterial disease, without leading to significant
bleeding or other adverse events that outweigh any
benefits. It is also assessing whether supplementation
with 1 g omega-3 fatty acids (FA) daily prevents CVD.
Aspirin in primary prevention
The Anti-Thrombotic Trialists' Collaboration (ATTC)
demonstrated conclusively that antiplatelet therapy
(chiefly aspirin) reduces the risk of myocardial infarction
(MI), stroke or cardiovascular death by about one-quarter
in people with occlusive vascular disease, including
among those who have diabetes.1 However, most of the 3
million people with diabetes in the UK, and the estimated
400 million worldwide,2 do not have manifest vascular
disease. The 2009 ATTC individual-patient-data meta-
analysis of 95,000 patients in 6 primary prevention trials
found that allocation to aspirin yielded a 12% (95% CI, 6%-
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18%) proportional reduction in occlusive vascular events,
mainly due to a reduction in non-fatal MI of about one
fifth.3 However, given the approximate 50% proportional
increase in the risk of bleeding with aspirin, on average
the bleeding hazard counterbalanced much of the benefit
in these low-risk primary prevention patients. Among the
participants in these primary prevention trials, only about
4% had diabetes and the relative risk reduction among
them was similar to that observed in those without
diabetes. Consequently, since people with diabetes are
generally at 2- to 3-fold higher risk of vascular events than
those without it,4 the absolute risk reduction with aspirin
is likely to be greater than for healthy volunteers.
However, the ATTC analyses also found that people
with diabetes had a higher risk of both major extra-cranial
bleeds (rate ratio [RR], 1.55; 95% CI 1.13–2.14) and of
hemorrhagic stroke (RR, 1.74; 95% CI, 0.95-3.17,
respectively) compared to those who did not have
diabetes irrespective of aspirin allocation.3
A further four trials of aspirin for primary prevention of
cardiovascular events have reported results since the ATTC
analyses were published in 2009: two specifically in
diabetes,5,6 and two in wider populations that included
people with diabetes.7,8 The Prevention of Progression of
Arterial Disease and Diabetes (POPADAD) trial in 1276
patients with diabetes and reduced ankle-brachial index
observed no effect on vascular events over 6.7 years (18.2%
vs 18.3%; HR, 0.98; 95% CI, 0.76-1.26), while the Japanese
Primary Prevention of Atherosclerosis With Aspirin for
Diabetes Trial (JPAD) in 2539 patients with type 2 diabetes
and no history of atherosclerotic disease followed for 4.4
years observed a non-significant reduction in vascular
events based on a very low event rate (1.36% vs 1.70%; HR,
0.80; 95% CI, 0.58-1.10). Neither of these trials reported
detailed information about bleeding, so the balance of
benefits and riskswith aspirin use for primary prevention in
diabetes remains uncertain.
Aspirin in primary prevention of cancer
Recent retrospective meta-analyses of randomized trials
have suggested that aspirin may produce 15% to 20%
proportional reductions in cancer incidence or death,
with 30% to 40% reductions in gastrointestinal cancers
(particularly colorectal cancer), and that these effects
increase with more prolonged exposure.9-13 If such effects
on cancer are confirmed prospectively in randomized trials
of sufficient duration, they could have significant implica-
tions for the balance of benefits and hazards of using aspirin
for primary prevention. ASCEND provides the opportunity
to test this hypothesis prospectively with good statistical
power since there about as many incident cancers
(approximately 1500 during the scheduled treatment
period) as in the meta-analyses that generated the
hypothesis of protection against cancer and it involves
prolonged exposure to aspirin (amedian of at least 7 years),
with longer-term follow-up available from central registers.
Omega-3 fatty acids in diabetes: adding to the
randomized evidence
A possible link between intake of omega-3 fatty acids
(FA) and prevention of coronary heart disease (CHD) was
first noted in the 1940s when the diets of Greenland
Eskimos, among whom CHD was rare despite a high fat
intake largely due to sea food, were compared with those
of Danes in Denmark who had similarly high fat intake
from more mixed diets but CHD rates that were about 10
times higher.14 A large number of observational studies of
omega-3 FA intake and heart disease risk were subse-
quently conducted in different populations. A systematic
review of these observational data concluded that
consumption of the equivalent of 40–60 grams of fish
per day (providing about 0.2–1 g daily of omega-3 FA,
depending on the type of fish) is associated with about a
halving in rates of cardiac death.15 However, there were
only limited data available from randomized controlled
trials of the effects of increasing omega-3 FA intake on
cardiovascular disease outcomes. The results in one small
randomized trial involving 2000 male heart attack
survivors were consistent with the observational studies,
with a 29% (95% CI, 7–46%) significant reduction in total
mortality and a 16% (95% CI, +7 to 24%) non-significant
reduction in ischemic heart disease events.16 Similarly, in
a trial of omega-3 FA (1 g daily) among 11,000 patients
who had survived a myocardial infarction, there was a
13% (95% CI, 1–24%) proportional reduction in coronary
events but, both this and the 10% (95% CI, 1–18%)
reduction in the primary outcome of cardiovascular
events, were only marginally significant.17 As a conse-
quence, several large randomized trials (including the
present ASCEND trial) were started in order to generate
more reliable evidence about the effects of omega-3 FA
supplementation. Some of those trials have now reported
their results, and combined in a tabular data meta-analysis
of 10 such trials that each included at least 500
participants treated for at least 1 year involved over
11,000 vascular events in 78,000 participants.18 Alloca-
tion to omega-3 FA supplements (weighted mean daily
dose of 1.1 g) for an average duration of 4.4 years
appeared to have no significant effect on major vascular
events, either overall (RR 0.97; 95% CI 0.93-1.01) or in any
particular subgroup. ASCEND will contribute important
additional data on both efficacy and safety of such
supplementation and, given its large size and longer
duration than any previous trial, may be able to detect any
modest effects of omega-3 FA supplementation.
Methods
Objectives
The aim of ASCEND is to determine whether daily
100 mg aspirin prevents cardiovascular events or cancer
in patients with diabetes who are not known to have
occlusive arterial disease, as well as to assess the
136 Bowman et al
American Heart Journal
Month 2018
magnitude of any effects on significant bleeding or other
serious adverse events. It is also assessing whether
supplementation with daily 1 g capsules containing 90%
omega-3 fatty acids (0.41 g eicosapentaenoic acid, 0.34 g
docosahexaenoic acid) prevents CVD.
Eligibility
Men or women aged at least 40 years at the time of
invitation for screening were eligible for the study,
provided they fulfilled all of the following criteria:
i) Clinical diagnosis of diabetes mellitus: the
participant's own doctor considered them to
have type 1 or type 2 diabetes (based on standard
WHO or ADA diagnostic criteria19,20);
ii) No clear indication for aspirin: the participant
had no diagnosed occlusive arterial disease (i.e. a
history of MI, angina pectoris, coronary or non-
coronary revascularization procedure [ie, periph-
eral arterial bypass surgery or angioplasty], stroke
or transient ischemic attack);
iii) No clear contra-indication to aspirin: The
participant was not at high risk of bleeding due
to gastrointestinal hemorrhage or peptic ulcer
within the previous 6 months, active hepatic
disease (such as cirrhosis or active hepatitis), or
use of warfarin or other anti-coagulant therapy;
and had no history of aspirin allergy;
iv) Substantial uncertainty about whether anti-
platelet or omega-3 FA therapy confers worth-
while benefit: the participant and their own
general practitioner (GP) did not consider there to
be a definite need to use aspirin or omega-3 FA
supplements regularly (or a definite need not to do
so);
v) No other predominant life-threatening medical
problem: the participant did not have some
condition (other than diabetes) that might be
expected to prevent them from taking at least
5 years of study treatment.
Participant recruitment and follow-up
In order to be cost-effective, UK-wide recruitment into
ASCEND was conducted by mail. The highly streamlined
recruitment methods have been described previously.21
The coordinating center provided a 24-hour Freefone
service to answer questions about the trial from
participants and their GPs.
Invitation and screening. In collaboration with
medical consultants and GPs around the UK, and
supported by the National Institutes for Health Research
(NIHR) Diabetes and Primary Care Research Networks
(DRN and PCRN), potentially eligible patients with
diabetes were identified from centrally-held registers
(e.g. for retinopathy screening) and GP-held disease
registers. Potential study participants were mailed an
invitation pack, including a cover letter, screening
questionnaire (to determine eligibility and to seek consent),
Freepost envelope and Information Leaflet.
Pre-randomization run-in period. Willing and
eligible patients entered a pre-randomization run-in
phase and were sent a run-in pack of medication (single
blind: containing placebo aspirin tablets and placebo
omega-3 FA capsules) and asked to take one tablet and
one capsule daily for 2 months. During the run-in period,
the participant's GP was informed by letter of their
patient's possible involvement in the study and asked to
return a form if they considered there to be any reason
not to randomize their patient. Patients were randomized
only if, at the end of the run-in period, they seemed likely
to comply with the study protocol for several more years.
By this process, many potential dropouts could be
excluded before becoming part of the randomized
comparison, with a consequent improvement in statisti-
cal sensitivity of the “intention-to-treat” analyses.22
Randomization. About 2 months after starting the
run-in, participants were sent a more detailed randomi-
zation questionnaire asking about any significant prob-
lems (including any cardiovascular events), their
compliance with the study treatments during the run-in
period, details of their diabetes history (to allow
classification as type 1 or 2),23 current medication,
ethnic group and smoking history.
Participants who remained eligible based on the
randomization questionnaire and were willing to contin-
ue on the study were randomized centrally at the Clinical
Trial Service Unit (CTSU), University of Oxford, using a
minimization algorithm to ensure balance by prognostic
variables (age, sex, duration of diabetes, history of treated
hypertension, smoking status, ethnic origin, and, if
available from centrally measured blood and urine
samples [see below], total cholesterol, HbA1c, and
urinary albumin/creatinine ratio). Eligible patients were
randomized in a 2 × 2 factorial blinded design between
aspirin 100 mg daily and matching placebo, and,
separately, between omega-3 fatty acid capsules 1 g
daily and placebo.
Post-randomization follow-up. Follow-up was also
conducted largely by mail, supplemented by information
from central registries. Randomized participants received
a follow-up questionnaire 6-monthly (either paper or via a
weblink to a secure online version24) asking about the
occurrence of any cardiovascular events, bleeding events,
cancer diagnoses, compliance with study medication and
use of other relevant medications (such as anti-platelet
agents or anti-coagulants). Confirmation and further
information was then sought from GPs about reports of
possible cardiovascular events and serious bleeds. All
such information is reviewed by coordinating center
clinicians, blind to treatment allocation, and events are
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adjudicated according to pre-specified criteria. Additional
follow-up for death, cancer and hospitalizations is being
obtained from NHS Digital (formerly the Health and
Social Care Information Centre) in England andWales and
the Information Services Division of NHS Scotland. Ethics
approval has been obtained for additional follow-up after
the scheduled treatment period via these central regis-
tries to assess the longer-term effects on cancer and on
other outcomes.
Central biological sample assays
About 2 to 4 weeks after entering the pre-randomization
run-in period, participants were sent an optional blood and
urine sampling kit, and asked to take it to their general
practice or other usual phlebotomy service for sample
collection. The kit was sent with an information leaflet
explaining the reasons for sample collection, a consent
form for sample storage and assay (which included a
section for recording blood pressure, pulse, height and
weight measured by the practice nurse), a letter for the
practice nurse with instructions for sample collection, and
barcoded labels for the sample tubes. The completed
consent form and blood (EDTA whole blood) and urine
samples were to be mailed to the central laboratory at
CTSU. Previous transport studies have demonstrated that a
wide range of analytes (including HbA1c, lipids and
cystatin C as a measure of renal function) and genetic
polymorphisms can be reliably measured in whole blood
samples despite delayed separation.25,26
Blood levels of total cholesterol, HDL-cholesterol,
apolipoprotein-B, apolipoprotein-A1, HbA1c and cystatin
C, and urinary creatinine and albumin were assayed (see
Supplementary Appendix 1 for methods) in the central
CTSU laboratory, which is a UKAS accredited testing
laboratory. Aliquots of plasma, urine, red cells and DNA-
containing buffy coat from all participants who provided
samples have been stored in liquid nitrogen for future
analyses (consistent with consent provided by
participants).
Sample size and predicted number of events
When ASCEND was designed in 2003, it was anticipat-
ed that 10,000 participants followed for 5 years with an
expected 2% annual rate (based on previous trials in
similar populations) of the composite primary efficacy
outcome of non-fatal MI, non-fatal stroke or vascular
death (excluding confirmed intracranial hemorrhage)
would provide sufficient power to detect a relative
reduction in vascular risk of 20–25%. However, as
specified in the protocol, the Steering Committee
monitored the overall (i.e. blinded) vascular event rate
among the randomized participants in order to decide
whether the original sample size assumptions remained
valid or whether changes might be needed.
Based on information that subsequently became
available from the ATTC meta-analysis of primary
prevention trials,3 a relative reduction in the risk of
occlusive vascular events with aspirin therapy seemed
more likely to be only about 12% to 15%. In addition, the
rate of the composite primary outcome observed among
the first few thousand randomized participants during the
first few years of the study was significantly lower than
anticipated, at around 0.6% per annum. Consequently,
the Trial Steering Committee decided to modify the trial
design blind to any treatment related results in the
following ways:
Inclusion of transient ischemic attacks (TIA) in
the primary efficacy outcome. Patients are now
routinely started on aspirin after a TIA,27 so its inclusion
in the primary efficacy outcome increases the chances of
detecting any effects of aspirin on cerebrovascular events
(rather than having them diluted by post-TIA treatment).
Increase in sample size. The availability of
large regional retinopathy registers from which
potential participants could be invited provided an
opportunity to increase the study population to 15,000
in a cost-effective manner.
Increase in study duration. It was possible to secure
additional funding and drug supplies to extend median
duration from 5 to at least 7 years.
Revised power calculations based on a 1.3% per annum
rate of the revised primary efficacy outcome of serious
vascular events (SVE: defined as non-fatal MI, non-fatal
stroke, or vascular death, excluding confirmed intracra-
nial hemorrhage but including TIA) indicate that ASCEND
has good statistical power (ie, N90% at 2P b .05) to detect
a 15% proportional reduction during extended follow-up
of 7.5 years. The expected 1300 incident vascular events
will approximately double the information currently
available about the effects of using aspirin for primary
prevention in people with diabetes. Consequently,
inclusion of these data in an updated meta-analysis should
help determine whether there are particular types of
diabetic patient (eg, those at higher vascular risk) who
would benefit.
Planned comparisons of outcome
For aspirin therapy, the primary efficacy comparison
will involve log-rank analyses of SVEs during the
scheduled treatment period among all those allocated
aspirin tablets versus all those allocated placebo tablets
(ie, “intention-to-treat” comparisons). Similarly, for the
omega-3 fatty acid supplementation, the primary efficacy
comparison will involve log-rank analyses of SVEs during
the scheduled treatment period among all those allocated
omega-3 fatty acid capsules versus all those allocated
placebo capsules. No allowance will be made for multiple
hypothesis testing in these 2 separate primary compar-
isons (see Data Analysis Plan).
A key secondary outcome for aspirin will be the
incidence of gastrointestinal tract cancers during the
scheduled treatment period. However, little or no
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treatment effect is expected before about 3 years,9
limiting the statistical power to detect plausible effects of
aspirin during the scheduled treatment period. There are
expected to be ~430 GI tract cancers during the 7.5 years
of follow-up. These numbers provide ~86% power at 2P b
.05 to detect a 40% reduction in risk and 60% power at
2P b .05 for a 30% reduction in risk. Analyses excluding
the first 3 years of follow-up are prespecified to assess
whether effects are increasing with time from randomiza-
tion. However, the main focus of the cancer analyses will be
during longer term follow-up, when there will be much
better power to detect plausible differences between the
arms due to larger numbers of events. At about 5 years after
the scheduled treatment period, there will be N90% at 2P b
.01 to detect a 30%or greater risk reduction andN90%at 2Pb
.05 to detect a 25% reduction in any GI tract cancer risk.
The key safety outcome for aspirin will be any major
bleed, defined as any confirmed intracranial hemorrhage
(including intracerebral, subarachnoid, subdural or any
other intracranial hemorrhage), sight-threatening eye
bleeding, or any other serious bleeding episode (i.e.
requiring hospitalization or transfusion, or fatal or
disabling). Further details regarding pre-specified com-
parisons and statistical methods are provided in the Data
Analysis Plan (see Supplementary Appendix 3).
Organization and funding
The University of Oxford is the academic sponsor
of ASCEND. The study is funded by a grant to the
University of Oxford (a Special Project Grant from 2003
to 2008 (SP/03/002), followed by two renewals of
the grant in 2009-2013 (SP/08/010/259) and 2015-2019
(SP/14/3/31114) from the British Heart Foundation (BHF)
to cover the administrative and coordination costs of the
trial. A separate BHF project grant (PG/05/013/18296)
was obtained for the addition of blood and urine sampling
to the study protocol. Aspirin and matching placebo are
being provided by Bayer AG, and omega-3 fatty acid and
matching placebo capsules by Mylan EPD (formerly by
Abbott Product Operations AG and Solvay Pharmaceuti-
cals GmbH), with funding from each company to cover
drug packaging. The MRC Population Health Research
Unit within the Clinical Trial Service Unit (CTSU) at
Oxford University supports some study staff and receives
additional funding from the British Heart Foundation and
Cancer Research UK. Staff from the National Institute for
Health Research Clinical Research Network, and the
Scottish Primary Care Research Network, assisted with
recruitment activities. The study was designed, and has
been conducted, analyzed, interpreted and reported,
independently by CTSU. The study is overseen by an
independent Steering Committee, including UK diabetol-
ogists, clinical trialists, statisticians and representatives
from the BHF. Representatives from Bayer AG and Mylan
attend Steering Committee meetings as non-voting
observers. The authors are solely responsible for the
design and conduct of this study, all study analyses, the
drafting and editing of the paper and its final contents.
The first and last authors act as guarantors for this work.
Results
Ethics, regulatory, and research governance approvals
Multi-centre Research Ethics Committee (MREC) ap-
proval was granted for ASCEND by the NorthWest MREC.
Doctors and Dentists Exemptions (DDXs) for the use of
aspirin and omega-3 fatty acids in ASCEND were obtained
from the Medicines and Healthcare products Regulatory
Agency (MHRA) prior to 1 May 2004. These DDXs were
automatically converted to clinical trial authorizations
following the implementation of the Medicines for Human
Use (Clinical Trials) Regulations 2004. A separate application
for research governance approval was made to all relevant
NHS Trusts (both Hospital Trusts and Primary Care Trusts
(PCTs), including Local Health Boards (LHBs) in Wales
and Scotland).
Participant recruitment
A total of 423,403 potentially eligible individuals were
invited via the different routes of recruitment,21 of which
29% (121,254 people) returned a screening question-
naire. About two-thirds of those who responded declined
to join the trial and a further 14,000 did not meet the
eligibility criteria (Table I). After review of the question-
naire data, 26,462 participants (6% of those originally
invited) were willing and eligible to join ASCEND and
entered the 2-month run-in period (Figure).
About 40% of all patients who entered the run-in
dropped out before randomization. Supplementary Table
I gives the reasons for withdrawal: about half had no
clinical reason but simply declined to continue. Without
this pre-randomization phase, many such withdrawals
might instead have occurred early after randomization,
resulting in a substantial reduction in statistical power.
Towards the end of the 2-month run-in, randomization
questionnaires were sent to 22,579 individuals, of whom
15,480 responded that they remained willing and eligible,
and were randomized into ASCEND (Figure). Overall
3.7% of those invited were randomized.
Baseline characteristics of randomized participants
In total 15,480 people (9684 men and 5796 women),
average age 63.3 years (SD 9.2) were randomized
between June 2005 and July 2011 (Table II). Participants
had diabetes (94% type 2) diagnosed a median of about 7
years before randomization. For 16% of participants, their
diabetes was managed by diet alone; 25% were using
insulin at baseline (with or without other agents); and
58% were using hypoglycemic agents but not insulin. The
majority (85%) were overweight or obese at baseline
(BMI ≥25 kg/m2), and 62% reported taking treatment for
hypertension. In those participants forwhombaseline blood
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pressure measurements were available (at the time of blood
sampling), themean systolic blood pressurewas 136mmHg.
Blood and urine kits were sent to 22,858 patients who
entered the pre-randomization phase and who had not
informed the coordinating center that they wished to
withdraw before the kits were due to be sent. Samples
(either blood or urine or both) were received by the
laboratory from 13,270 individuals, among whom 11,685
were subsequently randomized. Samples received from
about 1800 participants were not deemed usable as a
result of inadequate sample volume, incomplete consent
or delays in sample receipt at the central laboratory.
Table I. Reasons for not entering run-in at screening.
Reason for not entering run-in Number of patients
Declined to join the study 66,498 (70%)
Ineligible at screening* 14,004 (15%)
Prior coronary artery disease 6406
Declined to stop pre-study aspirin 3928
Declined to avoid non-study aspirin 3657
Prior stroke or transient ischemic attack 2374
On warfarin/acenocoumarol/phenindione 1312
Allergic to aspirin or omega-3 1224
Cancer in the last 5 years 871
Gastrointestinal bleeding in the last 6 months 780
Active peptic ulcer in the last 6 months 605
Did not have diabetes 501
Other serious illness 408
Prior non-coronary revascularization 230
Liver disease 158
Too young† 22
Incomplete questionnaire - unable to process 2465 (3%)
Potentially eligible at screening but subsequently ineligible‡ 447 (b1%)
Screening form not processed as recruitment target reached 11,378 (12%)
Total (completed a screening form but did not enter run-in) 94,792 (100%)
*More than one reason may apply per patient.
† This includes some individuals who recorded their date of birth incorrectly.
‡ This includes individuals who were potentially eligible on the basis of their screening form but who did not enter run-in for a variety of reasons including technical difficulties in
processing the form or further information from the patient indicating that they were ineligible or unwilling to take part.
Figure
Trial profile: Flow of participants through the ASCEND trial.
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Baseline biochemical measures are shown in Table III.
Among the 9813 participants with baseline HbA1c
available, only 31% achieved target levels for glucose
control of b6.5% (48 mmol/mol). By contrast, 4554
participants (46% of those with measures available) had a
total cholesterol b4.0 mmol/L. Supplementary Table II
provides the baseline characteristics of those participants
with a usable baseline blood sample and indicates that they
were generally representative of the full study population.
Non-study medication use was reported on the random-
ization form and is shown in Supplementary Table III.
Three quarters of participants reported taking a statin, and
over a third were previously on aspirin but had no clear
clinical indication for it (and they and their GP were
agreeable to stopping this in order to take part in ASCEND).
Post-randomization follow-up
Follow-up of ASCEND participants is scheduled to
finish in 2017, by which time there will be a median
duration of follow-up of at least 7 years. Follow-up
questionnaires are sent 6-monthly. In order to ensure
completeness of follow-up, if no reply is received to the
initial follow-up questionnaire (paper or emailed re-
quest), two reminders are sent to non-responders,
Table II. Baseline characteristics of study population.
Male Female Total
Total randomized 9684 (63%) 5796 (37%) 15,480 (100%)
Age at randomization (years)
b50 582 (6%) 507 (9%) 1089 (7%)
≥50, b60 2888 (30%) 1613 (28%) 4501 (29%)
≥60, b70 3944 (41%) 2303 (40%) 6247 (40%)
≥70 2270 (23%) 1373 (24%) 3643 (24%)
Mean age (SD) 63.3 (9.1) 63.1 (9.4) 63.3 (9.2)
Body mass index (kg/m2)⁎
b25 1385 (14%) 864 (15%) 2249 (15%)
≥25, b30 3883 (40%) 1646 (28%) 5529 (36%)
≥30, b35 2666 (28%) 1574 (27%) 4240 (27%)
≥35 1449 (15%) 1512 (26%) 2961 (19%)
Unknown 301 (3%) 200 (3%) 501 (3%)
Mean body mass index (SD) 30.1 (5.6) 31.7 (7.1) 30.7 (6.3)
Type of diabetes†
Type 1 518 (5%) 393 (7%) 911 (6%)
Type 2 9166 (95%) 5403 (93%) 14,569 (94%)
Diabetes management
Diet only 1502 (16%) 1027 (18%) 2529 (16%)
Any hypoglycemic agent but not insulin 5816 (60%) 3204 (55%) 9020 (58%)
Insulin +/− other hypoglycemic agent 2366 (24%) 1565 (27%) 3931 (25%)
Duration of diabetes (years)
b5 2991 (31%) 1900 (33%) 4891 (32%)
≥5, b10 2728 (28%) 1606 (28%) 4334 (28%)
≥10, b20 2287 (24%) 1250 (22%) 3537 (23%)
≥ 20 1150 (12%) 712 (12%) 1862 (12%)
Unknown 528 (5%) 328 (6%) 856 (6%)
Median duration of diabetes (IQR) 7 (3–13) 7 (3–12) 7 (3–13)
Systolic blood pressure (mmHg)‡
b130 1961 (20%) 1433 (25%) 3394 (22%)
≥130, b140 1931 (20%) 1160 (20%) 3091 (20%)
≥140 2965 (31%) 1590 (27%) 4555 (29%)
Unknown 2827 (29%) 1613 (28%) 4440 (29%)
Mean systolic blood pressure (SD) 136.9 (15.2) 134.9 (15.3) 136.2 (15.3)
Other Factors§
Reported treated hypertension (n = 15,368) 5854 (60%) 3679 (63%) 9533 (62%)
Current smoker (n = 15,307) 778 (8%) 501 (9%) 1279 (8%)
Diabetic retinopathy (n = 15,336) 1875 (19%) 1148 (20%) 3023 (20%)
Ethnic origin
White 9331 (96%) 5604 (97%) 14,935 (96%)
Indian/Pakistani/Bangladeshi 141 (1%) 43 (b1%) 184 (1%)
African/Caribbean 79 (b1%) 61 (1%) 140 (b1%)
Other/unknown 133 (1%) 88 (2%) 221 (1%)
⁎Based on self-reported height and weight
†Based on a broad clinical definition involving age at diagnosis of diabetes, use of insulin within one year of diagnosis and BMI
‡ From blood and urine consent form, generally before randomization
§Reported by participant on randomization questionnaire.
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followed by a telephone call by coordinating centre
staff. In late 2014, the option of completing a follow-up
form via the internet was introduced,24 and around 15%
to 20% of responses are now received online. In
addition, electronic information about all deaths and
cancers is received periodically from central NHS
registries.
Discussion
There remains continuing clinical uncertainty about
whether or not aspirin should be recommended for the
primary prevention of cardiovascular events in people
with diabetes.13 This is reflected in the differing and
changing recommendations in cardiovascular prevention
guidelines. When ASCEND was designed, the American
Diabetes Association recommended aspirin use for
primary prevention in people with diabetes with one
additional risk factor28 but, at that time, the UK and
European guidelines were more circumspect.29,30 More
recently, both the 2015 UK National Institute for Health
and Care Excellence (NICE) guideline for type 2 diabetes31
and the 2016 European Guidelines32 have advised not
offering antiplatelet therapy for adults with type 2 diabetes
Table III. Biochemical measures assessed during pre-randomization run-in phase.
Male Female Total
Total cholesterol (mmol/L) (n = 9819)
b4.0 3175 (52%) 1379 (37%) 4554 (46%)
≥4.0, b 5.0 2193 (36%) 1602 (43%) 3795 (39%)
≥5.0 716 (12%) 754 (20%) 1470 (15%)
Mean (SD) 4.0 (0.8) 4.4 (0.9) 4.2 (0.9)
HDL cholesterol (mmol/L) (n = 9800)
b1.0 1751 (29%) 419 (11%) 2170 (22%)
≥1.0, b 1.5 3466 (57%) 2057 (55%) 5523 (56%)
≥1.5 855 (14%) 1252 (34%) 2107 (22%)
Mean (SD) 1.2 (0.3) 1.4 (0.4) 1.3 (0.4)
Non-HDL cholesterol (mmol/L) (n = 9800)
b2.5 2187 (36%) 1203 (32%) 3390 (35%)
≥2.5, b 3.5 2693 (44%) 1700 (46%) 4393 (45%)
≥3.5 1192 (20%) 825 (22%) 2017 (21%)
Mean (SD) 2.9 (0.8) 3.0 (0.9) 2.9 (0.8)
Apolipoprotein B (mg/dL) (n = 9779)
b70 1900 (31%) 947 (25%) 2847 (29%)
≥70, b 90 2386 (39%) 1516 (41%) 3902 (40%)
≥90 1766 (29%) 1264 (34%) 3030 (31%)
Mean (SD) 80.8 (20) 84.3 (21) 82.1 (21)
Apolipoprotein A1 (mg/dL) (n = 9799)
b130 1781 (29%) 403 (11%) 2184 (22%)
≥130, b 160 3030 (50%) 1669 (45%) 4699 (48%)
≥160 1259 (21%) 1657 (44%) 2916 (30%)
Mean (SD) 143.5 (23) 159.3 (26) 149.5 (25)
HbA1c DCCT % (IFCC mmol/mol) (n = 9813)
b6 (42) 734 (12%) 454 (12%) 1188 (12%)
≥6 (42), b 6.5 (48) 1077 (18%) 744 (20%) 1821 (19%)
≥6.5 (48), b 7 (53) 1317 (22%) 790 (21%) 2107 (21%)
≥7 (53), b 7.5 (58) 1057 (17%) 651 (17%) 1708 (17%)
≥7.5 (58) 1895 (31%) 1094 (29%) 2989 (30%)
Mean (SD) 7.2 (55) (1.2 (13)) 7.1 (55) (1.2 (13)) 7.2 (55) (1.2 (13))
eGFR (ml/min/1.73m2) (n = 9815)⁎
≥90 2966 (49%) 1557 (42%) 4523 (46%)
≥60, b 90 2413 (40%) 1603 (43%) 4016 (41%)
≥45, b 60 490 (8%) 379 (10%) 869 (9%)
≥30, b 45 167 (3%) 155 (4%) 322 (3%)
b30 46 (b1%) 39 (1%) 85 (b1%)
Mean (SD) 86.9 (21) 82.3 (21) 85.2 (21)
Urinary albumin/creatinine ratio (mg/mmol) (n = 9774)
b3 5176 (85%) 3350 (90%) 8526 (87%)
≥3, b 30 764 (13%) 324 (9%) 1088 (11%)
≥30 123 (2%) 37 (b1%) 160 (2%)
Median 0.59 0.51 0.55
HDL, High-density lipoprotein; IFCC, International Federation of Clinical Chemistry
⁎Calculated from blood cystatin c concentration using the CKD-EPI formula.
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but without cardiovascular disease. By contrast, the US
Preventive Services Task Force now recommends low-dose
aspirin for the primary prevention of cardiovascular disease
and colorectal cancer in adults aged 50–59 years who have
a 10-year cardiovascular risk of at least 10% and are not
considered at increased risk for bleeding, irrespective of
their diabetes status.33
In addition to ASCEND, three other randomized trials of
aspirin therapy in similar intermediate-risk populations
are anticipated to announce their results during the next
2–3 years,34-36 providing substantially more data than is
currently available about the value of using aspirin in the
primary prevention setting. ASCEND will be responsible
for almost half of the available data in diabetes and, in
addition, will provide one of the first large-scale
prospective tests of aspirin for the prevention of cancer.
If aspirin is shown to be effective for cancer chemopre-
vention then this could significantly alter the balance of
benefits and risks for its use in primary prevention.
Given recent data, it is unlikely that ASCEND will show
benefits from the omega-3 fatty acid allocation of the
magnitude that had been anticipated. Nevertheless, the
increase in size and duration of exposure beyond that
originally planned means that its ability to detect more
modest effects of omega-3 fatty acids has increased. In
addition, it should be large enough to determine whether
(or not) any particular types of patient benefit to a
worthwhile extent from such supplementation.
Conclusion
The current global epidemic of diabetes makes robust
evidence about the effects of low-cost prophylactic
interventions especially important. For example, demon-
strating that primary prevention with aspirin prevents
cardiovascular events or cancers, and that the benefits
outweigh the risks of bleeding, would be relevant to some
hundreds ofmillions of peopleworldwidewho are at risk of
such events but are currently not taking low-dose aspirin.
On the other hand, if the risks of serious bleeding outweigh
any benefits then these risks could be avoided by the very
large numbers of peoplewho are currently using aspirin for
primary prevention.
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Associations of Omega-3 Fatty Acid Supplement Use
With Cardiovascular Disease Risks
Meta-analysis of 10 Trials Involving 77 917 Individuals
Theingi Aung, MBBS, FRCP; Jim Halsey, BSc; Daan Kromhout, PhD; Hertzel C. Gerstein, MD; Roberto Marchioli, MD; Luigi Tavazzi, MD;
Johanna M Geleijnse, PhD; Bernhard Rauch, MD; Andrew Ness, PhD, FFPH; Pilar Galan, MD, PhD; Emily Y. Chew, MD; Jackie Bosch, PhD;
Rory Collins, FMedSci, FRCP; Sarah Lewington, DPhil; Jane Armitage, FRCP, FFPH; Robert Clarke, MD, FRCP, FFPH;
for the Omega-3 Treatment Trialists’ Collaboration
IMPORTANCE Current guidelines advocate the use of marine-derived omega-3 fatty acids
supplements for the prevention of coronary heart disease and major vascular events in
people with prior coronary heart disease, but large trials of omega-3 fatty acids have
produced conflicting results.
OBJECTIVE To conduct a meta-analysis of all large trials assessing the associations of omega-3
fatty acid supplements with the risk of fatal and nonfatal coronary heart disease and major
vascular events in the full study population and prespecified subgroups.
DATA SOURCES AND STUDY SELECTION This meta-analysis included randomized trials that
involved at least 500 participants and a treatment duration of at least 1 year and that
assessed associations of omega-3 fatty acids with the risk of vascular events.
DATA EXTRACTION AND SYNTHESIS Aggregated study-level data were obtained from 10 large
randomized clinical trials. Rate ratios for each trial were synthesized using observed minus
expected statistics and variances. Summary rate ratios were estimated by a fixed-effects
meta-analysis using 95% confidence intervals for major diseases and 99% confidence
intervals for all subgroups.
MAIN OUTCOMES AND MEASURES The main outcomes included fatal coronary heart disease,
nonfatal myocardial infarction, stroke, major vascular events, and all-cause mortality, as well
as major vascular events in study population subgroups.
RESULTS Of the 77 917 high-risk individuals participating in the 10 trials, 47 803 (61.4%) were
men, and the mean age at entry was 64.0 years; the trials lasted a mean of 4.4 years. The
associations of treatment with outcomes were assessed on 6273 coronary heart disease
events (2695 coronary heart disease deaths and 2276 nonfatal myocardial infarctions) and
12 001 major vascular events. Randomization to omega-3 fatty acid supplementation
(eicosapentaenoic acid dose range, 226-1800 mg/d) had no significant associations with
coronary heart disease death (rate ratio [RR], 0.93; 99% CI, 0.83-1.03; P = .05), nonfatal
myocardial infarction (RR, 0.97; 99% CI, 0.87-1.08; P = .43) or any coronary heart disease
events (RR, 0.96; 95% CI, 0.90-1.01; P = .12). Neither did randomization to omega-3 fatty acid
supplementation have any significant associations with major vascular events (RR, 0.97; 95%
CI, 0.93-1.01; P = .10), overall or in any subgroups, including subgroups composed of persons
with prior coronary heart disease, diabetes, lipid levels greater than a given cutoff level, or
statin use.
CONCLUSIONS AND RELEVANCE This meta-analysis demonstrated that omega-3 fatty acids
had no significant association with fatal or nonfatal coronary heart disease or any major
vascular events. It provides no support for current recommendations for the use of such
supplements in people with a history of coronary heart disease.
JAMA Cardiol. doi:10.1001/jamacardio.2017.5205
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O bservational studies in Western and Asian popula-tions have reported that regular consumption of fishonce or twice a week is associated with lower risks of
death from coronary heart disease (CHD).1,2 These observa-
tions, together with the lower rates of CHD in populations that
consumed large amount of foods rich in very-long-chain poly-
unsaturated fatty acids containing omega-3 fatty acids have
prompted interest in assessing whether consumption of marine-
derived very-long-chain omega-3 fatty acids (abbreviated
“omega-3 FA” in this article) may be protective for CHD.3 These
marine-derived omega-3 FAs include eicosapentaenoic acid
(EPA) and docosahexanoic acid (DHA) found in fish and other
seafood, but not alpha-linolenic acid, which is plant-derived.
The initial Diet and Reinfarction Trial-1 study4 examined
the associations of consumption of oily fish twice or more per
week with CHD risk in men who had had a myocardial infarc-
tion and reported that fish consumption was associated with
a significant reduction in fatal CHD and all-cause mortality but
had no association with nonfatal myocardial infarction (MI)
recurrence.4 However, the subsequent Diet and Reinfarction
Trial-2 study in men with angina reported that consumption
of fish or fish oil supplements increased the risk of CHD death.5
Subsequently, several large trials have reported conflicting re-
sults of the associations of supplementation with omega-3 FA
supplements vs placebo or untreated controls on fatal and
nonfatal vascular events.6-16
Ten large randomized trials6-15 have been conducted com-
paring the associations of treatment with omega-3 FA supple-
mentation vs placebo or no treatment for at least 12 months
in populations with prior CHD, stroke, or high risk of cardio-
vascular disease (CVD). These trials have reported conflicting
results for the associations of treatment with fatal CHD, non-
fatal CHD, or other subtypes of CVD. The Gruppo Italiano per
lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-
Prevenzione trial,6 an open-label trial involving 11 323 recent
survivors of MI, reported that patients who received supple-
mentation with omega-3 FAs experienced a 10% reduced risk
of major cardiovascular events compared with untreated con-
trols. The Japan EPA Lipid Intervention Study (JELIS) trial, an
open-label trial involving 18 645 participants with total cho-
lesterol of 243.24 mg/dL (to convert to mmol/L, multiply by
0.0259) or greater, of whom only 20% with prior CHD, also
reported14 that supplementation with fish oil was associated
with a 19% reduction in major CHD events (95% CI, 5%-31%).
None of the other large placebo-controlled trials reported any
significant association with CHD or mortality. Hence, it is un-
clear whether the discrepant results reflect different associa-
tions of omega-3 FAs with CHD subtypes, different outcomes
in primary vs secondary prevention of CHD, increasing use of
statins with better control of lipid levels, or an artifact of chance
or bias in open-label trials. Previous meta-analyses of these
trials of omega-3 FA supplements16-18 appeared to suggest a sig-
nificant beneficial association of omega-3 FAs with fatal CHD
but not nonfatal CHD. However, these meta-analyses were con-
strained because they included trials of dietary advice to eat
fish17 or excluded trials that did not include a placebo control.18
The Omega-3 Treatment Trialists’ Collaboration was es-
tablished to conduct a collaborative meta-analysis based on
aggregated study-level data obtained from the principal
investigators of all large randomized clinical trials of omega-3
FA supplements for the prevention of cardiovascular disease,
using a prespecified protocol and analysis plan. The aims of
this meta-analysis were to assess the associations of supple-
mentation with omega-3 FAs on (1) fatal CHD, nonfatal MI,
stroke, major vascular events, and all-cause mortality and
(2) major vascular events in prespecified subgroups.
Methods
We performed a systematic search of randomized clinical trials
in PubMed and Medline data sets, supplemented by manual
hand-searching of reference lists from individual trials, re-
view articles, or previous meta-analyses of omega-3 FAs and
CVD (eFigure 1 in the Supplement). Search terms included
“omega-3 FA,” “omega-3 polyunsaturated fat,” “fish oils,” and
“ω-3 FA” and “cardiovascular disease” or “coronary heart dis-
ease” or “stroke” (eFigure 1 in the Supplement). The prespeci-
fied eligibility criteria were randomized clinical trials of marine-
derived very-long-chain omega-3 FA supplements vs placebo
or open-label control, with a sample size of at least 500 par-
ticipants and a scheduled duration of treatment of at least 1
year. All eligible trials required use of supplements, but no mini-
mum daily dose of EPA or DHA was specified. The prespeci-
fied end points included nonfatal MI; death caused by CHD;
ischemic, hemorrhagic, and unclassified stroke; coronary or
noncoronary arterial revascularization events; major vascu-
lar events (a composite of first occurrence of nonfatal MI or
death caused by CHD; nonfatal or fatal stroke; or any revas-
cularization procedure); and all-cause mortality. Deaths caused
by CHD included sudden cardiac deaths, deaths due to ven-
tricular arrhythmias, and heart failure in patients with CHD,
MI, or deaths occurring after coronary revascularization or
heart transplant.
All included trials were also assessed for risk of bias.
Individual trials had approval from their respective institu-
tional review boards, and all participants provided written
informed consent. No additional ethical approval was
required for this meta-analysis.
Key Points
Question Does supplementation with marine-derived omega-3
fatty acids have any associations with reductions in fatal or
nonfatal coronary heart disease in people at high risk of
cardiovascular disease?
Findings This meta-analysis of 10 trials involving 77 917 participants
demonstrated that supplementation with marine-derived omega-3
fatty acids for a mean of 4.4 years had no significant association with
reductions in fatal or nonfatal coronary heart disease or any major
vascular events.
Meaning The results provide no support for current recommendations
to use omega-3 fatty acid supplements for the prevention of fatal
coronary heart disease or any cardiovascular disease in people who
have or at high risk of developing cardiovascular disease.
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A protocol outlining the eligibility criteria, prespecified
analyses, and plans for publication together with standard-
ized data request forms were sent to the principal investiga-
tors of all eligible trials. The study used the PRISMA guide-
lines for the conduct of meta-analysis of randomized trials.19
Aggregated study-level (tabular) data were successfully
obtained from 9 of the 10 trials (Table; eTable in the
Supplement).6-13,15 The JELIS trial14 declined to participate in
this collaboration, but the published results of the trial were
sufficiently detailed to allow its inclusion in this study. Any dis-
crepancies between data supplied and the published reports
were clarified by contacting trial investigators.
Statistical Analysis
The association of treatment with outcomes in each trial was
analyzed separately, and summary statistics were calculated
for each trial. For each trial, we calculated the observed mi-
nus expected statistic (O−E) and its variance (V) from the num-
ber of patients who developed the relevant end point and the
total number of patients in each treatment group, using stan-
dard formulas for 2 × 2 contingency tables. One O−E value from
each trial was summed to produce a grand total (G), with vari-
ance (V) equal to the sum of their separate variances. The value
exp(G/V) is Peto 1-step estimate of the rate ratio (RR), and its
continuity-corrected 95% confidence interval is given by
exp(G/V ± [0.5/V + (1.96/V)]).20 Rate ratios are given with
95% CI for the overall results for major diseases and with 99%
CI (which is calculated by replacing 1.96 in the formula above
by 2.58) for the results of individual trials or subgroups of trials
or subgroups of such major diseases. Heterogeneity between
the different subgroups is assessed by first calculating
S−(G2/V), where S is the sum of (O−E)2/V for each trial (or sub-
grouping), and then testing this statistic against a χ2 distribu-
tion with the degrees of freedom equal to 1 fewer than the num-
ber of subgroups. The meta-analysis was repeated after
excluding the JELIS trial,14 since it tested EPA alone rather than
the combination of EPA and DHA used in all other trials.6-13,15
Additional analyses of the primary outcomes assessed the
associations of treatment with major vascular events in pre-
defined subgroups, including age, sex, prior CHD, prior stroke,
prior diabetes, blood lipids (total cholesterol, triglyceride,
high-density lipoprotein, and calculated or measured low-
density lipoprotein), prior use of statins, and trial design (open-
label or blinded). In interpreting subgroup results, the chief
emphasis was placed on the overall results, unless there was
strong evidence of heterogeneity (P < .001). Sensitivity analy-
ses compared the results of the Peto method with log-rank
method in the 1 trial that had also provided individual
participant data on all events.
Results
Characteristics of Individual Trials
Study level data were obtained on a total of the 10 trials6-15 that
met the inclusion criteria. A total of 77 917 participants were in-
volved, and trials ranged in size from 563 to 18 645 partici-
pants (Table; eTable in the Supplement). Of the 10 trials, 8 had
a double-blind design and used a placebo control, and 2 trials
had an open-label design.6,14 The risk of bias of the included trials
was low, with exception of the 2 trials that did not use a placebo-
treated control group6,14 (eFigure 2 in the Supplement).
Combinations of polyunsaturated fatty acid ethyl esters
of EPA and DHA were used in all but 1 trial,14 which tested daily
dose of 1800 mg EPA alone. The daily doses of EPA varied from
226 to 1800 mg/day, and DHA varied from 0 to 1700 mg/day.
The mean duration of treatment in individual trials varied from
1.0 year to 6.2 years (weighted mean, 4.4 years).
















Prior CHD Prior Stroke Prior Diabetes Statin Use
DOIT (2010) 563 1150/800 563 (100) 3 70 (3) 133 (23.6) 37 (6.6) 46 (8.2) NA
AREDS-2 (2014) 4203 650/350 1816 (43.2) 4.5 74 (NA) 405 (9.7) 211 (5.0) 546 (13.0) 1866 (44.4)
SU.FOL.OM3
(2010)
2501 400/200 1987 (79.4) 4.7 61 (NA) 1863 (74.5) 638 (25.5) 440 (17.9) 2079 (83.1)
JELIS (2007)a,b 18 645 1800/NA 5859 (31.4) 4.6 61 (8) NA NA 3040 (16.3) 18 645 (100.0)
Alpha Omega
(2010)
4837 226/150 3783 (78.2) 3.3 69 (6) 4837 (100.0) 345 (7.2) 1014 (21.0) 4122 (85.2)
OMEGA (2010) 3818 460/380 2841 (74.4) 1 64 (NA) 796 (22.5) 192 (5.5) 948 (27.0) 3566 (94.2)
R&P (2013) 12 505 500/500 7687 (61.5) 5 64 (NA) Not stated (30) 594 (4.8) 7494 (59.9) 12 505 (100.0)
GISSI-HF (2008) 6975 850/950 5459 (78.3) 3.9 67 (11) 3614 (51.8) 346 (5.0) 1974 (28.3) NA
ORIGIN (2012) 12 536 465/375 8150 (65.0) 6.2 64 (8) 8094 (64.6) 10 877 (86.8) 11 081 (88.4) 6739 (53.8)
GISSI-Pb (1999) 11 334 850/1700 9658 (85.2) 3.5 59 (11) 11 334 (100.0) NA 2139 (18.9) NA




28 722 (36.9) 49 522 (83.4)
Abbreviations: AREDS-2, Age-Related Eye Disease Study 2; DOIT, Diet and
Omega-3 Intervention Trial; GISSI-HF, Gruppo Italiano per lo Studio della
Sopravvivenza nell'Infarto Miocardico-Heart Failure; GISSI-P, Gruppo Italiano
per lo Studio della Sopravvivenza nell'Infarto Miocardico-Prevenzione;
JELIS, Japan Eicosapentaenoic Acid (EPA) Lipid Intervention Study; NA, not
available; OMEGA, Effect of Omega 3-Fatty Acids on the Reduction of Sudden
Cardiac Death After Myocardial Infarction; ORIGIN, Outcome Reduction With
Initial Glargine Intervention; SU.FOL.OM3, Supplémentation en Folates
et Omega-3; R&P, Risk and Prevention Study.
a All trials used eicosapentaenoic acid and docosahexanoic acid supplements,
with the exception of the JELIS trial (eicosapentaenoic acid only).
b All trials were blind, placebo-controlled randomized clinical trials with the
exception of JELIS and GISSI-P, which were open-label without placebo.
Meta-analysis of Associations of Omega-3 Fatty Acids and Cardiovascular Risk Original Investigation Research
jamacardiology.com (Reprinted) JAMA Cardiology Published online January 31, 2018 E3
© 2018 American Medical Association. All rights reserved.
Downloaded From:  on 02/11/2018
Of the 77 917 participants, 47 803 (61.4%) were men, and the
meanageatentrywas64years.Afteraccountingformissingdata,
abouttwo-thirdsofparticipantshadapriorhistoryofCHD(31 076/
46 767;66.4%),13 240of47 938(28%)hadpriorstroke,and28 722
of the total 77 917 participants (37%) had prior diabetes. Among
the 77 917 participants, there were a total of 12 001 major vascu-
lar events (15.4% of 77 917 participants), including 2276 incidents
ofnonfatalMI(2.9%),2695CHDdeaths(3.5%),1713strokes(2.2%),
and 6603 revascularization events (8.5%) during the study du-
ration (eTable in the Supplement). Data were available on the as-
sociation of treatment by prior use of statin therapy in 7 trials in-
volving 49 522 participants.8,10-12,14,15
Associations of Omega-3 Fatty Acid Use
With CHD and Major Vascular Events
Figure 1 shows that randomization to receive omega-3 FA supple-
mentation had no significant association with the rate ratios
(RRs) for any CHD event (RR, 0.96; 95% CI, 0.90-1.01; P = .12)
and no significant association with RRs in subgroups of CHD
events, including CHD death (RR, 0.93; 99% CI, 0.83-1.03;
P = .05) and nonfatal myocardial infarction (RR, 0.97; 99% CI,
0.87-1.08; P = .40). Likewise, randomization of patients to an
omega-3 FA supplementation regimen had no associations with
the RRs for major vascular events (RR, 0.97; 95% CI, 0.93–1.01;
P = .10), stroke (RR, 1.03; 95% CI, 0.93-1.13; P = .56), or revas-
cularization events (RR, 0.99; 95% CI, 0.94-1.04; P = .61). This
meta-analysis also showed no significant heterogeneity be-
tween the results of individual trials for nonfatal MI, CHD death,
any CHD events, or all major vascular events (Figure 2). The as-
sociation of omega-3 FA supplementation with major vascular
events were unaltered after excluding the JELIS trial14 (odds ra-
tio [OR], 0.98; 95% CI, 0.94-1.02; P = .30) (eFigure 3 in the
Supplement). Additional sensitivity analyses in 1 trial12 that com-
pared the results of the Peto method (O−E statistic) with the log-
rank method demonstrated that analysis of individual partici-
pant and study-level data yielded identical results for association
of omega-3 FA supplementation with major vascular events
(eFigure 4 in the Supplement).
Associations of Omega-3 Fatty Acid Use
With Major Vascular Events in Prespecified Subgroups
Figure 3 shows that after adjustment for multiple testing, ran-
domization of patients to study arms involving supplementation
by omega-3 FAs had no significant association with major vas-
culareventsinanyoftheprespecifiedsubgroups, includingthose
defined by sex, history of CHD, history of diabetes, pretreatment
levels of total cholesterol, high-density lipoprotein levels, low-
density lipoprotein levels, triglyceride levels, or prior use of stat-
in therapy. However, there was some evidence of heterogeneity
in the associations of omega-3 FAs with major vascular events
by age (unadjusted P = .02) and by history of stroke (P = .06), re-
spectively. While it was not possible to assess the associations
of treatment with race, the results were unaltered after exclusion
of the JELIS trial,14 which was conducted in a Japanese popula-
tion only (eFigure 3 in the Supplement).
Associations of Omega-3 Fatty Acid Use
With CHD Events by Study Design
Figure 4 demonstrates that randomization of patients to receive
omega-3 FAs had no significant association with their experience
ofnonfatalMI,CHDdeath,oroverallCHDintrialsthatusedeither
an open-label and blind design. However, there was some evi-
dence of heterogeneity between the results of open-label trials
vs blind trials for all participants with CHD (open-label trials: RR,
0.85; 99% CI, 0.72-0.99; P = .01; blinded trials: RR, 0.99; 99% CI,
0.91-1.07; P = .69; heterogeneity P = 0.03), but not for either fatal
CHD or nonfatal MI, respectively. Overall, the results of this meta-
analysis demonstrated no significant association of supplemen-
tation with omega-3 FAs for a mean duration of 4.4 years with the
risk of fatal CHD, nonfatal MI, any CHD, or any major vascular
events in the full study population and in all relevant subgroups.
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Any major vascular event
The number of events by allocated
treatment are presented for
individual trials and subgroups of
trials; participants can contribute
only once to subtotals and totals of
major vascular events. Rate ratios for
individual trials or subgroups of trials
are indicated by squares and 99% CIs
by horizontal lines. Overall totals and
their 95% confidence intervals are
represented by diamonds. The size of
the squares and the diamonds are
proportional to the statistical
information conveyed.
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Figure 2. Associations of Omega-3 Fatty Acids With Subtypes of Coronary Heart Disease
and Major Vascular Events, by Trial
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Any Coronary heart disease
DOIT
AREDS-2
29 (10.3) 35 (12.5) 0.81 (0.41-1.60)
213 (9.9) 208 (10.1)
1.02 (0.78-1.35)
0.98 (0.75-1.28)










































Symbols and conventions as in
Figure 1. Study names are
AREDS-2, Age-Related Eye Disease
Study 2; DOIT, Diet and Omega-3
Intervention Trial; GISSI-HF, Gruppo
Italiano per lo Studio della
Sopravvivenza nell'Infarto
Miocardico-Heart Failure;
GISSI-P, Gruppo Italiano per lo Studio
della Sopravvivenza nell'Infarto
Miocardico-Prevenzione;
JELIS, Japan Eicosapentaenoic Acid
(EPA) Lipid Intervention Study;
OMEGA, Effect of Omega 3-Fatty
Acids on the Reduction of Sudden





en Folates et Omega-3; R&P, Risk and
Prevention Study. Rate ratios for
individual trials or subgroups of trials
are indicated by squares and the 99%
CIs by the horizontal lines. Overall
totals and their 95% confidence
intervals are represented by
diamonds. Arrowheads indicate error
bars that extend beyond the area
shown. Heterogeneity between all
trials (χ 29 in all cases) for nonfatal
myocardial infarction, coronary heart
disease death, any coronary heart
disease, and major vascular events
were 10.18 (P = .34), 12.3 (P = .20),
12.92 (P = .17), and 7.68 (P = .57),
respectively.
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Associations of Omega-3 Fatty Acid Use
With All-Cause Mortality
Randomization to omega-3 FA intervention had no signifi-
cant association with RRs of all-cause mortality (RR, 0.96; 95%
CI, 0.92-1.01; P = .16). Further information is presented in
eFigure 5 in the Supplement.
Discussion
This meta-analysis of 10 randomized clinical trials, involving
77 917 participants, demonstrated that randomization to trial
arms with omega-3 FA supplementation for a mean of 4.4 years
had no significant effect on either of fatal CHD, nonfatal MI,
stroke, revascularization events, or any major vascular events.
Importantly, this meta-analysis also demonstrated no signifi-
cant effect on major vascular events in any particular sub-
groups, including prior vascular disease, diabetes, lipid lev-
els, or statin use. Likewise, the present meta-analysis showed
no significant association of omega-3 FA supplementation with
all-cause mortality or cancer (data not shown). Moreover, the
overall results were unaltered after exclusion of the JELIS trial,14
which tested the effects of EPA alone rather than EPA and DHA
combined.
The chief strength of this study was the availability of
study-level data extracted by the trial principal investigators
for all prespecified outcomes in this meta-analysis (with the
exception of the JELIS trial,14 in which the published data


















































































































































Symbols and conventions as in
Figure 1. Total cholesterol,
high-density lipoprotein cholesterol,
low-density lipoprotein cholesterol,
and triglycerides were measured in
mg/dL (to convert cholesterol to
mmol/L, multiply by 0.0259;
triglycerides, multiply by 0.0113).
Heterogeneity between all trials (χ 21
in all cases) was 0.04 (P = .84) for
sex, 5.59 (P = .02) for age, 0.0
(P = .96) for prior coronary heart
disease, 7.03 (P = .01) for prior stroke,
0.0 (P > .99) for prior diabetes, 0.87
(P = .35) for total cholesterol, 1.56
(P = .21) for high-density lipoprotein,
1.8 (P = .18) for low-density
lipoprotein, 0.02 (P = .89) for
triglycerides, and 2.55 (P = .11) for
prior statin use.
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were used). The inclusion criteria and vascular disease out-
comes differed from previous meta-analyses of the pub-
lished results.16-18 The present meta-analysis had a low risk
of selection bias or confounding because it did not include
trials testing the effects of dietary advice to eat fish nor trials
that were either too small or insufficient in treatment dura-
tion. In contrast with previous meta-analyses, the present
meta-analysis also examined effects of supplementation
with omega-3 FA supplementation in prespecified subgroups
of major vascular events by history of disease, history of dia-
betes, lipid levels, or statin use.
The reasons for the discrepant results of the previous trials
of omega-3 FA supplementation on fatal and nonfatal CHD
events are unclear. In contrast with the null findings for most
trials, the GISSI-Prevenzione trial6 reported a 14% reduction
in major vascular events, chiefly owing to an 11% reduction in
cardiac deaths. But the JELIS trial reported a 19% (95% CI, 5%-
31%) reduction in major CHD events (albeit based on only 586
events), chiefly owing to a reduction in nonfatal CHD events.14
It is unclear whether differences in inclusion criteria for prior
diseases, concomitant use of statins, or other secondary pre-
vention treatments may explain some of the conflicting
results of individual trials.
For example, previous reports had suggested that the ef-
fects of omega-3 FA use may vary by patients’ prior use of statin
medications.21,22 The Alpha Omega trial reported that use of
low-dose omega-3 FAs reduced the risk of major vascular events
in patients with prior MI who were not treated with statin
medications.22 However, the present meta-analysis demon-
strated no heterogeneity in the effects of omega-3 FA supple-
mentation on CHD death or nonfatal MI between the indi-
vidual trials and reported no differences in the effects of
omega-3 FAs on major vascular events by subgroups of those
with or without prior cardiovascular disease or diabetes; those
with lipid levels less than or greater than specified cutoff points;
or those who had histories of statin therapy. The results of the
present meta-analysis were also unaltered by the exclusion of
the JELIS trial,14 in which all participants were also treated with
statin medications.
The present meta-analysis reported weak evidence of
heterogeneity between the results of open-label vs blind trials
for any CHD. This may reflect reporting bias, chance, or greater
compliance in the open-label trials than in the blinded trials.
Previous meta-analyses of omega-3 FA trials,16-18 which
were limited by being incomplete, including trials of dietary
advice to increase fish consumption,16,17 or failure to distin-
guish the effects on a wide range of subtypes of CVD.16-18,23,24
In contrast, the present meta-analysis demonstrated that
omega-3 FA supplementation had no significant effect on fa-
tal CHD or any other CVD subtypes. Moreover, the conclu-
sions of the present meta-analysis are consistent with those
of a 2016 report24 for the US Agency for Healthcare Research
and Quality that also involved study-level data from the same
10 large trials for prevention of major vascular events, and con-
cluded that omega-3 FA supplementation had no association
with the risk of major vascular events, all-cause mortality, sud-
den cardiac death, or revascularization. In contrast with this
report, the present article was able to assess effects on a wide
range of subtypes of CVD and on major vascular events in all
relevant subgroups.24
Limitations
This meta-analysis had several limitations. The protocol did not
prespecify assessment of the effects of treatment by smoking
status or by site-specific cancer incidence. An additional limi-
tation of this meta-analysis involved the use of aggregated study-
level data rather than individual-level data. A meta-analysis of
individual participant data may have a greater chance of de-
tecting effects of omega-3 FA supplements on subtypes of fatal
CHD events (ie, sudden death or ventricular arrhythmias) in a
wider range of subgroups. However, the overall null results of
the present meta-analysis, which assesses effects on a wide
range of prespecified CVD subtypes, provides little encourage-
ment for such an approach. In addition, sensitivity analyses


















































Symbols and conventions as in
Figure 1. Heterogeneity between
trial designs (χ 21 in all cases) was
1.05 (P = .31) for nonfatal myocardial
infarction, 3.26 (P = .07) for coronary
heart disease death, and 4.81
(P = .03) for any coronary
heart disease.
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using data from 1 trial12 that also provided data on all indi-
vidual participants indicated identical effect estimates and
99% CI for analyses using both O-E and log-rank methods.
The 95% CI in the present meta-analysis of 10 trials, in-
volving 77 917 high-risk individuals, 12 001 major vascular
events, and 6273 CHD events, cannot exclude a 7% lower risk
of major vascular events and a 10% lower risk of CHD associ-
ated with omega-3 FA supplements. Several ongoing large ran-
domized trials involving a total of 54 354 additional partici-
pants (A Study of Cardiovascular Events in Diabetes
[ASCEND],25 n = 15 480; VITamin D and OmegA-3 TriaL
[VITAL],26 n = 25 874; STatin Residual risk reduction with
EpaNova in hiGh CV risk patienTs with Hypertriglyceridemia
[STRENGTH],27 n = 13 000 and Reduction of Cardiovascular
Events With EPA–Intervention Trial [REDUCE-IT], n = 8000)
will provide additional evidence about the associations of
omega-3 FA supplementation with the risk of major vascular
events, any CHD, and subtypes of fatal and nonfatal CHD.
Importantly, the STRENGTH27 and REDUCE-IT trials will test
the effects on major vascular events of much higher doses
of omega-3 FAs (3-4 g/d), which will lower plasma levels
of triglycerides.
Conclusions
The 2016 European Society of Cardiology and European
Atherosclerosis Society guidelines for prevention of cardio-
vascular disease28 indicated that it is debatable whether
omega-3 FAs may exert a protective effect, and the 2016
guidelines on the management of dyslipidaemia29 indicated
that more evidence on the efficacy of omega-3 FA supple-
ments for prevention of clinical outcomes is needed to
justify their prescription. In contrast, the American Heart
Association recommended30 that the use of omega-3 FAs for
prevention of CHD is probably justified in individuals with
prior CHD and those with heart failure and reduced ejection
fractions. However, the results of the present meta-analysis
provide no support for the recommendations to use
approximately 1 g/d of omega-3 FAs in individuals with a
history of CHD for the prevention of fatal CHD, nonfatal MI,
or any other vascular events. The results of the ongoing
trials are needed to assess if higher doses of omega-3 FAs
(3-4 g/d) may have significant effects on risk of major
vascular events.
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